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Introduction
Introduction
1 Premature aging in DNA repair deficient disorders
1.1.1 DNA damage 
Our genome is continuously damaged by environmental, endogenous agents as well as by 
the instrinsic instability of DNA. For example, UV light gives rise to helix-distorting cyclobu-
tane pyrimidine dimers (CPDs) and pyrimidine-(6,4)-pyrimidone adducts (6-4PPs). Ionizing 
radiation can cause both single and double strand breaks in DNA and numerous types of oxi-
dative lesions. Chemotherapeutics, that are used in cancer therapy, and other environmental 
chemical agents, which are present in e.g. polluted air and tobacco smoke, induce a plethora 
of DNA lesions, including intra- and inter-strand cross-links and mono-adducts. In addition, 
endogenous agents cause a wide variety of DNA lesions. Metabolic processes within our cells 
lead to reactive oxygen species (ROS), which react with proteins, lipids and DNA. Although 
ROS participate in beneficial physiological processes as growth factor signal transduction (1), 
these by-products of metabolism also underlie a broad spectrum of oxidative DNA lesions, 
including 8-oxo-2’-deoxyguanosine (8-oxodG), thymine glycols, cylcopurines, as well as 
single and double strand breaks (2). Finally, lesions in the DNA can also form without a direct 
damaging agent. E.g. spontaneous hydrolysis or modifications of nucleotides occurs in cells, 
which leaves non-informative a-basic sites or altered, miscoding nucleotides (3). 
1.1.2 Consequences of DNA damage
Lesions in DNA have immediate effects on cell function as well as long-term consequences. 
For instance, DNA lesions will interfere with transcription and replication (4,5). This causes 
dysfunctioning of cells and -depending on the damage load- will lead to cell cycle arrest or 
programmed cell death (apoptosis) (6). Apoptosis is a way of eliminating cells that are at risk 
of malignant transformation. In addition to apoptosis, cellular senescence, i.e. limited growth 
potential followed by growth arrest, can neutralize potentially malignant cells (7). De Waard 
and co-workers found that different cell types exhibit different responses to DNA damage 
(8). For instance, pluripotent embryonic stem cells show increased apoptosis after treatment 
with several types of DNA damaging agents compared to differentiated keratinocytes (8). 
Persistent DNA lesions that are misinterpreted by the replication machinery, result in the 
induction of mutations. These mutations, as well as other changes in the DNA that result 
from genome instability or miss-segregation (rearrangements, deletions, insertions, loss of 
heterozygosity and numerical aberrations), can on the long-term give rise to cancer or inborn 
diseases. Furthermore, cellular dysfunction or depletion of proliferative capacity of cells by 
senescence or apoptosis can contribute to aging (9,10). These processes lead to compromised 
tissue homeostasis, most likely through diminished self-renewal or altered tissue structure 
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(11). For example, cells that are lost via apoptosis might be replaced by progenitors and in 
time this may exhaust the regenerative capacity of a tissue.
1.2.1 Repair mechanisms
To counteract the deleterious effects of DNA damage, the cell is equipped with a wide variety 
of genome caretaking mechanisms (12,13) (Figure 1). On the one hand, a transient block 
in the cell cycle can provide an extended time window for repair to take place (14). Various 
DNA repair machineries exist to repair the different DNA lesions (reviewed by (12,13)). On the 
other hand, cells with persisting DNA damage may bypass DNA damage during replication 
at the risk of mutation induction. This process is called trans-lesion synthesis and involves 
several polymerases that are more or less error-prone (15-17). 
Nucleotide excision repair (NER), which is discussed in more detail below, functions by 
a ‘cut and patch’-like mechanism, in which damage recognition, opening of the DNA helix 
around the lesion, damage excision, and gap-filling are the successive steps (reviewed by 
(12,18,19)). This repair mechanism can remove numerous types of helix-distorting and bulky 
lesions. 
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Figure 1: DNA lesions and repair mechanisms. 
At the top of the figure, examples of common DNA damaging agents are depicted. As indicated by the arrows, many DNA damage inducing 
agents produce a spectrum of different (classes of) lesions. Oppositely, different DNA damaging agents can cause similar DNA lesions. The 
middle part of the figure shows the DNA helix, with several DNA lesions, as depicted under the figure. The lower part of the figure shows the 
various repair pathways that cells use to remove these lesions (adapted from de Boer et al., Carcinogenesis 2000).
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Base excision repair (BER) is another ‘cut and patch’-like mechanism that involves the con-
certed interplay of different specialized proteins. A battery of glycosylases with overlapping 
lesion specificity recognize and remove the lesions from the DNA. These different glycosyl-
ases allow BER to remove a wide variety of (non helix-distorting) nucleotide modifications 
(reviewed by (20,21)). As BER removes base adducts from ROS, methylation, deamination, 
and hydroxylation, it is considered as the main guardian against DNA lesions caused by cel-
lular metabolism. 
Mismatch repair is a ‘cut and patch’-like mechanism that removes single base-base mis-
matches and small insertion/deletion loops caused by erroneous base incorporation, and 
slippage of DNA polymerases during replication or recombination (reviewed by (22)). As such 
it prevents the accumulation of these mutagenic lesions and is important in the prevention 
of cancer. This is illustrated by the fact that mutations in mismatch repair genes cause Lynch 
syndrome (previously called hereditary non-polyposis colorectal cancer or HNPCC) (23). 
Double strand breaks (DSBs) are deleterious lesions that arise from ionizing radiation, 
free radicals or chemicals, or are formed during replication of single strand breaks. Cells are 
equipped with at least two double strand break repair mechanisms: homologous recombina-
tion and non-homologous end joining (NHEJ) (reviewed by (24,25)). The first uses the ho-
mologous sequence of the sister chromatid, present after DNA replication (or in meiosis the 
homologous chromosome) to accurately repair the DSB in an error-free manner. In contrast, 
NHEJ simply links two DNA ends together with little or no use of homologous sequences 
present in the ends and is thus an error-prone pathway.
Cross-link repair is capable of removing the highly toxic inter-strand cross-links. While the 
components of the Fanconi Anemia/ BRCA pathway are being unraveled, it’s mechanism is 
still not fully understood. This is probably due to the fact that it depends on many factors 
involved in other repair processes (NER, homologous recombination, mismatch repair and 
trans-lesion synthesis) and as such seems to be the result of a combination of interwoven 
repair pathways (reviewed by (26-32)). 
1.2.2 Nucleotide excision repair   
One of the most versatile DNA repair mechanisms is nucleotide excision repair (NER). This 
repair system can remove a wide variety of DNA helix-distorting lesions of both exogenous 
and endogenous origin. For example, NER is responsible for the removal of CPDs and 6-4PPs 
induced by UV light. NER can also remove bulky chemical adducts, intra-strand cross-links 
and several forms of oxidative damage such as cyclopurines induced by reactive chemicals 
as ROS or tobacco smoke (12,33). 
NER is composed of two sub-pathways that differ in the way lesions are recognized: global 
genome NER and transcription-coupled NER (Figure 2). In global genome NER, the hHR23B/
XPC complex recognizes the lesion. This recognition is dependent on the degree of helix 
distortion and as a consequence CPDs, that only mildly disturb the helix, are inefficiently 
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Figure 2: Mechanism of nucleotide excision repair.
This figure shows the principle of nucleotide excision repair (NER) and its two subpathways, global genome NER (GG-NER) and transcription-
coupled NER (TC-NER). In GG-NER, the XPC/hHR23B protein complex recognizes the helix distorting lesion. When RNA polymerase II is stalled 
upon a lesion, TC-NER is initiated by  the CSA and CSB protein. In both GG-NER and TC-NER the lesion recognition step is followed by recruitment 
of TFIIH. The XPB and XPD helicases from the TFIIH complex unwind the DNA around the lesion. The initial open complex is stabilized by XPG.  
Next, XPA verifies the lesion and RPA stabilizes the open intermediate by binding single stranded DNA. The structure specific endonucleases 
XPG and ERCC1/XPF cleave 3’and 5’of the lesion, respectively. The resulting 24-32 nucleotide fragment, containing the lesion, is subsequently 
removed and the remaining single strand gap is filled by the regular replication machinery and the resulting nick is sealed by ligase I or ligase III 
(adapted from Hoeijmakers, Nature 2001).
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repaired. In contrast, blockage of the elongating RNA polymerase II is believed to initiate 
repair in transcription-coupled NER. Lesions that block transcription as for example CPDs 
are efficiently repaired by transcription-coupled NER (34). This process requires the CSB and 
CSA proteins (19). In both global genome NER and transcription-coupled NER, the lesion 
recognition step is followed by recruitment of the ten subunit transcription factor TFIIH. 
TFIIH contains the XPB and XPD helicases that unwind ~30bp of DNA around the lesion 
with respectively it’s ATPase activity and it’s helicase activity (35). XPA then demarcates the 
damage and together with the single strand binding protein complex RPA stabilizes the NER 
complex. Next, endonucleases XPG and ERCC1/XPF cleave 3’and 5’of the lesion, respectively. 
Finally, the ssDNA gap is filled by the regular replication machinery and the resulting nick is 
sealed by ligase I or ligase III (36). In vivo, the NER complex assembles at the site of damage 
in a few seconds and remains stable for about 4 minutes during which the repair reaction is 
believed to take place (37). Global genome NER repairs lesions in the entire genome and is 
as such important in preventing cancer whereas transcription-coupled NER repairs lesions in 
transcribed strands enabling unhindered transcription. Transcription-coupled repair may be 
more extensive including transcription-coupled BER as well.
1.3.1 Repair-related disorders
A variety of rare (autosomal recessive) disorders illustrate the importance of DNA repair 
mechanisms and other vital genome caretaking processes (reviewed by (38)). Most of these 
DNA repair associated disorders show an elevated cancer risk and thus demonstrate the 
important function of DNA repair in preventing cancer. As mentioned previously, Lynch 
syndrome (hereditary non-polyposis colorectal cancer) is caused by mutations in mismatch 
repair genes (23), whereas autosomal recessive adenomatous polyposis is caused by bial-
lelic mutations in MYH, a glycosylase involved in BER (39,40). Ataxia telangiectasia, ataxia 
telangiectasia-like disorder and Nijmegen breakage syndrome are DSB-repair related disor-
ders and all display cancer predisposition and several aspects of accelerated aging as well as 
hypersensitivity to ionizing radiation and chromosomal instability (41). Mutations in genes 
involved in NER underlie three rare autosomal recessive disorders: xeroderma pigmentosum 
(XP), Cockayne syndrome (CS) and trichothiodystrophy (TTD) (reviewed by (42,43)). 
1.3.2 Xeroderma pigmentosum
The diagnostic features of XP are a dry scaly skin (xeroderma), abnormal pigmentation in 
sun-exposed skin-areas (pigmentosum), photosensitivity, and a 1000-fold increased risk of 
developing UV-induced skin cancer (mainly squamous cell carcinomas and basal cell carci-
nomas). However, these symptoms are heterogeneous in occurrence as well as in severity 
among the different XP patients. In addition to skin cancer predisposition, patients have a 
10-20 fold increased risk of developing several types of internal cancers before the age of 20 
(43). 
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Complementation studies have shown the involvement of 7 genes: XPA through XPG. XP-C 
and XP-E are specifically deficient in the global genome repair pathway (44-47) leaving the 
transcription-coupled NER intact. This is probably why, except for the cancer risk, XP-C and 
XP-E patients generally show mild XP features. The other five complementation groups 
display defects in both global genome repair and transcription-coupled NER. However, many 
mutations in XP genes do not cause a complete inactivation of proteins and thus provide the 
cell with residual repair capacity, which probably explains the milder forms of XP (reviewed 
in (43)). Most XP patients develop almost normally but die of cancer, which reduces their 
average life span by approximately 30 years (48). 
However, about 20-30% of XP patients show progressive neurological degeneration with 
a variable course. Features observed in these patients include diminished or absent deep 
tendon reflexes, high frequency hearing loss, abnormal gait, swallowing difficulties and 
mental retardation (49). A minority of patients show microcephaly and growth retardation, 
(43,50-52). The neurological symptoms in XP are caused primarily by neuronal degeneration 
(53) (54). 
The diagnosis of XP is based on the level of unscheduled DNA synthesis (UDS) measured by 
the incorporation of 3H- thymidine in non-S phase nuclei after UV-irradiation of skin fibro-
blasts from patients. When UDS levels are lower compared to control fibroblasts, the patient 
fibroblasts are subjected to complementation assays. 
1.3.3 Cockayne syndrome and XP/CS
As is the case for XP, patients with Cockayne syndrome can display photosensitivity of the 
skin. However, CS is not associated with an increased skin cancer risk. This low cancer predis-
position in CS patients is probably associated with functional global genome NER in addition 
to increased apoptosis of premutagenic cells due to improper TCR. In addition, CS patients 
display additional features that are not observed in XP. 
These features include a characteristic facies with deep set eyes, prominent ears and a wiz-
ened facial appearance (bird-like face), short stature, kyphosis, impaired sexual development, 
caries, thin hair, cachexia, and osteoporosis. Neurological features include progressive mi-
crocephaly, increased deep tendon reflexes, progressive sensorineural deafness, progressive 
visual loss with pigmentary retinal degeneration and involvement of the lens and cornea, 
progressive ataxia, delayed psychomotor development, and mental retardation (49). Brain 
imaging shows absence of myelin, cerebral atrophy and prominent calcification of among 
others the basal ganglia (49). The cerebral atrophy is due to degeneration of neurons, but the 
most striking neuropathological feature is abnormal myelination (53,54). 
Many of these features resemble aging and classify CS as a progeroid disease (reviewed by 
(43,55)). The mean age of death, mainly caused by respiratory infections, resulting from a 
poor overall condition, is 12.5 years.
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Similar to XP, CS is a heterogeneous disease. In order to diagnose CS, cellular studies must 
show impaired UV survival and lack of RNA synthesis recovery, which is the start of tran-
scription after a temporary UV-induced block in transcription. Cerebro-oculo-facio-skeletal 
syndrome (COFS) can be regarded as a severe form of CS (56). Symptoms of COFS include 
reduced birth weight, early microcephaly with subsequent brain atrophy, reduced white 
matter, patchy grey matter, hypotonia, deep-set eyes and cataracts. In addition, movement is 
markedly decreased and joint contractures are common. 
Defects in two genes, CSA and CSB, can cause CS (55). However, a correlation between 
complementation group and severity of CS has not been observed. Only few patients are 
known to suffer from COFS, but the genes that are known to be involved are CSB, XPG, 
XPD and ERCC1 (57). In addition, a subset of mutations in XPB, XPD and XPG can lead to the 
combined phenotype of XP and CS including predisposition to cancer (43). Patients with the 
XP/CS complex have the skin and eye phenotype as observed in XP patients in addition to 
the somatic and neurological abnormalities of CS patients including short stature, immature 
sexual development and retinal degeneration(49,58). The reported patients show progres-
sive neurological degeneration. 
1.3.4 Trichothiodystrophy and XP/TTD 
A third photosensitive disorder is trichothiodystrophy (TTD). TTD involves a broad spectrum of 
symptoms and as a result the nomenclature can be confusing. Over the years, many syndromes, 
such as the syndrome of Pollit, Tay’s syndrome, Sabinas syndrome, ONMR syndrome (ony-
chotrichodysplasia with neutropenia and mental retardation), and Amish brittle hair disease, 
have been described that retrospectively belong to the spectrum of TTD (59-61). PIBIDS is an 
acronym that is often used for the combination of symptoms that is displayed by TTD patients: 
photosensitivity, ichthyosis (scaly skin), brittle hair and nails, impaired intelligence, decreased 
fertility, and short stature (43,60). TTD encompasses PIBIDS, IBI(D)S and BI(D)S as well as SIBIDS 
Figure 3
Figure 3: ‘Tiger tail banding’ in hair from a TTD patient.
Adapted from Liang et al., J Invest Dermatol. 2006. 
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(osteosclerosis or skeletal abnormality and IBIDS) (43,62). The hallmark of TTD is the hair with 
it’s characteristic ‘tiger tail’ pattern (when viewed with polarised microscopy; Figure 3) that is 
dry, sparse and easily broken, as a result of the absence of cysteine-rich matrix proteins in the 
hair shaft (63). 
A recent literature review describes features of 112 patients that were included based on 
having at least two of four abnormalities ((1) presence of brittle hair and/or hair shaft ab-
normalities; (2) tiger tail banding; (3) decreased sulphur or cysteine content of hair; and (4) a 
DNA repair abnormality) (61). In this review, the spectrum of clinical features varied from mild 
disease with only hair involvement to severe disease with profound developmental defects, 
recurrent infections and a high mortality at a young age. The median age of these patients 
was 6 years (ranging from 12 weeks to 47 years of age). DNA repair abnormalities or gene 
defects were reported in 41 of these patients; 32 patients were reported as having mutations 
in XPD, two in XPB and two in TTDA. Five showed cellular UV hypersensitivity, but no spe-
cific gene defect determined. In addition, 6 patients had a mutation in the newly discovered 
TTDN1 gene. The majority of patients exhibited hair, skin and nail abnormalities: in addition 
to brittle hair or hair shaft abnormalities (96%), tiger tail banding (73%), and decreased sulfur 
or cysteine (71%), sparse hair (48%) and alopecia (39%) were described. 79% of patients had 
skin abnormalities; most frequently ichthyosis (65%) and photosensitivity (42%). Notewor-
thy, 37% of the patients with ichthyosis presented with a collodion membrane at birth. The 
nail abnormalities (63%) included onychodystrophy (37%), brittle nails (14%), hypoplasia 
(13%), and koilonychias, ie. spoonshaped nails (12%). 86% of patients presented with devel-
opmental delay or intellectual impairment. A notably sociable or outgoing behaviour, which 
is also a feature in Cockayne syndrome, was observed in 17% of patients. Further neurologi-
cal abnormalities included microcephaly (50%), abnormal gait/ataxia (26%), sensorineural 
hearing loss (5 out of 25 patients who underwent audiologic examination), increased deep 
tendon reflexes (13%), spasticity (10%), and tremor (7%). In 23% of patients neuroimaging 
abnormalities were described: dysmyelination (14%), cerebellar atrophy (4%), and dilated 
ventricles (4%), which are similar to features found in CS. Growth abnormalities (81%) in-
cluding short stature (73%) as well as facial dysmorphism (66%) were reported. In addition 
to microcephaly, large or protruding ears (30%), micrognathia (29%), and an aged (9%) or 
‘‘bird-like’’ appearance (8%) were recorded. Ocular abnormalities were reported in 51% of 
patients; most frequently cataracts (29%) of which 8/32 congenital cataracts, nystagmus 
(14%), and strabismus (10%). Infections were commonly (46%) reported and 65% of the 20 
reported deaths were related to infections. The high mortality rate, which might show some 
selection bias, highlights the potential severity of TTD in the neonatal and early childhood 
period. In less than half of the patients a radiological examination was performed. In total 
38% patients showed radiographic bone abnormalities including (axial) osteosclerosis (14%), 
delayed bone age (13%), (distal) osteopenia (9%), and kyphosis 6%. In addition, 19% showed 
dental abnormalities, most frequently caries (19%). 
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Haematologic abnormalities as anaemia and neutropenia, sexual/reproductive abnormalities 
like hypogonadism, cryptorchidism or delayed pubertal development, and cardiac defects 
including cardiomyopathy, pulmonic stenosis and ventricular septal defect were reported in 
respectively 21%, 14% and 7% of patients. Several of these features are shared with CS and 
categorize TTD as a premature aging syndrome. 
TTD results from phenotype-specific mutations in XPB, XPD, TTDA, which codes for TFIIH 
subunit p8, or the recently discovered TTDN1 gene (64-67). Notably, most patients have a 
defect in XPD. Several years ago, some patients with a combined form of XP/TTD have been 
described (68). So far, only mutations in XPD have been shown to cause XP/TTD. Interestingly, 
XPD mutations can thus cause several different diseases: XP, XP with additional neurological 
features, COFS, TTD and the combinations XP/TTD and XP/CS. The photosensitivity is due to 
a NER defect, but several other symptoms cannot be explained by a repair defect alone. The 
first clue in understanding the paradox of one gene causing these very different clinical phe-
notypes came from the discovery that XPB and XPD are part of a transcription factor, TFIIH 
that is required for transcription initiation (69,70). The role of TFIIH in repair and transcription 
is discussed further in the next paragraph. Impaired transcription (depressed RNA synthesis 
due to DNA damage) may account for some clinical features, such as growth retardation, 
neurological abnormalities, skin abnormalities, and brittle hair and nails.
1.3.5 TFIIH 
Already in 1993 it was known that XP-B, XP-D and XP-G can cause XP, XP/CS as well as PIBIDS 
(71). How features as neurodysmyelination, retarded development and brittle hair could 
originate from a repair defect was however not yet understood (71). This was especially diffi-
cult to understand since some of these features are not observed in completely NER deficient 
XPA patients (71). The first clue came by the discovery from the group of Egly in collaboration 
with the genetics department of the Erasmus MC that XPB was part of the transcription factor 
TFIIH (70). Thus, the CS features neurodysmyelination and retarded development and the 
brittle hair in TTD could be due to a subtle transcription defect (71). One year later, it was 
discovered that XPD was part of the TFIIH complex as well (69). Both XPB and XPD are DNA 
helicases unwinding DNA in the 3’-5’and 5’-3’ direction respectively (69,72). 
The TFIIH complex opens DNA around the lesion as well as around the promoter site in DNA 
repair and initiation of basal transcription respectively (19,73-77). The role of XPD in these 
two processes is however quite different. Whereas DNA repair is dependent on the helicase 
activity of XPD, transcription initiation just requires the structural presence of XPD for stabil-
ity of the complex (53,78-80). The helicase activity of XPD unwinds DNA in the 5’-3’direction 
(69,72), but the fairly low activity is stimulated by the interaction with p44 (81). In contrast, the 
XPB helicase activity is required for transcription initiation (35,53). As a consequence many 
mutations in XPD result in severe repair defects while they have little effects on transcription 
and thus viability (53). Indeed many different viable mutations have been detected in the 
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XPD gene whereas only few mutations in XPB are tolerated (82-87). Still, genotype-phenotype 
relationships have turned out to be exceedingly complicated, partly because most patients 
are compound heterozygotes. Dubaele and co-workers studied XPD mutations causing XP or 
TTD and found that additional effects on the stability of TFIIH can explain the different degree 
of severity of the clinical features in TTD patients (88). This difference in stability of TFIIH may 
also account for the difference in cancer risk between XP and TTD patients (89).
It is now known that TFIIH consist of 10 subunits of which the XPB helicase, p62, p52, p44, p34 
and p8 form a tight ‘core’ complex (67). The XPD helicase interacts with p44 and thus serves 
as a bridge between the core and the ternary cyclin-activating-kinase (CAK) complex, con-
sisting of CDK7, MAT1 and cyclinH (67,90-92). In addition, it was found that TFIIH also has a 
mechanistical role in transcription regulation, ie. it functions as a kinase that phosphorylates 
nuclear hormone receptors (92,93). 
In summary, TFIIH is involved in RNA-pol I transcription, RNA-pol II driven (basal) transcrip-
tion initiation, transcription regulation, global genome NER, transcription-coupled NER and 
perhaps general transcription-coupled repair as well. In addition some forms may have 
implications in cell-cycle regulation (70,94-99). 
1.3.5.1 TFIIH in TTD
In the case of TTD, disease-causing mutations are all found in components of the dual 
functioning TFIIH complex. Consequently, a link between defective basal transcription and 
the clinical onset of these TTD features has been made (62,71,88,100-103). For example, in 
the hair shafts that show transverse fractures, a ‘tiger-tail’ pattern, and severely damaged or 
absent cuticle, a strong reduction in the class of ultra-high sulphur-rich matrix proteins is 
observed. These proteins are composed of up to 30% of cysteine residues that are involved 
in disulfide cross-links (43). In addition, the cutaneous symptoms, such as acanthosis and 
hyperkeratosis, have been proposed to be associated with reduced transcription of the 
skin-specific, differentiation-related gene SPRR2, a member of the small proline-rich protein 
(SPRR) family expressed in the dermis (60). SPRR2 encodes a structural component of the cor-
nified envelope and is expressed in the final stage of terminal differentiation (60). Lehmann 
and co-workers also found that almost all TTD patients with an XPD mutation have elevated 
levels of haemoglobin A2 and reduced levels of β-globin in erythrocytes without a defect in 
a haemoglobin gene (53,104). It has been proposed that low TFIIH levels and/or the defect in 
TFIIH become apparent in terminally differentiated, enucleated cells, like keratinocytes and 
erythrocytes, which need to produce abundant protein. 
Recently, it was shown that TFIIH can function as a co-activator for thyroid hormone-depen-
dent gene regulation, and it was speculated that the loss of this co-activator function of TFIIH 
is responsible for some of the major neurological abnormalities observed in TTD patients 
(105).
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1.3.5.2 The 3D-structure of the XPD protein
Studies of the crystal structure of the XPD protein have recently given some insight in the 
genotype-phenotype correlation of XPD mutations which could not be understood solely by 
their position along the gene as adjacent mutations can cause different diseases (106). The 
XPD protein is folded into four differently active domains, two helicase domains (HD1 and 
HD2), the 4FeS domain involved in DNA- and ATP-binding and the Arch domain, named by 
its arch-shaped conformation (106). XP mutations are located along the ATP-binding edge 
of HD1 and the DNA-binding channel of HD1 and impair helicase activity essential for NER 
(106). XP/CS mutations not only impair helicase activity, but also have an effect on the func-
tional flexibility of the HD1 and HD2 domains which likely affects protein-protein interactions 
within the TFIIH complex as well as with other critical protein partners including XPG (106). 
TTD mutations may effect helicase activity, but map to sites in all four domains expected 
to cause framework defects impacting TFIIH integrity (106). These mutations are thought to 
result in destabilization of the interaction with p44 or the XPD structure itself and therefore 
TFIIH (107). 
1.4.1 TTD mouse model 
Mice carrying an XPD point mutation (Arg722→Trp (R722W)), which is found in patients, were 
generated in our laboratory (102). These TTD mice reflect the human disorder to a remark-
able extent and display partial defects in transcription and repair (102,108). In addition, it 
was observed that TTD mice develop premature aging features (Table 1) (100). This initial 
observation of premature aging features was made in TTD mice in a mixed (C57Bl/6/FVB) 
background.
Firstly, it was noticed that TTD mice acquire an ‘aged’ appearance. Whereas TTD mice develop 
normally, they show cachexia and kyphosis at 16 months of age. In addition, the average life 
span ranged from less than 12 months to 1,5 year compared to more than 2 years for wild 
type littermates. Closer examination revealed patchy depigmentation of the skin which was 
observed earlier and more frequently than in wild type littermates. The skin also showed 
hyperplasia of sebaceous glands as is observed in human aging. TTD females appeared to 
lose fertility early and indeed 16 months old TTD mice displayed ovarian dysfunction ranging 
Table 1: Premature aging features in TTD patients and mice.
mice patients
reduced life span reduced life span
cachexia cachexia
reduced fertility (in females) early arrest of sexxual development
aged-like apperance, cutaneous symptoms aged-like apperance
neurological problems neurological problems
skleletal abnormalities skleletal abnormalities
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from complete anovulation to sporadic, seemingly normal, ovulation. At 6 months of age, TTD 
mice showed mild normochrome anemia and an enlarged spleen. In addition, significantly 
reduced levels of the branched-chain amino acids (valine, leucine, and isoleucine) indicative 
of starvation were found. However, the starvation was not caused by aberrant food uptake 
or malabsorption.
After this first report, Wijnhoven and co-workers documented the overall phenotype of TTD 
mice in a pure C57Bl/6 background (109) and divided the observed pathology in three groups: 
(1) pathology consistent with accelerated aging, (2) trichothiodystrophy-specific pathology 
and (3) pathology consistent with dietary restriction. The first group includes osteoporosis of 
the femur, kyphosis, abnormalities in liver, kidney and lymphoid tissue, aortic sarcopenia and 
reduced hypodermal fat. For example, the increased levels of lipofuscin pigmentation in TTD 
livers can be related to oxidative damage. The second group harbours anorectal prolapse, 
which in addition to a general conditional decline is a common cause of death in TTD mice. 
Furthermore, typical skin lesions as acanthosis, hyperkeratosis and sebaceous hyperplasia are 
present in this group. Notably, the pathology in the last group that among others includes re-
duced hypodermal fat, is not caused by a difference in food uptake between TTD and C57Bl/6 
control mice. This dietary restriction pathology is in concordance with the observed reduced 
body weight in TTD mice. It was hypothesized that transcription problems in TTD mice could 
lead to a metabolic state with inefficient energy uptake. The decrease in metabolic side 
products as ROS could be favourable for DNA-repair deficient TTD mice. 
1.4.2 Mouse models showing premature aging 
In many progeroid disorders the underlying defect is a disturbance in DNA metabolism or 
genome maintenance. Mouse models are powerful tools in the analysis of the effect of defec-
tive genome maintenance on aging. Today, several mouse models with defective genome 
maintenance that also display symptoms of accelerated aging are available (reviewed by 
(10)). TTD mice with a defect in both global genome repair and transcription-coupled repair 
as well as transcription-coupled repair-deficient CSB mice show several features of acceler-
ated aging. In both TTD and CSB mice, the features of premature aging are severely enhanced 
by crossing them to XPA mutant mice that have a total NER defect but no overt features 
of premature aging. For example, TTD/XPA mice develop dramatically runted growth and 
extreme cachexia resulting in a severely shortened life span on average of only 22 days (100). 
In addition, they show disturbed gait and spinal kyphosis. This suggests that a complete 
NER defect, in combination with a defect in transcription-coupled repair that renders the 
transcription machinery very sensitive to lesions in transcribed genes, is responsible for the 
markedly accelerated aging of the double mutant mice (10). 
In addition, Ku80 mice with a defect in NHEJ exhibit an early onset of aging characteristics 
as among others a shortened life span, cancer, reduced weight, osteopenia, and alopecia. In 
ERCC1 mice, with a defect in NER and inter-strand cross-link repair, liver and kidney abnor-
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malities reminiscent of accelerated aging are present in addition to reduced life span, body 
weight and neuronal function (98). 
In many progeroid disorders the underlying defect is a problem in DNA metabolism which 
strengthens the hypothesis that DNA damage is an important factor in the aging process. 
1.5 Aging 
Aging is commonly defined as progressive loss of function accompanied by decreasing 
fertility and increasing mortality with advancing age (110). Time-dependent accumulation of 
damage is generally accepted to be the cause of aging (1,10,110). Already in 1957, Harman 
postulated the ‘free radical theory’ of aging speculating that endogenous radicals were gen-
erated in cells and resulted in a pattern of cumulative damage (1). However, endogenously 
produced ROS do not only cause damage to lipids, proteins and most importantly DNA, but 
also function as intracellular signalling molecules (1). So ideally there should be a balance: 
reducing detrimental effects of ROS while keeping oxidative metabolism and the role of ROS 
as intracellular signalling molecules intact. 
1.5.1 Genome maintenance
Humans have high metabolic rate, but keep ROS limited using defence mechanisms as ROS 
scavenging, damage removal, and repair (111). Indeed, DNA repair capacity of some repair 
systems has been reported to correlate with mammalian life span in several comparative 
studies (98). In addition, it has been claimed that MMR, BER, NER and DSB repair become 
less efficient with age leading to accumulation of mutations (112). As discussed above, 
inborn defects in proteins involved in DNA repair also give rise to symptoms that resemble 
segmental accelerated aging (10). As ROS are believed to result in at least 70 different types 
of DNA lesions (12) and the various DNA repair systems are highly specific, it is not surpris-
ing that defects in various DNA repair proteins occasionally result in segmental and not full 
reconstitution of aging. 
Further evidence supporting that premature aging is caused by defects in genome mainte-
nance comes from additional progeroid disorders as Werner syndrome, Bloom syndrome and 
Rothmund-Thomson syndrome. These syndromes are all triggered by mutations in Rec-Q like 
DNA helicases. Rec-Q like helicases are involved in DNA repair and replication and thereby 
safeguard genome stability. Mutations in the genes coding for these helicases lead to ac-
celerated aging features including early alopecia (loss of hair), osteoporosis, malignancies, 
atherosclerosis, diabetes, cataracts, telangiectasia, skin atrophy and greying of hair (113). 
Ataxia telangiectasia (AT) is caused by Ataxia Telangiectasia mutated (ATM) protein, which 
is a DNA damage sensing signalling protein kinase. Symptoms of AT include skin atrophy/
sclerosis, telangiectasia, immuno-deficiencies, malignancies (mainly lymphomas), greying of 
hair and neurodegeneration ((10) and references therein). 
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Mutations in the LMNA gene, which encodes for type A nuclear lamins are responsible for 
Hutchinson-Gilford progeria syndrome (HGPS) and atypical Werner syndrome. LMNA is a 
structural component of the nuclear envelope and is involved in regulating mitotic signal-
ling pathways. Mutations in LMNA cause nuclear fragility, rendering the nucleus sensitive 
to mechanical stress, reduced mitotic stability, shortened telomere length and diminished 
DNA repair (114,115). HGPS is known as a progeria of childhood with features including 
atrophy of subcutaneous fat, alopecia, short stature, premature atherosclerosis and a panel 
of musculoskeletal abnormalities. 
In conclusion, DNA maintenance is not only important in preventing cancer, but has a role in 
preventing premature aging as well. 
2 Trichothiodystrophy and bone aging
The TTD mouse model resembles the phenotype of TTD patients remarkably well. In order to 
gain insight in the premature aging phenotype, we focus on one tissue, the bone. In both TTD 
patients and mice skeletal abnormalities as osteoporosis have been described. 
2.1 Skeletal abnormalities in trichothiodystrophy patients
TTD patients exhibit photosensitivity, ichthyosis (scaly skin), brittle hair and nails, impaired 
intelligence, decreased fertility, and short stature (60,116). In addition to these features, 
skeletal abnormalities, like a bird-like face, thoracic kyphosis, axial osteosclerosis, and pe-
ripheral osteoporosis, have been described. In 1979 Leupold described a 13-year-old girl with 
axial osteosclerosis and peripheral osteopenia who was later thought to have suffered from 
TTD (117). In 1980 Price et al. introduced the term trichothiodystrophy in an article where 
they report a male patient who at the age of 7 years showed axial and cranial osteosclerosis 
and demineralisation in the distal bones on roentgenographic examination (63). Chapman 
reported another patient, a 5-year old boy who showed osteosclerosis in the axial skeleton 
and proximal limbs while the bone density was decreased further down in the limbs and 
the distal parts were osteopenic (118). In 1989, Civitelli et al. describe a 9-year-old boy with 
marked axial osteosclerosis and peripheral osteopenia (119). Besides low serum osteocalcin, 
no abnormalities in mineral homeostasis were noted. Histological analysis of the iliac crest 
specimen showed marked increase in trabecular bone whereas the femoral neck specimen 
showed decrease in cortical thickness and increased porosity (119). McCuaig et al. report 
three patients with striking osteosclerosis of the vertebral column and skull and additionally 
mentions two previously reported patients with osteopenia and osteosclerosis (59,120,121). 
Toelle et al. reported on two sisters with TTD and severe cardiac and neurological involve-
ment who also have kyphosis, sclerosis and osteopenia (122). A few years ago, Wakeling et 
al. reported a boy with normal bone density at 3 months of age, increased bone density at 5 
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years of age, and marked increase in density of the spine, ribs, scapulae, clavicles, skull, facial 
bones and proximal humeri at 7 years of age (123). At that time, he also had a mild kyphosis. 
In her review, Wakeling suggests that central osteosclerosis and peripheral osteoporosis are 
distinctive features of TTD that may easily remain undetected (123). 
2.2 Premature bone changes in TTD mice
TTD mice reflect the human disorder to a remarkable extent displaying partial defects in tran-
scription and repair as well as premature aging features. The TTD mouse model showed no 
skeletal abnormalities around 3 months of age, whereas at 14 months radiographs revealed 
prominent kyphosis and generalized reduction in radio-density of the skeleton (100). The 
TTD skull, however, showed higher radio-density. The kyphosis was thought to be a result of 
the osteoporosis (100). However, as commented by Gerhard and Kasales, osteoporosis is not 
the only factor that can underlie kyphosis (124). Next to deformity of the vertebral bodies 
caused by osteoporosis, growth plate abnormalities, osteosclerosis, annulus degeneration, 
and muscular dystrophy or degeneration can lead to kyphosis (124). Indeed, the initial 
roentgenographic analysis of the TTD skeleton as described by de Boer et al. (100) should be 
followed up by a more detailed analysis of the bone phenotype as described in this thesis.
3 Bone metabolism 
3.1 The constituents of bone
For better comprehension of bone loss with aging, the structure of bone, bone forming and 
bone resorbing cells, the extracellular matrix (paragraph 3.1) as well as the remodelling pro-
cess and factors that influence bone metabolism will be discussed separately (paragraph 3.2). 
3.1.1 Cortical and trabecular bone 
The skeleton contains two types of bone: cortical bone and trabecular bone. Long bones, as 
femurs and tibiae have more cortical bone, which is calcified to a much larger extent than 
trabecular bone, rendering optimal structure and strength for their mechanical and protec-
tive function. In contrast, vertebrae and flat bones as the skull and pelvis mainly consist of 
trabecular bone. Trabecular bone has a metabolic function: storage of essential minerals, 
including calcium thus aiding optimal calcium homeostasis (see paragraph 3.2.3 on calcium 
homeostasis). 
In addition, the loss of bone occurs in different ways in trabecular and cortical bone. The 
cortical bone volume is regulated by periosteal bone formation, remodelling within the cor-
tex (leading to increased porosity) and endosteal bone resorption whereas loss of trabecular 
bone is caused by complete perforation and fragmentation of trabeculae when bone resorp-
tion outpaces bone formation. 
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3.1.2 Osteoblasts 
The bone forming osteoblasts are derived from mesenchymal stem cells that can also dif-
ferentiate into chondrocytes, adipocytes, myoblasts, and fibroblasts (125,126). In the case of 
the bone forming cells, mesenchymal stem cells differentiate into osteoprogenitor cells and 
later further into osteoblasts (see Figure 4). The osteoprogenitor cells contribute to mainte-
nance of the osteoblast population. Osteoblasts produce the components of the extracellular 
matrix, such as collagen (125-128). The newly produced, non-calcified bone matrix is called 
osteoid. Osteoblasts are also able to induce mineralization of the bone matrix. This calcifica-
tion occurs at a later stage, which is about 10 days after deposition of osteoid in humans. Two 
types of osteoblasts reside on the bone surface: active cuboidal osteoblasts and inactive, i.e. 
not active bone matrix producing osteobasts, flat lining cells. Active osteoblasts are found 
in clusters of 100-400 cells per bone-forming site. When the process of bone formation has 
taken taken place, osteoblasts can either go into apoptosis, become osteocytes or lining cells. 
Within the calcified bone matrix thousands of osteocytes are embedded. Osteocytes are ter-
minally differentiated osteoblasts that got trapped in the bone matrix they produced (129). 
They have long processes that are in contact with other osteocytes, osteoblasts, lining cells at 
the bone surface and the blood supply. These processes are created before and during matrix 
synthesis and form a network that permeates the entire bone matrix through thin channels 
called canaliculi. The primary function of this network is considered to be mechanosensory, 
by transducing and translating mechanical signals into biological signals and activity and 
to regulate osteoblast and osteoclast activity (130). Osteocytes can produce various bioac-
tive peptides of which the recently identified, sclerostin, is a very important one. The SOST 
gene, encoding sclerostin, was found by linkage analysis of families with sclerosteosis and 
Figure 4
Figure 4: Different lineages derived from the mesenchymal stem cell.
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van Buchem disease, two closely related bone disorders characterized by progressive bone 
thickening due to increased bone formation (131,132). Sclerosteosis is associated with muta-
tions in the SOST gene whereas in van Buchem disease a 52 kb deletion downstream of the 
SOST gene, which probably affects transcription of the gene, is found (131). Sclerostin inhibits 
osteoblast proliferation, differentiation and mineralization (133). Sclerostin expression is 
reduced by mechanical loading thereby providing a mechanism by which bone formation is 
increased after mechanical loading (133). Osteocytes can reside in healthy bone for long pe-
riods of time. They have an average half-life of 25 years (129). In aging bone, however, empty 
or mineralized lacunae have been observed as well as an increase in the percentage of dead 
osteocytes (134-136). To date it is known that osteocytes can go into apoptosis upon aging 
and that this eventually is followed by resorption of the matrix (129,137). It was shown that 
osteocyte death is induced by fatigue loading and microcracks and that this coincides with 
osteoclastic bone resorption (138). In addition, a correlation between osteocyte apoptosis 
and the withdrawal of oestrogen was found (139). In contrast, no correlation between the 
percentage of empty lacunae and age was found in trabecular bone of the iliac crest (140). 
It has been suggested that this difference can be explained by different sites. Indeed, one 
group found a decrease in viable osteocytes in femur heads of older patients whereas they 
found no difference in viability in the second lumbar vertebra (136). 
3.1.3 Osteoclasts 
Osteoclasts are the cells responsible for bone resorption. The process of resorption consists 
of osteoclast formation and activation, polarization, formation of a ruffled border, resorption 
by secretion of proteolytic enzymes and hydrogen ions, and ultimately apoptosis, which 
terminates the activity of osteoclasts and thus resorption (125) (see Figure 5). This process of 
apoptosis is favoured by estrogens. When estrogen levels decline after menopause or gonad-
Figure 5
Figure 5: Bone remodelling phases.
During bone remodeling resting bone lining cells secrete RANKL which activates mononuclear cells of the haematopoietic lineage to fuse on 
the activated bone surface and form differentiated active osteoclasts. Subsequently, osteoclasts resorb bone after which formation is coupled to 
resorption by the appearance of pre-osteoblasts in the resorption cavity. A cement line is formed which marks the limit of resorption and acts as 
attachment or glue between the old and new bone. Finally, in the formation phase osteoblasts fill the resorption cavity with new bone. Initially 
this is osteoid, unmineralized bone matrix, which then becomes mineralized. 
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ectomy, osteoclast apoptosis decreases and consequently bone resorption increases (125). 
Osteoclasts are large multinucleated cells originating from the mononuclear/phagocytic 
differentiation lineage of haematopoietic stem cells (141,142). Two molecules, that are se-
creted by osteoblasts, are essential to promote osteoclastogenesis: macrophage-stimulating 
factor (M-CSF) and receptor activator of nuclear factor (NF)-κB (RANK) ligand (RANKL), while 
osteoblasts also secrete an inhibitor, osteoprotegerin (OPG) which acts as a decoy receptor 
for RANKL (128,141,142). These proteins together with RANK, the receptor of RANKL on the 
osteoclast, are the major regulators of osteoclastogenesis, as well as bone resorption and 
skeletal remodelling (141,142). The importance of RANKL and OPG emphasizes the central 
role of osteoblasts in this process as these cells express RANKL and OPG and are the actual tar-
gets of osteoclastogenic agents (127,141,143). The osteoclastogenic agents enhance RANKL 
expression and increase the quantity of this molecule relative to that of OPG (141,143). It is 
the balance between the expression of the stimulator RANKL and of the inhibitor OPG that 
dictates the quantity of bone resorbed (141,143). 
3.1.4 The extracellular matrix 
About 90% of the total protein in the extracellular matrix consists of collagen type I fibres. 
Collagen type I fibres are triple-helix molecules that contain two identical chains (α1) and one 
different chain (α2). These α-chains are characterized by repeating Gly-X-Y triplets, where X is 
usually proline and Y is often hydroxyproline. Several post-translational modifications which 
are important for both the structural and mechanical properties of the matrix, occur: (1) hy-
droxylation of certain (hydroxyl-)lysyl residues with glucose and/or galactose residues and (2) 
formation of distinct intra- and intermolecular covalent cross-links (144). The importance of 
these post-translational modifications is illustrated by for example Ehlers-Danlos syndrome 
type V. In this syndrome the level of hydroxylation is reduced to 17% of normal in bone due 
to a deficiency in the enzyme lysyl hydroxylase and this results in connective tissue dysfunc-
tions such as kyphoscoliosis, osteoporosis and ruptures of eyes and arteries (144). The level of 
collagen cross-links measured in serum or urine is a reliable marker of bone resorption (145). 
With aging, the collagen can become denatured and/or accumulate cross-links. Denaturation 
of collagen can result in reduced toughness while alteration of the cross-link profile affects 
the stiffness (146,147). 
The remaining 10% of the total protein consists of non-collagenous proteins as albumin, 
osteocalcin and numerous growth factors like bone morphogenetic proteins (BMPs), trans-
forming growth factor-ß (TGFß), and insulin-like growth factor-I (IGF-I) (125,148). They seem 
to play a role in initiation as well as the control of mineralization. For example, the majority 
of the newly produced osteocalcin is incorporated into the bone matrix, where it binds to hy-
droxy-apatite during matrix mineralization (149). The remainder of the osteocalcin is released 
into the circulation where it can be measured as a sensitive marker of bone formation (150). 
The growth factors stored in the bone matrix can be released during bone resorption and 
29
Introduction
may play a role in the control of bone formation following the resorption (148,151). A large 
amount of bone consists of mineral although this percentage can vary with age, anatomic 
location, diet, and health status. For example, bone mineral content is positively correlated to 
age whereas it is negatively correlated to the rate of remodelling (152). The mineral provides 
mechanical rigidity and load bearing strength to the bone. In contrast, the extracellular ma-
trix provides elasticity and flexibility to the bone and determines the structure of the bone. 
Together they provide the bone with optimal strength and flexibility. 
3.2 Bone remodelling
Bone remodelling is a turnover mechanism by which old bone is replaced by new bone in 
order to maintain optimal bone quality. Bone remodelling occurs in local groups of osteo-
clasts and osteoblasts called bone multicellular units (BMU) (153). The bone-remodelling 
process includes five stages: (1) activation of bone multicellular units, (2) bone resorption, (3) 
‘coupling’ or reversal, (4) bone formation and mineralization of the newly formed bone ma-
trix, and (5) the resting stage (154). Frost was the first to describe this activation-resorption-
formation sequence of bone remodelling. During activation, resting bone lining cells change 
from their normal flat shape to a cuboidal shape and then secrete RANKL. Activated by 
RANKL, mononuclear cells of the haematopoietic lineage fuse on the activated bone surface 
and form differentiated active osteoclasts. Subsequently, osteoclasts resorb bone after which 
formation is coupled to resorption by the appearance of pre-osteoblasts in the resorption 
cavity. A cement line is formed which marks the limit of resorption and acts as attachment 
or glue between the old and new bone. Finally, in the formation phase osteoblasts fill the 
resorption cavity with new bone. Initially this is osteoid, unmineralized bone matrix, which 
then becomes mineralized. Bone formation and bone resorption are coupled: when one goes 
up or down, the other one follows. However, bone resorption is much faster than bone forma-
tion: it takes at least 3 months to rebuild bone that is resorbed in 2-3 weeks (126,128). Thus, 
increased resorption can cause bone loss even when it is accompanied by increased bone 
formation, e.g. in estrogen deficiency or hyperparathyroidism (126).
Many factors have effects on bone formation, resorption or the coupling between the two. 
Among these factors are the previously mentioned growth factors stored in the bone matrix. 
Growth factors play an important role in the bone microenvironment, acting on the bone 
cells directly or influencing other factors. As discussed, the RANK signalling pathway controls 
osteoclastogenesis and bone resorption. The influence of sex steroids, serum calcium ho-
meostasis, leptin, the GH-IGF-I axis and mechanical action on bone remodelling are discussed 
below. 
3.2.1 Sex steroids 
Sex steroids play an important role in skeletal homeostasis. However, the mechanism of ac-
tion of sex steroids on bone is still not entirely clear (155). The actions of estrogen, together 
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with biomechanical strain, are major physiological mechanisms of bone mass conservation 
(156). Most importantly, estrogen inhibits bone resorption by inhibiting osteoclastogenesis 
and osteoclast function and favouring osteoclast apoptosis (125,126). Recently, it was found 
that estrogen also decreases osteoblast apoptosis (156). In addition, estrogen promotes the 
development of osteoblasts from the osteoblast-adipocyte-precursor, and increases the 
production of a number of osteoblast proteins as e.g. IGF-1 in mice (157-159). A decrease in 
estrogen due to menopause or ovariectomy (OVX) results in increased bone loss and adipo-
cyte formation (160). Estrogens are synthesized in the ovaries as well as in many other tissues 
including adipose tissue, bone and brain, where androgens are converted to estrogens by 
aromatase (161,162). This extra-ovarian estrogen synthesis is of great importance in slowing 
down the rate of postmenopausal bone loss (161). During growth, estrogen is responsible for 
initiation of the pubertal growth spurt and closure of the growth plate (163). 
Testosterone affects bone in several ways. It can be converted into estradiol by aromatase to 
inhibit bone resorption, but it also seems to inhibit bone resorption directly in males, and to 
stimulate bone formation in males and females (126). Like estrogen, testosterone increases 
the lifespan of osteoblasts and decreases that of osteoclasts by affecting apoptosis (164). On 
the other hand, there is an important difference between testosterone and estrogen that 
accounts for the larger skeleton that males obtain in puberty; control of bone formation on 
the outerside of the bone, i.e. periosteal apposition. 
3.2.2 Periosteal apposition
The size of a bone is of particular importance to bone strength as the resistance of bone to 
bending or torsional forces is exponentially related to its diameter (165). In other words, a 
small addition to the circumference of a bone adds considerably to its fracture resistance. 
Gradual periosteal apposition occurs during childhood and accelerates at puberty in parallel 
with accelerated growth in bone length (166). The precise mechanism regulating periosteal 
apposition is unclear. Growth factors, like insulin-like growth factor-I (IGF-I; see below), affect 
periosteal apposition (167). Sex steroids are likely to be important regulators with androgens 
having a positive effect while estrogens are believed to have a negative effect on periosteal 
apposition (156,168,169). Indeed periosteal apposition increases in women after menopause 
and following subsequent bone loss. However, recent studies have shown that estrogens 
may stimulate periosteal apposition as well (169,170). It was suggested that a low dose 
of estrogen (as in males and young girls) promotes periosteal apposition whereas higher 
concentrations of estrogen (as in females in late puberty and adulthood) inhibit periosteal 
growth. In addition, the degree of periosteal apposition is likely to be site specific as increases 
in bone area at central sites were equal in men and women whereas men showed a larger 
increase in periosteal apposition at peripheral sites (171). 
Furthermore, mechanical loading is supposed to be an important modulator of periosteal 
apposition (172). With aging, increased bending stress on the outer surface of bone due 
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to endosteal bone loss and subsequent cortical thinning, is thought to lead to stimulation 
of periosteal bone apposition (173). Noteworthy, there has been an observation on bone 
resorption on the periosteal surface so that bone size could decrease with aging (165). How-
ever, this observation requires further investigation. An interesting link between estradiol 
and mechanical loading is the observation that the estrogen receptor α is required for the 
osteogenic response to mechanical loading whereas the role of estrogen receptor ß has not 
been clarified as experiments show apparently contradictory results (174).
3.2.3 Calcium homeostasis
Parathyroid hormone (PTH), 1,25-dihydroxyvitamin D3 (1,25(OH)2D) and calcitonin, an in-
hibitor of osteoclastic bone resorption, regulate serum calcium homeostasis via effects on 
the intestine, kidney and bone (126,141,175,176). PTH up-regulates RANKL expression and 
decreases OPG expression (128,142) resulting in a increase in osteoclast differentiation and 
bone resorption increasing serum calcium. Surprisingly, intermittent PTH treatment favours 
bone formation instead of increasing bone resorption and has proven to be an effective 
therapy in osteoporosis, although the mechanism remains poorly understood. However, 
inhibition of resorption, by e.g. bisphosphonates, has been noted to attenuate or abolish the 
anabolic effect of PTH. This points to a role for the osteoclast in osteoblast activation (177). 
Vitamin D is synthesized in the skin or taken up from the diet. After C-25 hydroxylation in 
the liver, the biologically most active metabolite 1,25(OH)2D is synthesized in the kidney by 
25-hydroxy-vitaminD-1α-hydroxylase (1α(OH)ase) (178). PTH and hypocalcemia are potent 
activators of this enzyme whereas 1,25(OH)2D itself and hypercalcemia are potent inhibitors 
of enzyme activity (178). 1,25(OH)2D is the most potent stimulator of intestinal calcium ab-
sorption and renal reabsorption of calcium to increase serum calcium levels (176). In addition, 
it has been suggested that PTH has a direct effect on the intestine with regard to calcium ab-
sorption (179). The resulting increase in serum calcium levels stimulates bone mineralization 
(176). In addition to calcium, extracellular phosphate is necessary for matrix mineralization. 
The PTH/ 1,25(OH)2D axis regulates phosphate homeostasis as well. PTH inhibits phosphate 
reabsorption in the kidney whereas 1,25(OH)2D increases phosphate absorption in the small 
intestines (180). 
3.2.4 Central control of bone formation 
Recently, much interest has gone out to leptin and its effect on bone formation. Leptin is an 
endocrine factor synthesized mainly by adipocytes, and acts primarily in the hypothalamus, 
where the long form of the leptin receptor is expressed, to regulate body weight and fat 
mass through appetite suppression and increased energy expenditure (126,127,181,182). In 
ad libitum fed animals, leptin levels are positively correlated to body fat and adipocyte size 
(181). In addition to the effects on body weight and fat mass, leptin has an inhibitory effect 
on bone formation (127). For example, leptin deficient ob/ob mice are very obese, and have 
Chapter 1
32
high bone mass in spite of low levels of sex steroids and high corticosteroid concentrations 
(126,127,183). High bone mass with increased bone formation is also observed in leptin 
receptor-deficient mice as well as in leptin-deficient lean lipodystrophic mice which argues 
for a role of leptin signalling per se, rather than obesity, in the bone phenotype (126). Ob/
ob mice and leptin receptor deficient mice are the only known animal models with both 
hypogonadism and high bone mass (127). Unlike in mice, leptin deficiency cannot override 
bone loss due to estrogen deficiency in humans as illustrated by bone loss observed in an-
orexia nervosa patients or amenorrhoeic female athletes with both low levels of leptin and 
estrogens (126). 
When injected in the cerebral ventricles, leptin suppresses bone formation and reduces bone 
mass (126). In contrast, systemic administration of leptin reduces bone fragility (184). The 
latter effect could contribute to the high bone mass and low fracture rates observed in obese 
people (184). 
3.2.5 The GH/IGF axis 
The GH/IGF-I axis has an important role in the development and growth of the skeleton as 
well as in the maintenance of bone mass and bone density (185). For example, adults with 
GH deficiency display osteopenia, increased fat mass and decreased lean body mass (186). 
Growth hormone (GH) secretion by the pituitary is stimulated by growth hormone releasing 
hormone (GHRH) and inhibited by somatotropin release-inhibiting factor (SRIF or somatosta-
tin) from the hypothalamus. The effect of GHRH on GH secretion is potentiated by estrogen as 
well as glucocorticoids. GH can act directly on target tissues, but most prominently indirectly 
on several tissues via stimulation of IGF-I synthesis and secretion. In the liver, which is the 
main source of IGF-I, IGF-I synthesis is also regulated by insulin (187). Both GH and IGF-I act on 
target organs as bone and muscle. They stimulate development, growth, tissue regeneration 
and the metabolism of carbohydrates and lipids.
In bone IGF-I secretion is stimulated by GH, estrogens, PTH, 1,25(OH)2D and calcitionin (187). 
In addition, stored IGF-I is released from the bone matrix during bone resorption. Together 
with several other growth factors IGF-I stimulates the remodelling process in bone (187). IGF-I 
stimulates collagen synthesis, bone formation (especially periosteal apposition) as well as 
mineralization and inhibits collagen degradation (185,187). Reduced levels of autocrine or 
paracrine IGF-I are thought to play a role in the decline in remodelling and the pathogenesis 
of osteoporosis at old age (187). 
3.2.6 Micro-damage in bone
Low habitual strains maintain bone mass whereas increased strain stimulates bone forma-
tion and decreased strain is associated with bone loss (188). Over-loading of bone causes 
micro-damage in the bone matrix that is observed as micro-cracks, diffuse damage or 
micro-fractures (152,189). For example, significant levels of microdamage can be found in 
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the ribs of rowers (190) and the long bones of race horses (191). The effect of strain caused 
by physical activity on the bone could be due to repair of micro-damage (192). Furthermore, 
it is known that exercise can reduce bone resorption (192). The amount of micro-damage in 
both cortical and trabecular bone increases dramatically with increasing age (152,189). This 
accumulation of micro-damage is due to reduced remodelling and repair and thereby con-
tributes to a decrease in strength of bones with increased fracture risk (189,193). It has been 
shown that induction of damage in bone is associated with an increase in osteocyte death by 
apoptosis (137). Furthermore, a decrease in estrogen levels is accompanied by an increase in 
osteocyte apoptosis (139). Osteocyte apoptosis at the site of microdamage is likely to play a 
role in the targeting of repair although the specific signals have not yet been identified (137). 
One model suggests that actually all cortical bone remodelling is initiated by and in close 
proximity to micro-cracks (194). However, especially early in life, remodelling takes place 
while no microdamage is present. In contrast, others did not find micro-cracks in physiologi-
cally loaded bones and suggested that most of the previously observed cracks were due to 
preparation artefacts (134). Not surprisingly, micro-cracks are still a topic of much debate. In 
general, it is believed that evolvement of damage is prevented by repair of micro-cracks by 
resorption and by bone deposition in areas under high strain (195) and it can be envisaged 
that impaired repair of microcracks (with aging) can lead to reduced bone strength. 
3.3 Age-related bone loss 
Age-related bone loss in the human population is an area of broad interest due to the per-
sonal consequences of fractures for quality of life, the high morbidity as well as the budgetary 
implications for our health care system. The more so considering the aging of the population 
that will cause an increase in age-related diseases of which osteoporosis is a prominent 
example. Humans reach a peak bone mass at 23-35 years, after which bone is lost at a rate of 
about 0.4% per year due to incomplete filling of resorption holes. Women undergo two major 
phases of bone loss: a first phase of accelerated bone loss that begins at menopause and a 
second phase of slow, continuous bone loss. The first phase accounts for 20-30% of trabecu-
lar bone loss, but for only 5-10% of cortical bone loss (see Figure 6) (156). Trabecular bone 
loss is associated with increased bone resorption; both the number of remodelling units as 
the duration of the resorption phase are increased (156). The increase in resorption depth 
leads to trabecular plate perforation and loss of trabecular connectivity (156). This occurs 
at different rates at different skeletal sites. In cortical bone an increase in cortical porosity is 
observed. In the second phase, a slow decline in bone mass leads to overall losses of about 
20-25% in both cortical and trabecular bone (156). Men lack the early, accelerated phase of 
bone loss, but have a similar slow phase of bone loss (156). 
During aging, periosteal apposition i.e. bone formation on the outside of the bone (periost, 
see Figure 6), continues in both men and women, and this process partially preserves bone 
strength as the resistance of bone to bending or torsional forces is exponentially related to its 
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diameter (156,165,196). Men have more prominent periosteal apposition (197). Nevertheless 
both men and women are subject to age-related bone loss, increase in bone fragility, and 
susceptibility to fracture.
The introduction of high resolution quantitative computed tomography (QCT) made it pos-
sible to asses age-related changes in more detail (198-201). Riggs et al. used this technique to 
study age-related changes in volumetric bone mineral density (vBMD), geometry, and bone 
microstructure in the spine, femur neck, distal radius, and distal tibia in a large population of 
men (n=323) and women (n=373) aged 20 to 97 yr (171). They observed large decreases in 
vBMD at all these sites with aging. The decreases in trabecular vBMD were somewhat smaller 
in men (approximately 46%) compared to women (approximately 55%) at central sites, but 
were similar (24% and 26%) at peripheral sites. A small midlife acceleration in the slope of the 
decrease in women accounted for much of the significantly greater decrease in trabecular 
vBMD at the spine. In contrast, the cortical vBMD at the radius, the distal tibia and femur 
neck showed little change until midlife in either men or women. Thereafter, cortical vBMD 
decreased in both sexes, but the decreases were greater in women (25%) than in men (18%) 
consistent with menopausal-induced increases in bone turnover and porosity. In addition, 
aging was associated with increases in bone cross-sectional area at various sites due to 
continued periosteal apposition throughout life. However, the cortical area and thickness 
decreased as endocortical resorption increased even more than periosteal apposition. The 
decrease in bone strength resulting from decreased cortical area was partially offset by the 
outward displacement of the cortex, which increases the strength of bone to bending stress-
es. The same group studied the microstructure of the forearm and found that men had 28% 
thicker trabeculae in young adulthood resulting in a 26% greater trabecular bone volume/
total volume (BV/TV) (202). BV/TV decreased similarly in women (−27%) and in men (−26%) 
with aging (202). However, whereas women showed significant decrease in trabecular num-
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Figure 6: Tibia showing different areas of the long bone. 
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ber and increase in trabecular spacing, men showed little net change in these parameters, 
but a greater decrease in trabecular thickness than women. These findings are very similar 
to earlier studies by Aaron et al. using cadaveric transiliac bone biopsies (203). This suggests 
that the pattern of changes in trabecular bone may be similar at multiple skeletal sites. In 
addition, these data suggest that whereas decreases with age in trabecular BV/TV are similar 
in men and women, the structural basis for the decrease in trabecular volume might be dif-
ferent between the sexes. It has been shown that decrease in trabecular number, leading to 
loss in connectivity, has a much greater impact on bone strength compared to decreases in 
trabecular thickness (204), which may help explain the higher risk of fractures in women. In 
a recent study part of these cross-sectional findings were confirmed by longitudinal data, 
which showed significant trabecular bone loss at the spine, distal radius, and distal tibia 
before midlife in men, whereas cortical vBMD remained relatively stable until age 65–70 yr, 
with loss of cortical bone thereafter (205). Thus, trabecular bone loss begins in young adult 
life in both sexes whereas cortical bone loss begins after midlife, with overall decreases in 
vBMD being smaller in men compared to women. 
The cellular basis of age-related bone loss as well as osteoporosis is an imbalance in bone 
remodelling where bone resorption exceeds bone formation (141). With aging, the process 
of coupled bone formation is affected by the reduction of osteoblast differentiation, activity, 
and life span, which is due to a higher frequency of apoptosis (125). As the trabecular volume 
decreases, the adiposity in bone marrow increases and osteoblast development decreases 
(see paragraph on osteoblasts and sex steroids) (125). In perimenopausal women, the imbal-
ance is further potentiated by hormone deprivation and increased osteoclast activity (see 
also paragraph on sex steroids) (125). Next to the decline in osteoblast function and hormone 
secretion, age-related abnormalities in calcium homeostasis and vitamin D metabolism as 
well as inadequate intake of vitamin D and calcium cause bone loss in subsets of the aging 
population (156).
3.4 Bone aging in mice
In recent years age-related bone loss has been studied in mice as well. Already in 1987 a study 
on bone aging in wild type mice was published. Silbermann and co-workers measured a 
decrease in cortical thickness and a larger width of the total midshaft as well as the medullary 
diameter in femurs of 28-months-old female C57BL/6 mice compared to 7-months-old mice 
(206). In addition, they observed cortical porosity and a decrease in number of osteocytes as 
well as preosteoblasts along the periosteum. Moreover, these preosteoblasts seemed to have 
lower proliferative capacity. A few years later, Weiss and co-workers studied the femurs of CW-1 
female mice over a broad age-range while Bar-Shira-Maymon and co-workers studied the lum-
bar vertebrae of these mice. It was observed that as in humans, the pattern of age-related bone 
loss differs at different skeletal sites (207-210). A study in healthy women showed that bone 
mineral content in the lumbar vertebrae decreased mainly during menopause whereas bone 
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mineral content in the femoral neck decreased from young adulthood to old age and the femo-
ral shaft remained nearly unaltered until the seventh decade after which bone mineral content 
declined significantly (210). Another study showed progressive age-related loss of trabecular 
bone and the development of marrow-filled cavities within cortical bone in proximal femurs 
whereas the lumbar vertebrae only showed a reduction in number and size of trabeculae. 
Recently, several studies on bone development and aging in mostly male C57BL/6 mice were 
published (143,211-213). Using microcomputed tomography (μCT) age-related changes 
in tibiae of male C57BL/6 mice between 1,5 and 24 months of age were studied (211). A 
decrease in trabecular bone characterized by decreased trabecular number, decreased con-
nectivity and increased trabecular spacing was observed. Cortical bone thickness decreased 
after 6 months of age whereas cortical bone area remained constant. Using histomorphom-
etry and mechanical testing, the long bones of these aging male C57BL/6 mice were also 
found to exhibit excessive endocortical resorption and an increase in periosteal apposition 
but also reduced mechanical strength (212). In addition, 6- and 24- month-old C57BL/6 
mice showed increased expression of RANKL and decreased expression of OPG in total bone 
extracts compared to 6 week old C57BL/6 mice (143). This would be expected to stimulate 
bone turnover and promote bone loss, which was indeed observed (143). In addition, these 
changes were shown to be accompanied by an increase in osteoclast progenitor pool (143). 
This age-associated increase in osteoclast progenitor pool and osteoclast formation was pre-
viously studied in 4-6 and 24 month old mice (214). A 20-30% increase in hematopoietic cells 
obtained from long bones and a 2-3.5-fold increase in macrophage/mononuclear colonies 
in bone marrow cultures from the aged animals was observed. However, others showed that 
the functionality of the formed osteoclasts was lower as established by a decrease in bone 
degradation capacity (214). 
3.4.1 Differences in bone metabolism between different mouse strains
It has been established that there are large differences in bone mass between different mouse 
strains as well as between different skeletal sites. For example, C57BL/6 mice that are widely 
used have low bone density in long bones and intermediate bone mass in vertebrae. C3H/
HeJ mice with a similar body size and adult weight have 53% higher peak bone density in the 
femora, but have about half the number of trabeculae in the vertebral bodies (215,216). In 
addition, the pattern of response to mechanical loading differs. It was shown that C57BL/6 
mice are more sensitive to endosteal bone loss from hind-limb immobilization than C3H/HeJ 
mice (215). Furthermore, C57BL/6 mice display significantly more endosteal and periosteal 
bone formation after loading (217). These strains also differ in calcium metabolism, i.e. at 
low dietary calcium levels, C57BL/6 mice rely more on mobilization of calcium from bone to 
maintain extracellular calcium homeostasis than C3H/HeJ mice (218). The effect of ovariec-
tomy on calcium metabolism is also stronger in C57BL/6 mice compared to C3H/HeJ mice. 
After ovariectomy, C57BL/6 mice show significantly decreased calcium absorption and thus 
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more calcium in the faeces than non-treated C57BL/6 mice (219). In this regard, C57BL/6 mice 
are comparable to hypoestrogenic women (219). In addition, the effect of ovariectomy on 
trabecular bone varies with mouse strain as well as with skeletal site. Trabecular bone volume 
(BV/TV) in vertebrae and femora declined after ovariectomy in BALB/cByJ, C57BL/6J, CAST/EiJ 
and DBA/2J mice, but not in C3H/HeJ mice (220). In contrast, at the proximal tibia, C3H/HeJ 
mice had a greater decline in trabecular BV/TV (-39%) than C57BL/6J (-18%), DBA2/J (-23%), 
and CAST/EiJ mice (-21%) (220). Ovariectomy induced declines in cortical bone properties, 
but in contrast to trabecular bone, the effect of ovariectomy did not vary by mouse strain 
(220). The extent of trabecular bone loss after ovariectomy was greatest in BALB/c mice, 
which had the highest vertebral trabecular bone volume at baseline (220). In contrast to 
cortical bone loss, trabecular bone loss thus seems to be partly genetically regulated. 
In humans, bodyweight has an important effect on bone mineral density whereas this relation 
seems to be lacking in mice. No correlation between body weight and femoral or vertebral 
parameters was found in 11 inbred strains although body weight varied by 86% among the 
strains (221). C57BL/6J and A/J mice showed differences in bone mass although they were 
similar in body weight; overall C57BL/6J animals had higher bone mass in both femur and 
tibia (222). Moreover, Jepsen et al. found that A/J femurs were more brittle than C57BL/6J 
femurs (223). This was explained by the fact that A/J mice had more slender femurs which 
was compensated by increased tissue stiffness which ultimately led to increased fragility. 
Additional differences between A/J, C57BL/6J and C3H/HeJ mice were observed in vertebrae 
(224). A/J mice had slender axial and appendicular bones with a high mineral content whereas 
C57BL/6J mice had wider bones with a lower mineral content. The vertebrae of these mice 
had a similar stiffness, but different failure modes with C57BL/6J again being more ductile. 
C3H/HeJ femora and vertebrae showed a greater cortical area and mineral content and thus 
an increased stiffness and fragility. In addition, the architecture of the trabeculae seemed 
to be coupled to the amount of mineral within the tissue suggesting that these multiple 
physical traits that explain the genetic variation in whole bone mechanical properties might 
be co-ordinately regulated. When compared to five other mouse strains, the widely used 
C57BL/6J mice seem to have an intermediate bone phenotype. 
4 Scope of this thesis
Nucleotide excision repair deficient TTD mice display many features of the human syndrome 
and exhibit signs of segmental premature aging, including skeletal abnormalities. In order 
to gain insight in the aetiology of premature aging and associated pathology in DNA repair 
disorders, we set out to extensively analyse the bone phenotype of TTD mice in relation to 
age. In chapter 2 we describe the age-related changes in the structure of long bones of wild 
type and TTD female mice by microCT and histomorphometric analysis, mechanical test-
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ing, as well as by characterizing osteoprogenitor cells in bone marrow cultures. In chapter 
3 we extend this study to male wild type and TTD mice to address the question whether 
the TTD bone phenotype is subject to gender differences. In chapter 4 we describe the 
aging-associated changes in the vertebrae of female TTD mice. Finally, chapter 5 addresses 
whether aging-associated changes in endocrine parameters that relate to bone metabolism 
are altered in TTD mice. 
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Abstract 
Trichothiodystrophy (TTD) is a rare, autosomal recessive Nucleotide Excision Repair (NER) 
disorder caused by mutations in components of the dual functional NER/basal transcription 
factor TFIIH. TTD mice, carrying a patient-based point mutation in the Xpd gene, strikingly re-
semble many features of the human syndrome and exhibit signs of premature aging. Here we 
show that female TTD mice exhibit accelerated bone aging from 39 weeks onwards as well as 
lack of periosteal apposition leading to reduced bone strength. Prior to 39 weeks long bones 
of wild type and TTD mice are identical excluding a developmental defect. Albeit that bone 
formation is decreased, osteoblasts in TTD mice retain bone-forming capacity as in vivo PTH 
treatment leads to increased cortical thickness. In vitro bone marrow cell cultures showed 
that TTD osteoprogenitors retain the capacity to differentiate into osteoblasts. However, 
after 13 weeks of age TTD females show decreased bone nodule formation. No differences 
in osteoclasts or bone resorption were detected. In conclusion, TTD mice show premature 
bone aging, which is preceded by a decrease in mesenchymal stem cells/ osteoprogenitors 
and a change in systemic factors, identifying DNA damage and repair as key determinants for 
osteoporosis by influencing osteogenesis and bone metabolism. 
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Introduction 
TTD is a rare, autosomal recessive DNA repair disorder in which patients present an array 
of symptoms, including photosensitivity, ichthyosis, brittle hair and nails (hallmark feature), 
impaired intelligence, decreased fertility, short stature and a severely reduced life span (1-3). 
In addition, skeletal abnormalities have been described (2,4-11). A significant proportion of 
TTD patients also exhibit marked photosensitivity, due to impaired repair of UV-induced DNA 
lesions. Complementation analysis of UV-sensitive TTD patients revealed the involvement of 
three genes (XPB, XPD and TTDA), encoding subunits of the dual functional DNA repair/basal 
transcription factor TFIIH (12). This 10-subunit protein complex is involved in the Nucleotide 
Excision Repair (NER) pathway, as well as in the initiation of transcription by RNA polymerases 
I and II (13-17). NER consists of a complex ‘cut and patch’ type reaction involving ~30 proteins 
and is comprised of 2 sub-pathways, differing in the initial steps of DNA damage recognition. 
Global genome NER removes a wide class of helix-distorting DNA damage (e.g. UV-induced 
photoproducts) from the overall genome. This pathway is primarily important for preventing 
DNA damage-induced mutations and thereby for preventing cancer. The second sub-path-
way called transcription-coupled NER focuses on the preferential excision of lesions in the 
transcribed strand of active genes that actually block transcription elongation, to allow rapid 
resumption of arrested gene expression and thereby promoting cell survival after genotoxic 
stress (18,19). This sub-pathway is thought to counteract the cytotoxic consequences of DNA 
damage. TFIIH is as DNA helix opener implicated in both NER sub-pathways as well as in 
transcription initiation by promoter opening to allow the RNA polymerase to get hold of the 
transcribed strand for transcription elongation. 
We have generated a mouse model in which we precisely mimicked a causative point 
mutation in the essential XPD gene of a TTD patient (TTD1BEL, mutation at the protein 
level R722W) (20). TTD mice have a phenotype that strikingly resembles the symptoms of TTD 
patients and they were found to exhibit several premature aging-like features. Although 
TTD was not recognized as a segmental premature aging syndrome, some of the features 
observed in the mouse model were also incidentally reported in patients: deterioration of 
renal, liver and heart tissues, lymphoid depletion, reduced hypodermal fat, aortic sarcopenia, 
skeletal abnormalities and an (in patients strongly, in mice moderately) reduced life span 
(4-11,21-23). For instance, Price and co-workers reported a patient who at the age of 7 years 
showed decreased bone density in the distal bones on roentgenographic examination (10). 
Chapman reported a 5-year old child who exhibited decreased bone density in the distal 
limbs and osteopenia in the most distal parts (9). 
In postmenopausal women, accelerated loss of predominantly trabecular bone, due to 
increased number and activity of osteoclasts, is followed by a slow continuous phase of 
decrease in bone mass in which the density of trabecular bone reduces and cortical bone 
thins, leading to an increased fracture risk (24-28). This is partly counteracted by increased 
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periosteal apposition (29), i.e. bone formation on the outside of the bone (periosteum), a 
critical process that continues throughout life (26,27,30). Periosteal apposition is thought to 
be a response to the loss of trabecular bone as well as endosteal resorption and aims to 
maintain bone strength by increasing the bone perimeter (31). The mechanisms underlying 
these age-related changes are poorly understood. 
To assess the contribution of deficiencies in DNA repair/basal transcription in skeletal 
aging and to determine to which extent the progeroid features in the mouse and human 
disorder truly reflect bona fide aging we decided to thoroughly examine the skeletal aging 
as this process has been amply characterized in normal aging. The TTD mouse model may 
provide a unique tool to study aging and bone metabolism and to assess the impact of DNA 
repair on skeletal aging. 
Materials & Methods 
Mice and bones
The cohort of wild type and TTD female mice included 8 animals per age group per genotype. 
Mice were sacrificed at 13-week intervals up to an age of 104 and 78 weeks for wild type and 
TTD mice respectively. All mice were on a C57BL/6J background, maintained on a 12:12 h 
light-dark cycle and fed ad libitum with ‘rat and mouse breeder and grower diet’ from Special 
Diet’s Services (minimal 0.5% Ca and 0.3% Pi). The animals were injected intra-peritoneal with 
calcein (10 μg /g body weight) 10 and 3 days before sacrifice in order to study the bone 
formation occurring in one week. After anaesthetization with isoflurane, blood was collected 
by an orbital puncture; subsequently the mice were killed by cervical dislocation. Femurs 
and tibiae were isolated and were either snap frozen in liquid nitrogen and stored at -80ºC 
or fixed in Burkhardt, which was replaced by 70% ethanol after 3 days. As required by Dutch 
law, formal permission to generate and use genetically modified animals was obtained from 
the responsible local and national authorities. All animal studies were approved by an inde-
pendent Animal Ethical Committee (Dutch equivalent of the IACUC).
Micro-computed tomography 
Fixed tibiae from wild type and TTD mice of different ages (n = 4-6 per group) were scanned 
by micro-computed tomography (μCT) from proximal end to mid-diaphysis using the 
SkyScan 1072 microtomograph (SkyScan, Antwerp, Belgium) with a voxel size of 8.82 μm. 
The reconstructed data sets were segmented using an automated algorithm based on local 
thresholds (32). Three-dimensional (3D) morphometric analysis of the bone was performed 
using freely available software of the 3D-Calculator project (http://www.erasmusmc.nl/or-
thopaedie/research/labor/downloads). For all mice a standardized metaphyseal – diaphyseal 
area (3.7-6.9 mm from the proximal end; Figure 1) was selected for analysis. This area mainly 
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consists of cortical bone and to a much lesser extent of trabecular bone. This precluded 
reliable analyses of trabecular bone parameters separately. The parameter bone volume we 
present reflects mainly cortical bone including the few trabeculae present. In addition, 3D 
thickness distribution (33), cortical thickness, periosteal perimeter and endocortical volume 
were determined. Polar moment of inertia (measure of the geometrical distribution and a 
proxy for mechanical stiffness and strength per transverse cross-section) was determined to 
analyse the consequence of differences in geometry. 
Histomorphometric analysis
To assess dynamic histomorphometric indices, mice received intraperitoneal injections 
with calcein 10 days and 3 days prior to sacrifice. One tibia of each mouse was dehydrated 
in ascending alcohol concentrations and embedded in poly-methylmetacrylate (PMMA) 
as described previously (34). Sections of 5 µm were cut in the sagittal plane on a Microtec 
rotation microtome (Techno-Med GmbH, Munich, Germany) and stained by toluidine blue, 
van Gieson/von Kossa and Giemsa procedures as described (34). Parameters of static and 
dynamic histomorphometry were quantified on these undecalcified proximal tibia sections. 
Osteocyte numbers were counted and expressed per bone area (per mm2) according to stan-
dardized protocols (35) using the OsteoMeasure histomorphometry system (Osteometrics 
Inc., Atlanta, Georgia, USA). For each animal, the bone formation rate was determined by 
fluorochrome (calcein) measurements using two non-consecutive 12µm-sections per animal. 
Figure 1
Figure 1: Area of interest for micro-computed tomography analyses. 
360 sections of 8,82 μm were analysed in the metaphyseal-diaphyseal area of tibiae from the aging-cohort of wild type and TTD mice. 
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Mechanical testing 
Defrosted femurs from 13, 26, 52 and 78-week old wild type and TTD females as well as 
from 104-week-old wild type females (5-8 mice/group) were excised from the soft tissues. 
Femurs were tested in a three-point bending assay using a Lloyd LRX mechanical test frame, 
constructed with 3mm hemi-cylindrical supports with a 9 mm total span. The femurs were 
aligned such that the neutral axis was parallel to the sagittal plane (i.e. the femoral head 
was in the horizontal plane and the posterior aspect of the condyles were facing down). The 
lesser trochanter was used as a reference point and aligned with one of the two supports. All 
samples were preconditioned for 5 cycles to 2N at a rate of 0.01 mm/s before testing to failure 
at a rate of 0.02mm/s. 
Backscatter Scanning Electron Microscopy
Processing and analyses were done as described previously (36). In short, from each group 
(i.e. 26, 52 and 78-week-old wild type and TTD mice) the distal halves of the femurs used 
for mechanical testing were embedded in blocks of MMA, such that each block contained 
one distal femur from each genotype and age group. Within a block, all femurs were placed 
within a plane, such that the longitudinal lateral-medial plane of the femurs coincided with 
the plane of embedding. Embedding several samples in one block enabled us to image these 
samples within one scanning electron microscopy (SEM) session, thus decreasing the vari-
ance in the measurements. 
After embedding, the blocks were cut in two on an electric band saw (Exakt, Norderstedt, 
Germany), resulting in a slab of plastic with two parallel surfaces, parallel to the plane of em-
bedding of the femurs. Starting from the posterior side of the bones, material was removed 
using an automatic grinding system (Buehler Phoenix 4000) with p400 grid paper until an 
interior surface, halfway between the ventral and dorsal external surfaces, was exposed. To 
reduce the roughness of the surface the blocks were ground with p1200 paper followed by 
polishing using 3 mm diamond paste with polishing paper (Buehler Texmet 1000). The result-
ing surface had a roughness (Ra) smaller than 0.05 mm. The blocks were cleaned, sonicated 
and sputter coated with a thin layer of carbon (Bio-Rad Temcarb Carbon Coater, Bio-Rad 
Microscience Division) to enable conduction of the electron beam to the sample surface.
Backscatter SEM images were taken of trabecular bone of the metaphyseal and epiphyseal 
regions of each bone sample, and of the cortex using methods described in detail previ-
ously (36). The images were taken at an accelerating voltage of 25 kV, a working distance of 
17 mm and 50x magnification. Before and after imaging calibration images were taken of 
an aluminum standard embedded in each block and of the MMA material. The equivalent 
Z-value (atomic number) of the MMA was obtained by calibration with aluminum (Z=13) and 
carbon (Z=6) standards (Micro Analysis Consultants).
From each image the histogram of equivalent Z-values was calculated of which the mean 
value represented the mean mineralization of the bone tissue (37).
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Tartrate-resistant acid phosphatase assay
Bone resorption was determined by measuring serum tartrate resistant acid phosphatase 
(TRAP) levels using the TRAP assay purchased from SBA Sciences (Turku, Finland).
Bone marrow isolation, cell culture and cell culture staining 
Bone marrow was collected by spinning down the bone marrow into an eppendorf tube at 
5000rpm for 2 min. Erythrocytes were lysed using erylysis buffer (1.55M NH4Cl, 0.1M KHCO3, 
1mM EDTA (10x)) and cells were washed and seeded at 1.000.000 cells/well (12 wells) for 
osteoblasts, 100.000 cells/well (96 wells) for osteoclasts and 750.000 cells/well, for adipocytes 
(24 wells). Cells were cultured at 37°C and 5% CO2 in a humidified atmosphere in either 
osteogenic (a-MEM (GIBCO, Paisley, UK) supplemented with P/S, 1.8 mM CaCl2 (Sigma), 
Amphotericin B (250 ng/ml,Sigma) and 15% heat-inactivated FCS (GIBCO)), osteoclastogenic 
(MEM (GIBCO, Paisley, UK) supplemented with P/S, amphotericin B (250 ng/ml, Sigma) and 
10% heat-inactivated FCS (GIBCO)) or adipogenic (D-MEM (GIBCO, Paisley, UK) supplemented 
with P/S, amphotericin B (250 ng/ml,Sigma) and 15% heat-inactivated FCS (GIBCO)) medium. 
Addition of b-Glycerophosphate (10mM) and Vitamin C (50 mM) from day 3 onwards induced 
osteoblast differentiation. Osteoclast differentiation was induced by adding RANK-L (20ng/ml, 
R&D systems) and M-SCF (30ng/ml, R&D systems) to the medium starting at day 0. Osteoclast 
cultures on plastic or bone slices were cultured for 6 days. Adipogenesis was induced after 
a 3-week expansion phase by adding insulin (0.1mg/ml, Sigma), indomethacin (1mM, Sigma) 
and dexamethasone (1*10-7M, Sigma) to the adipogenic medium for another two weeks.
In osteogenic condition bone nodule formation was measured as parameter of mesenchymal 
stem cell number and bone forming capacity after 14 days of cultures. At day 14 cultures 
were stopped by washing with PBS, fixated in 70% EtOH for 10 min., rinsed in 0.2MTris-HCl 
(pH 9.5) and stained using NBT (100mg/ml) and BCIP (10mg/ml) diluted in Tris-HCl with MgCl2 
in order to detect alkaline phosphatase as measure for bone nodule formation. Colonies were 
counted by eye and colony surface area was determined by computer analysis (Bioquant 
software). The reaction was followed by eye and stopped by washing with PBS. In order to 
detect mineralisation after 21 days osteoblast cultures were washed with PBS, fixed with cold 
70% EtOH O/N at 4°C and stained in a saturated Alizarin Red Solution (Alizarin Red S (Sigma) 
in H2O pH 4.2). After staining cells were washed with H2O. Alizarin Red staining was then 
extracted from the cultures and measured on a plate reader at 405 nm.
Osteoclast cultures were washed in PBS, fixated for 10 min. in 10% formaline and washed 
with warm H2O before they were stained for 30 min. using the Sigma Acid phosphatase 
leukocyte kit (Sigma), using a 1M Tartrate stocksolution instead of the solution supplied by 
the kit in order to detect TRAP-positive cells. Washing the cells with PBS stopped the reaction. 
Cultures were photographed and the number of TRAP-positive cells per photograph was 
determined. Mature osteoclasts were defined as TRAP-positive cells with more than 2 nuclei. 
Resorption pits on bone slices were visualised by staining them with Coomassie solution 
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(Phast Gel Blue R tablet, Coomassie R350). Slices were photographed and the resorption area 
was determined by computational analysis (Image J).
Adipocyte cultures were fixated O/N with 10% formaline, washed with 60% IPOH and stained 
with Oil-Red O solution (60-40 dilution of Oil-Red O stock solution (Clin-Tech limited) in H2O) 
after which the total amount of adipocytes per well was determined.
PTH treatment
Twenty TTD females were weighed at the age of 45 weeks and randomly divided into the 
following two groups (n=10 per group): subcutaneous injection with human parathyroid 
hormone(1-34) (Bachem, Germany) (40 µg/kg body weight) in a weekly alternating regimen 
(PTH); or subcutaneous injection with phosphate buffered saline in a weekly alternating regi-
men (VEH). Animals were weighed at the start of every injection week. At 65 weeks of age 
animals were sacrificed and femurs were prepared for µCT scanning. 
Statistics 
Micro-CT parameters, histomorphometric data, femur length, ultimate load, bone resorption 
data and parameters of cell culture analyses were compared between the age groups (sig-
nificance compared to 13 or 26 weeks of age) of both genotypes separately using one-way 
ANOVAs with Tukey post-hoc test (Graph Pad InStat version 3.05: Graph Pad Software, San 
Diego California, USA, www.graphpad.com). In addition, the micro-CT parameters, histo-
morphometric data, femur length, ultimate load, bone resorption data, and parameters of 
cell culture analyses were compared between genotypes for all age groups separately using 
unpaired t-tests. For comparisons of the mineralization data between genotypes unpaired 
t-tests were performed. The P-values of the unpaired t-test are two-tailed. 
Results 
To study the bone phenotype in normal and premature aging female TTD mice, we per-
formed a systematic cohort study including 8 mice per age group per genotype. A previous 
study, performed on a hybrid C57BL/6J 129ola genetic background, showed that TTD mice 
live shorter than wild type mice (21). In a homogeneous C57Bl/6 genetic background we 
were able to analyse 13, 26, 39, 52, 65 and 78 weeks-old wild type and TTD mice. For wild type 
control mice we could in addition analyse 91 and 104 weeks old mice. 
Bone geometry 
First, 3D thickness distribution was analysed using micro-computed tomography (μCT). In 
tibiae from wild type mice, a gradual progressive decline in 3D thickness distribution was ob-
served with age (Figure 2A). In TTD mice this process was accelerated with a severe decrease 
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in 3D thickness distribution after 39 weeks of age (Figure 2B). Already at 52 weeks of age, 3D 
thickness distribution in TTD tibiae reached a level that in wild type mice was only reached at 
91 weeks of age (Figure 2C). Thus age-related decrease in bone mass occurred earlier in TTD 
mice than in wild type mice.
To study this difference in onset of decrease in bone mass in more detail, we analysed 
specific µCT parameters. In wild type mice, bone volume gradually decreased with age, only 
reaching significance at 104 weeks of age at which time a 12% decrease in bone volume com-
pared to 26-week-old wild type bones was observed (Figure 2D). At 26 and 39 weeks of age, 
tibiae of TTD mice had a bone volume similar to that of wild type mice (Figure 2D). However, 
in the period thereafter, bone volume rapidly decreased to 31% (78-week-old TTD mice drop-
ping to 69% of the bone volume of 26-week-old TTD mice), which was significantly lower 
than the 9% decline in age-matched wild type mice at 78 weeks of age (Figure 2D). Already at 
52 weeks of age TTD mice reached a bone volume comparable to that of 104-week-old wild 
Figure 2
wt 91w
TTD 52w
Figure 2: Thickness distribution and bone parameters in wild type and TTD mice. 
Cortical thickness distribution in aging wild type (A) and TTD mice (B) with the arrow indicating the direction of change with aging. Comparison 
of thickness distribution in 52-week-old TTD mice (dotted line) compared to 91-week-old wild type mice (solid line) (C). Bone parameters 
in aging wild type mice (solid triangles) and TTD mice (open triangles): bone volume (D), cortical thickness (E) and perimeter (F). TTD mice 
compared to wild type animals: # p<0.05, ## p<0.01, ### p<0.001; TTD mice and wild type animals compared to their 26 week time point: * 
p<0.05, ** p<0.01, *** p<0.001; error bars represent SEM. 
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type mice (Figure 2D). In line with bone volume, wild type tibiae maintained their cortical 
thickness up to 78 weeks of age and showed a decrease thereafter while TTD tibiae already 
displayed a rapid drop in cortical thickness after 39 weeks of age (Figure 2E). 
Next, we analysed the bone perimeter. As depicted in Figure 2F, tibiae from young mice 
had a similar perimeter (at 26-weeks: 5,80 mm in wild type and 5,96 mm in TTD mice), again 
indicating normal bone development in TTD mice. From 52 weeks onwards, wild type tibiae 
showed a progressive increase in perimeter reaching 6,33 mm at 78 weeks (9 % increase) 
and 6,78 mm at 104 weeks (17% increase). In contrast, TTD mice failed to show an increase in 
perimeter (5,88 mm at 78 weeks). In 78 week-old wild type mice the perimeter is significantly 
higher compared to TTD mice (Figure 2F). Thus, TTD mice lack the age-related increase in 
perimeter as seen in wild type tibiae (Figure 2F). 
The endocortical volume was larger in TTD than in wild type mice in the early phase of life 
but later in life endocortical volume in wild type mice increased and becomes equal to that of 
TTD mice (data not shown). The temporal dynamics in endocortical volume in wild type mice, 
showing an increase after 52 weeks, match that observed for perimeter, showing an increase 
from 52 weeks of age onwards (data not shown). However, periosteal apposition could no 
longer match the endocortical bone loss in wild type mice after 78 weeks of age leading to a 
decrease in cortical thickness (Figure 2E).
Histomorphometric analysis of bone
In order to analyse the lack of periosteal expansion in TTD mice in more detail, we examined 
endosteal and periosteal bone apposition by double labelling studies. In wild type mice 
both periosteal and endosteal bone formation were present throughout life (Figure 3A). In 
contrast, in TTD mice endosteal apposition was present whereas periosteal apposition was 
virtually absent in older TTD mice (Figure 3A). Quantitative analyses revealed no significant 
difference in endosteal bone formation between 13-week old wild type and TTD mice (Figure 
3B). At 39 weeks of age, endosteal bone formation was significantly decreased in TTD mice 
compared to wild type mice, but after 39 weeks of age endosteal bone formation decreased 
in wild type mice as well (Figure 3B). At 78 weeks of age, wild type and TTD mice showed a 
20-25% decrease in endosteal bone formation when compared to 13-week-old animals. At 13 
weeks of age, periosteal apposition showed no significant difference between wild type and 
TTD mice (Figure 3C). However, after 13 weeks of age, TTD mice showed a dramatic and sig-
nificant decrease in periosteal apposition compared to wild type mice (Figure 3C). Only at 78 
weeks of age, when periosteal apposition in wild type mice decreased as well, there was no 
significant difference compared to TTD mice anymore (Figure 3C). At that time, however, TTD 
mice exhibited a 60% decrease in periosteal apposition compared to a 25% decrease in wild 
type mice when compared to 13-week-old animals. Osteocytes in cortical sections of tibiae 
of wild type and TTD mice were measured to assess whether a reduced number of osteocytes 
in TTD mice could play a role in impaired periosteal apposition. However, no significant dif-
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ference in the number of osteocytes was found between wild type and TTD mice or in aging 
animals (data not shown). Quantitative Backscatter Scanning Electron Microscopy on femurs 
A
Figure 3
Figure 3: Histomorphometric analysis of cortical bone and Backscatter Scanning Electron 
Microscopy of wild type and TTD mice. 
Calcein double labeling of endosteal and periosteal bone formation in wild type and TTD mice (A). Quantified endosteal apposition (B), 
quantified periosteal apposition (C) and mineralization status (D) in wild type (solid symbols) and TTD (open symbols) mice. TTD mice compared 
to wild type mice: # p<0.05, ### p<0.001; TTD mice compared to their 13 week time point: * p<0.05, ** p<0.01; error bars represent SEM. 
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of wild type and TTD mice demonstrated no significant difference in mineralization of the 
cortex between genotypes or with aging (Figure 3D). 
Mechanical testing of bone strength 
The overall picture that emerges is that compared to wild type mice, aging TTD mice show 
an accelerated decrease in bone mass, which initiated between weeks 39 and 52, and that 
TTD mice lack the age-related increase in perimeter. To analyse the consequence of these 
geometric changes, we calculated the polar moment of inertia, which is a measure of the 
geometrical distribution and a proxy for mechanical stiffness and strength per transversal 
cross-section. This demonstrated that tibiae from wild type mice maintained polar moment 
of inertia at a constant level throughout life, even at 91 and 104 weeks of age when bone 
volume and cortical thickness were reduced (Figure 4A). In contrast, TTD tibiae failed to main-
tain the polar moment of inertia and even showed a progressive decrease throughout life 
starting at 39 weeks of age (Figure 4A), i.e. 78-week old TTD mice showed a 65% decrease in 
moment of inertia compared to 39-week old TTD mice whereas the moment of inertia in 78-
week old wild type mice showed a 106% increase compared to 39-week old wild type mice. 
Using a three-point bending assay, we tested whether the differences in polar moment of 
inertia and lack of periosteal apposition in TTD mice resulted in a difference in bone strength. 
Femurs from wild type and TTD mice showed a comparable and increasing ultimate fracture 
load up to 26 weeks of age (Figure 4B). After 26 weeks there was a progressive decrease in 
ultimate fracture load in both genotypes but this was clearly more prominent and significant 
in TTD mice showing a 50% decline compared to a 25% decline in wild type mice (Figure 4B). 
Femurs of TTD mice fractured at a lower ultimate load than femurs of wild type mice, which 
reached significance in 52 and 78 weeks old animals. 
Bone resorption 
In wild type and TTD mice the levels of tartrate resistant acid phosphatase (TRAP) were 
measured to assess whether differences in bone resorption could explain the observed mor-
phometric differences. As expected, bone resorption seemed to increase with aging in both 
wild type and TTD mice (Figure 4C). In addition, TTD seemed to have higher levels of TRAP. 
However, no significant differences were observed between genotypes or with age. 
Bone marrow cell cultures 
To assess whether the differences in bone phenotype in TTD mice are due to an impaired 
osteoblast and/or osteoclast differentiation we performed bone marrow cultures and as-
sessed the capacity to form osteoblasts and adipocytes from mesenchymal stem cells as well 
as osteoclasts from hematopoietic stem cells for wild type and TTD mice of various ages. The 
number of TRAP-positive osteoclasts was similar in 13-weeks-old wild type and TTD cultures 
(Figure 5A). In the following period wild type but not TTD mice showed a significant decline 
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in the number of osteoclasts resulting in a significant higher number of osteoclasts at 26 
weeks of age in TTD mice. At later ages the number of osteoclasts was similar in wild type and 
TTD mice (Figure 5A). The amount of resorption by mature osteoclasts was not significantly 
different between wild type and TTD (Figure 5B). At 13 weeks of age, the number of bone 
nodules was similar for wild type and TTD mice (Figure 5C). However, the number of bone 
nodules in TTD mice showed a rapid decline resulting in significantly lower numbers of bone 
nodules at 26 and 39 weeks of age compared to wild type mice (Figure 5C). Subsequently, 
the number of bone nodules in wild type mice also declined resulting in similar numbers as 
in 45-week old TTD mice (Figure 5C). There was no significant difference in bone nodule size 
Figure 4Figure 4: Mechanical testing and TRAP assay in wild type and TTD mice. Polar moment of inertia in tibiae (A), ultimate load applied on femurs (B) and serum TRAP levels (C) of wild type (solid symbols) and TTD (open 
symbols) mice. TTD mice compared to wild type animals: # p<0.05, ### p<0.001; TTD and wild type mice compared to their 26 week time 
point: * p<0.05, *** p<0.001; error bars represent SEM. 
65
Osteoporosis and decline in stem cells in TTD mice
between wild type and TTD mice at any age (Figure 5D). Both wild type and TTD nodules 
mineralized but no significant differences between the genotypes could be detected at any 
age (data not shown). Similarly, both wild type and TTD mice were able to form adipocytes 
but no significant differences between the genotypes could be detected at any age (data not 
shown). 
PTH treatment 
Albeit with an accelerated decrease in bone nodule formation the bone marrow cultures 
of TTD mice retained their capacity to generate osteoblasts and form bone. To investigate 
whether this bone forming capacity is still present and can be stimulated in vivo as well, 
we analyzed the effect of intermittent PTH treatment on bone structure in TTD mice. PTH 
treatment was started at 45 weeks of age, i.e. after the accelerated bone loss has started. 
Cortical thickness showed an increase after 20 weeks intermittent PTH treatment as can be 
seen from the right-shift in the 3D-thickness distribution (Figure 6A). The perimeter was not 
significantly changed by PTH treatment (data not shown). Although endocortical volume 
showed a decrease as expected from the increase in cortical thickness and unchanged pe-
rimeter, the decrease in endocortical volume after PTH treatment did not reach significance 
Figure 5
Figure 5: Stem cell cultures of wild type and TTD mice. 
Analyses of osteoclast and osteoblast differentation capacity in bone marrow cell cultures in wild type (solid bars) and TTD mice (open bars). 
Number of TRAP-positive osteoclasts (A), resorption surface per mature osteoclast (B), number of alkaline phosphatase-positive bone nodules 
(C) and size of alkaline phosphatase-positive bone nodules (D). TTD mice compared to wild type animals: # p<0.05, ### p<0.001; error bars 
represent SEM. 
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(data not shown). The increase in cortical thickness as well as the increase in trabecular bone 
volume were significant (Figure 6B and data not shown). 
Discussion  
TTD mice display features of premature aging in many organs and tissues (21,23), but the 
progeroid symptoms do not affect all tissues to the same extent. In fact, paradoxically, a 
detailed, systematic large cohort analysis revealed that some organs and tissues even exhibit 
features resembling caloric restriction and delayed ageing. For instance, the occurrence of 
cataract in the eyes in TTD mice was found to be significantly less compared to the isogenic 
wild type control mice kept under the same conditions (23). This extends the notion that all 
human progeroid syndromes are segmental (38), i.e. that multiple organs suffer from rapid 
aging, yet others seem relatively unaffected and as shown by TTD mice may even age slower 
than wild type controls. Microarray expression analysis of various accelerated aging mice 
revealed a strong parallel with expression profiles of normal aging (39). To examine at the 
level of physiology, whether TTD mice are indeed a bona fide model for aging and to rule out 
that it is a developmental disorder, we examined in great detail the effect of aging on bone 
Figure 6
Figure 6: PTH treatment in TTD mice. 
Cortical thickness distribution (A) and cortical thickness (B) in femora from PTH treated (PTH) and control (VEH) TTD mice. * p<0.05; error bars 
represent SEM. 
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parameters of female wild type mice as well as progeroid TTD mice. The systematic analysis 
uncovered the consequence of a defect in DNA repair and basal transcription on the veloc-
ity of age-related skeletal changes and assessed to which extent the skeletal abnormalities 
reflect normal bone aging.
Normal skeletal development but accelerated skeletal aging in progeroid TTD mice
It should be emphasized that by all parameters measured bone develops normally in TTD 
female mice, i.e. bone volume, cortical thickness and perimeter are similar in wild type and 
TTD mice up to 39 weeks of age. In addition, similar numbers of osteoblasts and osteoclasts in 
bone marrow cultures as well as periosteal apposition are present up to at least 13-weeks of 
age. This observation excludes a developmental defect as explanation for the TTD phenotype 
and is in line with other studies on TTD mice (23). 
After 39 weeks of age profound accelerated decrease in bone volume is observed in TTD 
mice. The decrease in bone volume and cortical thickness in TTD mice is almost 40 weeks 
ahead of that in wild type mice. This accelerated form of natural bone aging strongly under-
lines the premature aging phenotype of TTD mice. 
Notably, the decrease in bone volume is paralleled by an accelerated decrease in bone 
strength in TTD mice after 26 weeks of age; i.e. an ultimate fracture load as observed in 
52-week-old TTD mice was only noticed in 104-week-old wild type mice (Figure 4B). An 
important mechanism underlying the accelerated decrease in bone strength is that in TTD 
mice the larger endocortical volume is not compensated by an increase in age-related 
periosteal apposition and perimeter as seen in wild type mice. The accelerated decrease in 
bone strength does not appear to be due to a change in mineralization grade of the matrix 
as assessed by quantitative Backscatter Scanning Electron Microscopy analyses nor due to 
increased bone resorption as assessed by measurement of serum TRAP. 
Lack of periosteal apposition as a cause of decreased bone strength in TTD mice
The lack of effective periosteal apposition in TTD mice is intriguing as it is a localized phenom-
enon. Despite the important role of periosteal apposition in establishing structural strength 
during growth and in maintaining strength during aging, little is known about the mecha-
nism and control of periosteal apposition (40). Currently, it is tempting to speculate that, 
with aging, increased bending stress on the outer surface of bone (due to endosteal bone 
loss and subsequent cortical thinning) leads to the stimulation of periosteal bone apposition 
(41-43). The force of mechanical bending and torsion varies linearly with the distance from 
the neutral axis and therefore bending stress is larger on the periosteal side of the bone (44). 
Mechanical loading could thus influence periosteal apposition and a change in mechanical 
loading could consequently affect this process. In wild type mice we see the perfect coupling 
between thinning of the cortex, increase in endocortical volume, the presence of periosteal 
apposition and increase in perimeter. In TTD mice this coupling is absent. As TTD mice, in 
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contrast to wild type mice do not accumulate fat with aging, the difference in weight (23) 
might contribute to the difference in periosteal apposition. However, we could not detect 
an obvious correlation between body weight and perimeter (unpublished observations). In 
addition, it should be noted that controversy exists regarding the influence of fat mass versus 
muscle mass on bone formation ((45) and references therein). Moreover, in mice a relation-
ship between body weight and femur, vertebral and phalangeal bone parameters has not 
been found (46). TTD mice may provide an excellent tool to study periosteal apposition and 
to unravel the underlying mechanisms. 
DNA repair defect and bone marrow stem cells in TTD mice 
With regard to the accelerated decrease in bone formation and bone mass, the deficiency 
of DNA damage repair is very likely to have a causative effect. DNA lesions e.g. induced by 
free radicals, which are a byproduct of normal metabolism, are incompletely repaired by 
DNA-repair deficient TTD mice (21). The increased damage load will lead to dysfunctional 
senescent cells or will cause apoptosis (47). Indeed, TTD mice appear to exhibit a decreased 
spontaneous tumor formation rate likely at least in part by an increased rate of apoptosis 
(23,48), which protects from cancer but at the same time likely accelerates aging. An increased 
rate of apoptosis can therefore be expected to cause accelerated depletion of stem cells or 
early progenitor cells leading to a disturbed osteoblasts and adipocyte differentiation from 
mesenchymal stem cells and osteoclasts derived from the hematopoietic stem cell lineage. A 
decrease in mesenchymal stem cell number or disturbed differentiation is suggested by the 
fact that TTD mice lack abdominal fat mass (49). As the structural differences in bone became 
apparent after 39 weeks we analysed bone marrow mesenchymal and hematopoietic stem 
cell differentiation in the period around this age starting at 13 weeks of age. Osteogenic 
analyses of the bone marrow cultures demonstrated an accelerated decrease in bone nodule 
formation implicating an accelerated reduction in the number of mesenchymal stem cells 
that can differentiate into osteoblasts that precedes the decrease in bone mass. The absence 
of differences in size of the bone nodules shows that the proliferative capacity of the stem 
cells present is not changed in TTD mice. These data might indicate that DNA damage levels 
in TTD mice reach a critical threshold in (mesenchymal) stem cells between 13 and 26 weeks, 
which translates into reduced numbers of differentiated osteoblasts and a bone phenotype 
between 39 and 52 weeks of age. Although we only studied bone marrow cultures up to 45 
weeks, bone nodule formation in wild type mice seems to decrease starting at 45 weeks of 
age. This is in line with data from the literature; it was shown previously that old mice had sig-
nificantly fewer stem cells with osteogenic potential than young animals (50,51). In humans, 
the number of stem cells with osteogenic potential was shown to decrease already at young 
age (52-54). Only at 26 weeks of age a significant difference in in vitro osteoclast formation 
was observed with TTD mice having an increased osteoclast number without a difference in 
resorption capacity. This together with the decreased osteoblast differentiation at 26 weeks of 
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age may explain the decrease in bone volume and structure as first observed after 39 weeks. 
Obviously, definite proof that the observed accelerated decrease in mesenchymal stem cells 
in TTD mice is due to accumulation of DNA damage as a consequence of deficient DNA repair 
is lacking and with current technology very difficult to obtain. However, the most plausible 
scenario is that loss of DNA repair indeed leads to accumulation of otherwise repaired DNA 
lesions, which triggers cell death and cellular senescence. In the case of bone metabolism 
this results in an accelerated decrease in mesenchymal stem cells, suppression of growth and 
differentiation, deranged bone metabolism and inevitably premature loss of bone strength 
as shown by the mechanical testing. Although there is an accelerated decrease in bone 
nodule formation, the current data show that TTD bone marrow mesenchymal stem cells 
retain bone forming capacity. This is further substantiated by the in vivo intermittent PTH 
treatment studies. Intermittent PTH administration to TTD mice demonstrated an increase in 
cortical thickness implicating that the stem cells/osteoblasts can still be stimulated to form 
bone. Considering the above mentioned relationship between DNA repair and apoptosis, it 
is interesting to note that PTH has been reported to inhibit osteoblast apoptosis (55,56). The 
PTH effect on cortical thickness in TTD mice appears to be the result of increased endosteal 
bone formation and not periosteal apposition, as perimeter was not significantly changed. 
Interestingly, a recent study showed differences in mechanism by which intermittent PTH 
treatment increases bone formation at the endosteal and at the periosteal surface (57). The 
increase in endocortical osteoblasts after intermittent PTH treatment is predominantly due to 
attenuated osteoblast apoptosis (57). In periosteal bone where the rate of osteoblast apop-
tosis is low, PTH does not increase the number of osteoblasts by attenuating apoptosis, but 
by exerting pro-differentiating and/or pro-survival effects on post-mitotic pre-osteoblasts 
(57). These data are suggestive for different age-related mechanisms at the endosteal and 
periosteal level. The adipocyte cultures support the fact that the intrinsic differentiation 
capacity of mesenchymal stem cells is not affected. In vivo TTD mice lack fat accumulation, 
but in vitro normal adipocyte differentiation is observed. Overall these observations point 
to an altered systemic environment in TTD mice. Currently, it should be concluded that the 
observed accelerated skeletal aging observed in TTD mice is the result from a combination of 
an accelerated decline in the number of osteogenic stem cells together with altered systemic 
influences. 
In conclusion, we demonstrate that the increased and accelerated decrease in bone mass 
in DNA repair-deficient TTD mice is a premature aging feature, which implies that the other 
aging-like features in TTD mice and patients may also represent bona fide premature aging 
symptoms and which in a broader context substantiates the importance of DNA repair in 
healthy aging. Proper DNA repair, notably transcription-coupled repair, is thus required to 
maintain optimal bone characteristics and strength as long as possible. Prevention and/or 
limitation of DNA damage may therefore be novel targets for prevention or therapy of os-
teoporosis and to maintain healthy, strong bones. The TTD mouse mutant constitutes a valid 
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model for bone aging and the absence of periosteal apposition provides for identification of 
new targets for maintaining bone strength with aging.
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Abstract 
The accumulation of DNA damage is one of the main contributors of human tissue aging. 
Trichothiodystrophy (TTD) mice have a mutation in a DNA repair gene, resulting in a process 
of accelerated aging. In order to study the effect of accumulated DNA damage on bone 
development and mesenchymal stem cell differentiation, we used these mice as a model sys-
tem for our studies. Analysis of bone parameters, measured by micro computed tomography, 
displayed an overall accelerated aging of male TTD bone. This was accompanied by a rapid 
90% decrease in periosteal apposition at 78 weeks and an overall decline in bone strength of 
about 25% compared to male wild type mice. After 42 weeks, mesenchymal differentiation 
potential towards the osteoblast lineage was significantly decreased in male TTD mice. Min-
eralization of osteoblast colonies was not affected. Adipocyte and osteoclast differentiation 
was not impaired. Our findings reveal the importance of genome stability and proper DNA 
repair for skeletal aging. The data show a predominant effect of impaired DNA repair at the 
osteoblast level. An early disruption in the bone formation-bone resorption balance, caused 
by a decrease in mesenchymal stem cell differentiation towards the osteoblast lineage, can 
be the basis of accelerated aging of bone in TTD mice. Periosteal apposition, a hallmark of 
aging long bones and important to maintain bone strength, is strongly reduced in TTD mice 
implicating an important role for DNA repair in this process albeit that the precise mechanism 
remains elusive. However, the absence of periosteal apposition provides a tool to unravel 
this mechanism and to identify new targets to control bone strength. In comparison with 
their female counterparts, TTD males are not as strongly affected and the dynamics of their 
accelerated skeletal aging seem to be slightly delayed. 
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Introduction 
Trichothiodystrophy (TTD) is a rare, autosomal recessive DNA repair disorder presenting a 
wide range of characteristic features like brittle hair and nails, impaired intelligence, short 
stature, infertility and a severely reduced lifespan. Additionally, skeletal abnormalities have 
been described (1). Changes in the XPB, XPD and TTDA genes and their proteins, are described 
to be the underlying cause of TTD (2). These proteins are all components of the TFIIH com-
plex, which is essential in transcription initiation as well as in the Nucleotide Excision Repair 
(NER) pathway (3).
The NER pathway is activated during global genome repair in order to remove helix-
distorting damage. Similarly, it regulates the excision of lesions in the transcribed strand of 
active genes during transcription. Consequently NER promotes cell survival and prevents 
DNA damage induced cancer (4,5). Within this complex, multi-factorial pathway TFIIH opens 
up the DNA helix to allow other proteins to remove the induced damage. XPB and XPD are 
the helicases involved in this process (6).
Previously, an XPD mouse model was generated that precisely mimics a causative point 
mutation in the essential XPD gene of a TTD patient (7). TTD mice, in a C57BL/6J background, 
have strikingly similar symptoms and show several premature aging-like features (8). 
Throughout life, both men and women undergo bone loss due to an unbalanced increase in 
bone resorption. This usually leads to a reduction of trabecular bone and thinner bone cor-
tices, causing osteoporosis and a severe increase in fracture risk (9-11). Men, unlike women 
miss the rapid bone loss phase caused by reduced hormone levels, but also develop senile 
osteoporosis; a fact that can be used to gain insight into the mechanisms behind age-related 
bone loss (10). 
Both osteoblasts and osteoclasts, the main players in bone formation and bone resorption 
are derived from stem cells that populate the bone marrow cavities of long bones. Osteoblasts 
rise from mesenchymal stem cells (MSC), which can differentiate into a whole range of cells 
including adipocytes, chondrocytes and myocytes (12). Osteoclasts on the other hand rise 
from the hematopoietic stem cells (HSC), which also differentiate into blood cells, immune 
cells and macrophages (13). A disturbance in either of the differentiation pathways could 
cause a disbalance in the number of osteoblasts and osteoclasts, leading to either excessive 
bone gain or bone loss. 
We studied the impact of DNA repair deficiency on the dynamics of skeletal aging and 
the osteoblast/ osteoclast balance in male TTD mice by micro computed tomography (mCT) 
analysis of bone architecture and analyses of osteoblast and osteoclast differentiation poten-
tial in in vitro bone marrow cultures.
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Material and Methods 
Mice and bones
All mice were on a C57BL/6J background and all mice within one cohort were kept under 
equal conditions. In the mCT cohort, 8 wild type and TTD mice were sacrificed at 13, 26, 39, 
52, 65 and 78 weeks of age. Wild type mice were also kept until 91 and 104 weeks of age but 
only few TTD mice survived till this age not allowing age-matched analyses at these ages. 
The animals were injected intra-peritoneal with calcein (10 μg /g body weight) 10 and 3 days 
before sacrifice in order to study the bone formation occurring in one week. The mice were 
killed by cervical dislocation. Femurs and tibiae were isolated and were either snap frozen in 
liquid nitrogen and stored at -80ºC or fixed in Burkhardt, which was replaced by 70% ethanol 
after 3 days. For bone marrow isolation 10 wild type and TTD mice were sacrificed at 26, 39, 
45 and 78 weeks of age. On the day of sacrifice, bones were isolated and were either used for 
bone marrow isolation, or fixed in Burkhardt or 10% formalin depending on further testing. As 
required by Dutch law, formal permission to generate and use genetically modified animals 
was obtained from the responsible local and national authorities. All animal studies were 
approved by an independent Animal Ethical Committee (Dutch equivalent of the IACUC).
Micro-computed tomography 
Fixed tibiae from wild type and TTD mice of different ages (n = 4-6 per group) were scanned 
by micro-computed tomography (μCT) from proximal end to mid-diaphysis using the 
SkyScan 1072 microtomograph (SkyScan, Antwerp, Belgium) with a voxel size of 8.82 μm. 
The reconstructed data sets were segmented using an automated algorithm based on local 
thresholds (14). Three-dimensional (3D) morphometric analysis of the bone was performed 
using freely available software of the 3D-Calculator project (http://www.erasmusmc.nl/or-
thopaedie/research/labor/downloads). For all mice a standardized metaphyseal – diaphyseal 
area (3.7-6.9 mm from the proximal end) was selected for analysis. This area mainly consists of 
cortical bone and to a much lesser extent of trabecular bone. This precluded reliable analyses 
of trabecular bone parameters separately. The parameter bone volume we present reflects 
mainly cortical bone including the trabeculae present. In addition, 3D thickness distribution 
(15) cortical volume, cortical thickness, and the periosteal perimeter were determined. Polar 
moment of inertia (MOI; measure of the geometrical distribution and a proxy for mechanical 
stiffness and strength per transverse cross-section) was determined to analyse the conse-
quence of differences in geometry. 
Histomorphometric analysis
To assess dynamic histomorphometric indices, mice received intraperitoneal injections 
with calcein 10 days and 3 days prior to sacrifice. One tibia of each mouse was dehydrated 
in ascending alcohol concentrations and embedded in poly-methylmetacrylate (PMMA) 
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as described previously (16). Sections of 5 µm were cut in the sagittal plane on a Microtec 
rotation microtome (Techno-Med GmbH, Munich, Germany) and stained by toluidine blue, 
van Gieson/von Kossa and Giemsa procedures as described (16). Parameters of static and 
dynamic histomorphometry were quantified on these undecalcified proximal tibia sections. 
Osteocyte numbers were counted and expressed per bone area (per mm2) according to stan-
dardized protocols (17) using the OsteoMeasure histomorphometry system (Osteometrics 
Inc., Atlanta, Georgia, USA). For each animal, the bone formation rate was determined by 
fluorochrome (calcein) measurements using two non-consecutive 12µm-sections per animal. 
Mechanical testing 
Defrosted femurs were excised from the soft tissues. Femurs were tested in a three-point 
bending assay using a Lloyd LRX mechanical test frame, constructed with 3 mm hemi-
cylindrical supports with a 9 mm total span. The femurs were aligned such that the neutral 
axis was parallel to the sagittal plane. The lesser trochanter was used as a reference point and 
aligned with one of the two supports. All samples were preconditioned for 5 cycles to 2 N at 
a rate of 0.01 mm/s before testing to failure at a rate of 0.02 mm/s. 
Backscatter Scanning Electron Microscopy
Processing and analyses were done as described previously (18). In short, from each group 
(i.e. 26, 52 and 78-week-old wild type and TTD mice) the distal halves of the femurs used 
for mechanical testing were embedded in blocks of MMA, such that each block contained 
one distal femur from each genotype and age group. Within a block, all femurs were placed 
within a plane, such that the longitudinal lateral-medial plane of the femurs coincided with 
the plane of embedding. Embedding several samples in one block enabled us to image these 
samples within one scanning electron microscopy (SEM) session, thus decreasing the vari-
ance in the measurements. 
After embedding, the blocks were cut in two on an electric band saw (Exakt, Norderstedt, 
Germany), resulting in a slab of plastic with two parallel surfaces, parallel to the plane of em-
bedding of the femurs. Starting from the posterior side of the bones, material was removed 
using an automatic grinding system (Buehler Phoenix 4000) with p400 grid paper until an 
interior surface, halfway between the ventral and dorsal external surfaces, was exposed. To 
reduce the roughness of the surface the blocks were ground with p1200 paper followed by 
polishing using 3 mm diamond paste with polishing paper (Buehler Texmet 1000). The result-
ing surface had a roughness (Ra) smaller than 0.05 mm. The blocks were cleaned, sonicated 
and sputter coated with a thin layer of carbon (Bio-Rad Temcarb Carbon Coater, Bio-Rad 
Microscience Division) to enable conduction of the electron beam to the sample surface.
Backscatter SEM images were taken of trabecular bone of the metaphyseal and epiphyseal 
regions of each bone sample, and of the cortex using methods described in detail previ-
ously(18) . The images were taken at an accelerating voltage of 25 kV, a working distance of 
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17 mm and 50x magnification. Before and after imaging calibration images were taken of 
an aluminum standard embedded in each block and of the MMA material. The equivalent 
Z-value (atomic number) of the MMA was obtained by calibration with aluminum (Z=13) and 
carbon (Z=6) standards (Micro Analysis Consultants).
From each image the histogram of equivalent Z-values was calculated of which the mean 
value represented the mean mineralization of the bone tissue (19).
Bone marrow isolation, cell culture and cell culture staining 
Bone marrow was collected by spinning down the bone marrow into an eppendorf tube at 
5000rpm for 2 min. Erythrocytes were lysed using erylysis buffer (1.55M NH4Cl, 0.1M KHCO3, 
1mM EDTA (10x)) and cells were washed and seeded at 1.000.000 cells/well (12 wells) for 
osteoblasts, 100.000 cells/well (96 wells) for osteoclasts and 750.000 cells/well, for adipocytes 
(24 wells). Cells were cultured at 37°C and 5% CO2 in a humidified atmosphere in either 
osteogenic (a-MEM (GIBCO, Paisley, UK) supplemented with P/S, 1.8 mM CaCl2 (Sigma), 
Amphotericin B (250 ng/ml,Sigma) and 15% heat-inactivated FCS (GIBCO)), osteoclastogenic 
(MEM (GIBCO, Paisley, UK) supplemented with P/S, amphotericin B (250 ng/ml, Sigma) and 
10% heat-inactivated FCS (GIBCO)) or adipogenic (D-MEM (GIBCO, Paisley, UK) supplemented 
with P/S, amphotericin B (250 ng/ml,Sigma) and 15% heat-inactivated FCS (GIBCO)) medium. 
Addition of b-Glycerophosphate (10mM) and Vitamin C (50 mM) from day 3 onwards induced 
osteoblast differentiation. Osteoclast differentiation was induced by adding RANK-L (20ng/ml, 
R&D systems) and M-SCF (30ng/ml, R&D systems) to the medium starting at day 0. Osteoclast 
cultures on plastic or bone slices were cultured for 6 days. Adipogenesis was induced after 
a 3-week expansion phase by adding insulin (0.1mg/ml, Sigma), indomethacin (1mM, Sigma) 
and dexamethasone (1*10-7M, Sigma) to the adipogenic medium for another two weeks.
In osteogenic condition bone nodule formation was measured as parameter of mesenchymal 
stem cell number and bone forming capacity after 14 days of cultures. At day 14 cultures 
were stopped by washing with PBS, fixated in 70% EtOH for 10 min., rinsed in 0.2MTris-HCl 
(pH 9.5) and stained using NBT (100mg/ml) and BCIP (10mg/ml) diluted in Tris-HCl with MgCl2 
in order to detect alkaline phosphatase as measure for bone nodule formation. Colonies were 
counted by eye and colony surface area was determined by computer analysis (Bioquant 
software). The reaction was followed by eye and stopped by washing with PBS. In order to 
detect mineralisation after 21 days osteoblast cultures were washed with PBS, fixed with cold 
70% EtOH O/N at 4°C and stained in a saturated Alizarin Red Solution (Alizarin Red S (Sigma) 
in H2O pH 4.2). After staining cells were washed with H2O. Alizarin Red staining was then 
extracted from the cultures and measured on a plate reader at 405 nm.
Osteoclast cultures were washed in PBS, fixated for 10 min. in 10% formaline and washed with 
warm H2O before they were stained for 30 min. using the Sigma Acid phosphatase leukocyte 
kit (Sigma), using a 1M Tartrate stocksolution instead of the solution supplied by the kit in 
order to detect TRAP positive cells. Washing the cells with PBS stopped the reaction. Cultures 
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were photographed and the number of TRAP positive cells per photograph was determined. 
Resorption pits on bone slices were visualised by staining them with Coomassie solution 
(Phast Gel Blue R tablet, Coomassie R350). Slices were photographed and the resorption area 
was determined by computational analysis (Image J).
Adipocyte cultures were fixated O/N with 10% formaline, washed with 60% IPOH and stained 
with Oil-Red O solution (60-40 dilution of Oil-Red O stock solution (Clin-Tech limited) in H2O) 
after which the total amount of adipocytes per well was determined.
Statistics
Micro-CT parameters, histomorphometric data, femur length, ultimate load, bone resorption 
data and parameters of cell culture analyses were compared between the age groups (sig-
nificance compared to 13 or 26 weeks of age) of both genotypes separately using one-way 
ANOVAs with Tukey post-hoc test (Graph Pad InStat version 3.05: Graph Pad Software, San 
Diego California, USA, www.graphpad.com). In addition, the micro-CT parameters, histomor-
phometric data, femur length, ultimate load, bone resorption data, and parameters of cell 
culture analyses were compared between genotypes for all age groups separately using one-
way ANOVAs (SPSS.11.0, SPSS software Chicago, USA). For comparisons of the mineralization 
data between genotypes unpaired t-tests with two-tailed P-values were performed. 
Results
Bone architecture
In order to analyse bone dynamics in wild type and TTD mice throughout life we started 
out by studying the 3D thickness distribution of bone fragments by mCT analysis. The bones 
of wild type mice underwent a gradual decline in 3D thickness throughout life (Fig. 1A left 
panel). In TTD mice this process was accelerated and showed a large decrease after 39 weeks 
without clear further changes at later ages (Fig. 1A right panel). The acceleration of skeletal 
aging in TTD mice is even better illustrated in Figure 1B showing the thickness distribution of 
52-week-old TTD left of that of 91-week-old wild type mice. 
To study this difference in onset of decrease in bone mass in more detail we analysed 
specific µCT parameters. Total cortical bone volume decreased gradually in wild type mice 
throughout life (Fig. 2A). TTD mice followed the same pattern but the decline observed was 
steeper and led to a significant decrease in cortical volume at 78 weeks compared to wild 
type mice (Fig. 2A). In neither wild type nor TTD mice significant changes in cortical thickness 
were observed throughout life (Fig. 2B). TTD mice however had significantly thinner cortices 
than wild type mice (Fig. 2B). No significant changes in the endocortical volume of either wild 
type or TTD mice were observed throughout their lives (Fig. 2C). From 39 weeks onwards, 
TTD mice showed significantly higher endocortical volumes compared to their age-matched 
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wild type males (Fig. 2C). This was accompanied by a significantly decreased trabecular bone 
volume fraction (BV/TV) at 26 and 39 compared to wild type mice (Fig. 2D). At 26 weeks of 
age, wild type mice had a high BV/TV which decreased up to 52 weeks of age after which 
it stabilized. TTD mice on the other hand started out with a much lower BV/TV, which only 
slightly declined (Fig. 2D). 
Bone strength
Structural changes in bone architecture, like thinner cortices, or changes in matrix deposition 
can lead to changes in bone strength. To study changes in bone strength, we performed 
3 point bending assays on wild type and TTD femurs. Early on we observed no significant 
differences between 13-week-old wild type and TTD mice (Fig. 3A). Wild type bones showed 
a gradual decrease in energy required to break throughout life; from 18 N at 13 weeks to 
15,5 N at 78 weeks (Fig. 3A). Albeit not significant, already at 13 weeks of age less energy 
was required in order to break TTD bones compared to wild type bones. Subsequently, a 
quick drop to about 12,5 N at 26 weeks of age was observed after which the energy required 
to break TTD bones remained stable up 78 weeks (Fig. 3A). Starting at 26 weeks of age, sig-
nificantly less energy was required in order to break TTD bones compared to their wild type 
counterparts (Fig. 3A).
Quantitative Backscatter Scanning Electron Microscopic analysis on femurs of wild type and 
TTD males demonstrated no significant difference in mineralization of the cortex between 
genotypes or with aging (Fig. 3B). In addition, we studied the decrease in bone strength 
by analysing two additional mCT parameters related to bone strength: perimeter and MOI. 
Perimeter and MOI did not differ significantly between wild type and TTD mice throughout 
most of their life (Fig. 3C,D). Only at 78 weeks of age both perimeter as well as MOI of wild 
type mice became significantly larger than that of TTD mice (Fig. 3C,D) Following this obser-
vation, we assessed the perimeter and MOI in wild type mice of 91 and 104 weeks of age . This 
demonstrated that after 78 weeks the perimeter of wild type tibiae increased up to 91 weeks 
of age followed by an increase in MOI (Fig. 3C,D). The observed increase in bone perimeter in 
old wild type mice can be explained by the natural process of periosteal apposition, which 
takes place in order to maintain bone strength by depositing new bone on the outside of 
the cortex in order to make up for the bone that is removed on the inside. To study this 
process we measured bone formation rates using calcein labeling (Fig. 3E,F). Endosteal bone 
formation, on the inside of the bone, was largely unaffected in both genotypes throughout 
life (Fig. 3G). Periosteal apposition on the other hand, was extremely reduced in old TTD mice 
(Fig. 3H). 
Stem Cell Differentiation Potential
Besides a decrease in bone strength and a lack of periosteal apposition, TTD mice have been 
reported to lack body fat as well (8,20). This suggests that the mesenchymal stem cell (MSC) 
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differentiation pathway towards osteoblasts and adipocytes might be impaired leading to a 
decrease in bone and fat formation. In order to study MSC differentiation we set up a new 
cohort of wild type and TTD mice and isolated bone marrow at 26, 42 and 78 weeks of age 
and analyzed osteoblast and adipocytes as well as osteoclast differentiation. 
Bone nodule formation per se was not affected in in vitro TTD cultures, but the number of 
nodules was significantly reduced in cultures from 42 and 78-week-old TTD mice (Fig. 4A). 
Both wild type and TTD mice displayed a trend towards reduced bone nodule formation 
capacity with aging, but this only reached significance in TTD mice (Fig. 4A). Bone nodule 
size did not differ significantly between wild type and TTD cultures indicating an unaffected 
proliferation (Fig. 4B). Both wild type and TTD nodules mineralised to the same extent sug-
gesting that mineralisation was not affected in TTD mice (data not shown). In contrast to the 
number of bone nodules, we did not observe a significant difference between wild type or 
TTD adipocyte differentiation potential as assessed by the number of lipid-vesicle-forming 
adipocytes (Fig. 4C). 
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Figure 1: TTD mice show accelerated skeletal aging. 
(A) 3D thickness distribution (volume density) in aging male (A left panel) wild type and (A right panel) TTD mice, with the arrow indicating the 
direction of change with aging. (B) Comparison of thickness distribution in 52-week-old TTD male (dotted line) compared to 91-weeks-old wild 
type male (solid line). 
85
Age-related skeletal dynamics in male TTD mice
In parallel to the osteoblast and adipocyte cultures, bone marrow was cultured under 
osteoclastogenic conditions to assess formation of osteoclasts from hematopoietic stem 
cells (HSC). The total number of TRAP+ osteoclasts found in these in vitro cultures was stable 
throughout life in wild type mice, but significantly decreased in TTD mice (Fig. 4D). When 
focussing on multinucleated osteoclasts (two nuclei or more), there was no significant dif-
ference between wild type and TTD mice although TTD cultures showed a decline in the 
number of osteoclasts at 78 weeks of age (Fig. 4E). Additionally, osteoclasts were cultured on 
bone slices to see whether resorption pits could be detected. Since mature osteoclasts are 
the TRAP+ cells responsible for resorption, we calculated the average size of a pit formed by a 
multinucleated osteoclast (Fig. 4F). For both wild type and TTD mice we observed a decrease 
in resorbed area with age (Fig. 4F). At none of the ages studied there was a significant dif-
ference between wild type and TTD albeit that at both 26 and 42 weeks the resorbed area 
seemed about twice the size in TTD mice while at 78 weeks it was smaller. 
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Figure 2: Changes in bone architecture throughout life.
 (A-D) Bone parameters in aging wild type (solid squares) and TTD males (open squares). (A) Total bone volume, (B) cortical thickness, (C) 
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Discussion 
In this study, we examined the effect of aging on bone parameters of male wild type mice as 
well as progeroid TTD males. We showed that a defect in DNA repair and basal transcription 
leads to accelerated skeletal aging; TTD mice showed an accelerated decrease in 3D thick-
ness distribution, bone volume and bone strength. This is most clearly demonstrated by the 
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Figure 3: Decreased bone strength in TTD mice.
 Bone strength, mineralization and bone formation rates in long bones of aging wild type (solid bars/ symbols) and TTD males (open bars/ 
symbols). (A) Bone strength depicted as Ultimate Load, (B) bone mineralization, (C) perimeter and (D) MOI. Calcein labelling at sites of 
periosteal apposition in 78-week-old (E) wild type and (F) TTD mice. (G) Endosteal apposition and (H) periosteal apposition. TTD vs. wild type: 
ANOVAs * p<0.05, *** p<0.001; error bars represent SEM. 
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observation that TTD mice reach the same bone volume as wild type males about 40 weeks 
earlier.
Before discussing our findings it should be emphasized that earlier studies showed that in 
female TTD mice there is normal early bone development excluding a developmental defect 
as the cause of our results ((21) and Diderich et al, Chapter 2). However, our current data on 
male mice show already bone differences, e.g in cortical thickness and BV/TV, starting earlier 
in life than that observed in female mice. Our observations on cortical thickness and BV/TV 
in wild type male mice are in line with those reported earlier (22). Whether, in contrast to 
females, this does reflect developmental differences in male TTD mice is unclear but unlikely 
as like in females the body weight development is similar for wild type and TTD male mice up 
to 39 weeks (Diderich et al, Chapter 5). Albeit there are already differences early in life most 
differences appear later in life or become more pronounced later in life. 
At 78 weeks of age, TTD mice show a decreased total bone volume, perimeter and MOI, 
reduced cortical thickness, and a larger endocortical volume. All these findings point towards 
a model in which the bone cortex becomes thinner and therefore more fragile at an acceler-
ated speed. This is supported by the lack of periosteal apposition in TTD mice. Together these 
findings explain (at least part of ) the decrease in bone strength. 
Periosteal apposition is an important process during skeletal aging. Bone is added to 
the outside of the cortex in order to compensate loss at the endocortical side in order to 
maintain bone strength as long as possible (23,24). Disturbances in periosteal apposition 
and lack to compensate endocortical bone loss will lead to decreased bone strength and 
increased fracture risk. Involvement of estradiol, with opposite roles for estrogen receptors 
α and ß, testosterone and mechanical loading in the control of periosteal apposition have 
been reported (10). However the precise mechanisms underlying these age-related changes 
in bone and periosteal apposition are still poorly understood. The current studies show an 
important role for age-related DNA repair for proper periosteal apposition and implicate 
the importance of limiting DNA damage for maintaining bone strength with aging. Albeit 
the current data do not provide a mechanism explaining the altered periosteal apposition, 
the TTD mouse model will provide excellent opportunities to further unravel this important 
skeletal process with aging.
A significant difference in perimeter and MOI is first observed in 78-week-old wild type 
and TTD mice. Unfortunately, we do not have many data points past the 78 week mark since 
TTD mice tend to die around this time point. To be able to take this further in at least wild 
type mice, we obtained perimeter and MOI analyses from older wild type males. This demon-
strated an increase in perimeter and MOI between 78 and 91 weeks after which it stabilized. 
This implies that the loss of bone strength in aging wild type mice will not be a severe as 
in TTD mice. This is based on the observations of a significant reduction in perimeter, MOI 
and strength while periosteal apposition is practically absent strongly indicating that TTD 
mice over 78 week of age would not show restoration of bone strength, but would have 
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Figure 4: Mesenchymal and hematopoietic stem cell differentiation.
 Mesenchymal and hematopoietic stem cell differentiation in aging wild type (solid bars) and TTD males (open bars). (A) Average number of 
ALP+ colonies that rise from bone marrow cultures after 14 days of culture. (B) Average colony size at day 14 of culture. (C) The average number 
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compared to the 26 week time point; error bars represent SEM. 
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even weaker bones. Our data showing a more or less stable perimeter up to 78 weeks of 
age are in line with previous reports that showed no change in cross-sectional area after 
the initial growth phase up to 20 months of age (about 86 weeks) in male wild type mice 
(22). Apparently, an increase in perimeter is not important to maintain bone strength up to 
about 86 weeks of age, but becomes important afterwards. The absence of a further increase 
in perimeter after 91 weeks of age and a decreasing trend in both perimeter and MOI sug-
gest that also in aging wild type mice the process of periosteal apposition to maintain bone 
strength eventually becomes impaired. 
TTD mice have deficient DNA repair which might lead to an increase in cellular DNA dam-
age and an increase in senescent or apoptotic cells. Indeed, it has previously been observed 
that TTD mice have a decreased tumour formation rate which could protect against cancer, 
but could also cause accelerated aging (21,25). An increase in damage and apoptosis might 
lead to a decrease in overall stem cell numbers or precursor cells and changes in their dif-
ferentiation potential. Both mesenchymal and hematopoietic stem cell differentiation are 
complex processes that go through a number of precursor stages and are tightly regulated 
in order to maintain a balance between the number of osteoblasts and osteoclasts present at 
one time (13,26,27). Additionally the balance between osteoblast and adipocyte formation 
within the mesenchymal lineage is known to be regulated and can be tipped either way by 
disrupting one of the differentiation pathways (28). An age-related decrease in osteoblast 
colony formation potential has been previously described and can also be observed in our 
aging wild type mice (29).
Our current, ex vivo TTD bone marrow cultures showed a reduction in the capacity to form 
bone nodules and a trend towards reduced osteoclast activity with age. The reduction in 
osteoblasts and osteoclasts with age may indicate a reduced bone turnover capacity and 
thereby a reduced capacity to maintain healthy bone in e.g. the case of microcracks. How-
ever, this should be proven in further studies focussing on fracture repair. It is tempting to 
conclude that this is part of the mechanism underlying the observed accelerated skeletal 
ageing and decrease in bone strength. In addition, earlier in life at 26 and 42 weeks of age the 
number of multinucleated osteoclasts and resorbed area are higher in TTD mice than in wild 
type mice which may also contribute to the accelerated bone loss and increased endocortical 
volume earlier in life. This effect on osteoclasts is supported by FACS analysis of wild type 
and TTD bone marrow (data not shown) showing a shift in HSC differentiation towards the 
myeloid lineages in TTD mice. Besides direct effects on MSCs the data on adipocyte develop-
ment suggest that in vivo additional factors are involved to explain the observed phenotype. 
A very marked characteristic of TTD mice is complete lack of fat deposition ((20) Diderich et 
al., Chapter 5). This would suggest a severly disturbed adipocyte differentiation from MSCs. 
However, our current data show no difference in development of adipocytes between wild 
type and TTD males at any age. This means that the capacity of MSC to differentiate into 
adipocytes is not impaired and that in vivo additional signals or absence of signals explain the 
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observed fat-less phenotype. At this moment it is elusive which factor(s) form these signals 
and extensive additional investigation is needed to clarify this. However, it is known that 
levels of hormones and cytokine and growth factors may change with age and that for ex-
ample the growth hormone/insulin-like growth factor cascade is impaired in another murine 
DNA repair deficient mouse model (30). A role for systemic factors in the development of the 
skeletal phenotype may explain the mild effects on osteoblasts and osteoclasts observed in 
the ex vivo studies. 
In conclusion, accumulation of DNA damage due to defective DNA repair causes an accel-
eration of skeletal aging in male TTD mice. More specifically, aging TTD mice show an acceler-
ated decrease in bone volume and bone strength as well as lack of periosteal apposition. Part 
of the underlying cause might be the diminished differentiation potential of mesenchymal 
stem cells towards the osteoblastic lineage, but most likely alterations in additional systemic 
factors are also implicated. Overall, the data stress the importance of proper DNA repair for 
healthy skeletal ageing. 
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Increased bone mass in vertebrae of DNA repair deficient 
trichothiodystrophy mice strongly resembling patients
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Abstract 
Trichothiodystrophy (TTD) is a rare, autosomal recessive Nucleotide Excision Repair (NER) 
disorder caused by mutations in components of the dual functional NER/basal transcription 
factor TFIIH. TTD mice, carrying a patient-based point mutation in the Xpd gene, strikingly 
resemble many features of the human syndrome and exhibit signs of premature aging. In 
TTD patients demineralization of long bones and sclerosis of the vertebrae is observed. 
Previously, we reported accelerated bone loss in the long bones of TTD mice. Here we show 
that vertebrae of TTD mice exhibit increased bone mass compared to wild type mice. This 
osteosclerotic phenotype in vertebrae is strikingly similar to the phenotype observed in TTD 
patients. In addition, it shows that TTD mice exhibit a different pattern of age-related changes 
in vertebrae compared to long bones. The bone phenotype in mice thus closely resembles 
the bone phenotype in TTD patients showing osteopenic long bones and osteosclerotic 
vertebrae. 
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Introduction 
Trichothiodystrophy (TTD) is a rare, autosomal recessive DNA repair/ basal transcription 
disorder in which patients present an array of symptoms, including photosensitivity, ichthyo-
sis, brittle hair and nails (hallmark feature), impaired intelligence, decreased fertility, short 
stature, a severely reduced life span and skeletal abnormalities (1-11). 
In TTD patients demineralization of long bones and sclerosis of the vertebrae is observed 
(4,5,8-10,12-14). In 1980 Price et al. reported a boy who developed axial and cranial sclerosis 
at the age of 4 years and an osteoporotic phenotype in distal bones at the age of 7 years 
(10). Several years later, Chapman reported a 5-year old boy who exhibited osteosclerosis in 
the skull, chest, spine and pelvis with a wooly appearance of the trabeculae in addition to 
osteopenia of the distal limbs (9). In 1989 Civitelli et al. performed further studies in two boys 
with axial osteosclerosis and mild osteopenia in the extremities and found no abnormalities 
of mineral homeostasis (8). Wakeling et al. described a boy who showed normal bone density 
on a chest radiography at the age of 3 months, but increased bone density at the age of 5 
years and who consecutively developed a mild kyphosis between 6 and 7 years of age (4). 
Toelle et al. reported two sisters who showed marked kyphosis before the age of 4 years (5). 
In conclusion, TTD patients exhibit a difference in bone phenotype in long bones compared 
to the axial skeleton. 
We have generated a mouse model in which we precisely mimicked a causative point mu-
tation in the essential XPD gene of a TTD patient (TTD1BEL) (15). TTD mice have a phenotype 
that strikingly resembles the symptoms of TTD patients and they exhibit several premature 
aging-like features some of which incidentally reported in patients: deterioration of renal, 
liver and heart tissues, lymphoid depletion, thymic involution, reduced hypodermal fat, 
aortic sarcopenia, early infertility in females, a reduced life span and skeletal abnormalities 
resembling those observed in TTD patients (4-14,16-18). Previously, we reported an analysis 
of long bones of an aging cohort of female wild type and TTD mice, which showed acceler-
ated bone aging in TTD females demonstrated by an early decrease in bone volume, cortical 
thickness and strength in long bones (Diderich et al., Chapter 2). 
The aim of the current study was to assess whether the TTD mouse skeletal phenotype truly 
reflects that observed in patients. To achieve this we investigated the axial skeleton in aging 
female wild type and TTD mice by microcomputed tomography CT (µCT) and histological 
analysis and compared it with our previous data on long bones.
Material & Methods 
Mice 
We generated a cohort of female wild type and TTD mice including 5 mice per age group 
per genotype. Mice were sacrificed at 39, 52, 65 and 78 weeks. All mice were in a C57Bl/6 
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background, maintained on a 12:12 h light-dark cycle and fed ad libitum with a standard 
rodent diet (0.5% Ca and 0.3% Ph). The mice were killed by cervical dislocation. Bones were 
isolated and fixed in Burkhardt, which was replaced by 70% ethanol after 3 days. As required 
by Dutch law, formal permission to generate and use genetically modified animals was ob-
tained from the responsible local and national authorities. All animal studies were approved 
by an independent Animal Ethical Committee (Dutch equivalent of the IACUC).
Micro-CT 
Fixed vertebrae from the lumbar spine (L4-L6) of female, wild type and TTD mice of differ-
ent ages (n = 5) were scanned using a SkyScan 1072 microtomograph (SkyScan, Antwerp, 
Belgium) with isotropic voxelsize of 8.82 μm. Scans were processed and a three-dimensional 
morphometric analysis of the bone was performed, using software of the 3D-Calculator pro-
ject (http://www.erasmusmc.nl/ orthopaedie/research/labor/downloads). Trabecular thick-
ness distribution, trabecular bone volume (BV), total endocortical volume (TV), trabecular 
bone volume fraction (BV/TV), trabecular number, trabecular thickness, trabecular spacing, 
Structure Model Index (SMI) and vertebra width were determined. Figure 1 depicts the area 
in which BV, TV and vertebra width were determined. Measured parameters were expressed 
according to bone histomorphometry nomenclature (19). 
Histomorphometric analysis 
After fixation the skeletons were incubated in 70 % ethanol. The lumbar vertebral bodies 
(L3 to L5) were thereafter dehydrated in ascending alcohol concentrations and embedded 
in methylmetacrylate as described previously (20). Sections of 5 µm were cut in the frontal 
plane on a Microtec rotation microtome (Techno-Med GmbH, Munich, Germany). Static 
histomorphometry was performed according to standardized protocols (21) using the Osteo-
Measure histomorphometry system (Osteometrics Inc., Atlanta, Georgia) on lumbar vertebral 
sections of 5 µm which were stained by the van Gieson / von Kossa staining procedures as 
described (20). 
Statistics 
To analyze the changes in the micro-CT parameters and histomorphometric data over time 
(significance compared to 39 weeks of age) one-way ANOVAs with Tukey post-hoc test were 
performed using Graph Pad InStat version 3.05 for Windows 95 (Graph Pad Software, San 
Diego California, USA, www.graphpad.com). For comparisons of the micro-CT parameters 
and histomorphometric data between genotypes unpaired t-tests were performed per time 
point using Graph Pad InStat version 3.05 (Graph Pad Software, San Diego California, USA, 
www.graphpad.com). The P-values of the unpaired t-test are two-tailed. An univariate Gen-
eral Linear Model (SPSS 15.0) was used to analyze the effect of age in the different genotypes 
as wells as the effect of genotype over all ages. 
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Results
Micro-CT analysis of vertebrae 
We analyzed various structural parameters including trabecular bone volume fraction, 
trabecular number and trabecular thickness. Trabecular bone volume fraction (BV/TV) in 
wild type mice showed a gradual decline with age (Figure 2A). At 78 weeks of age BV/TV 
had decreased 16% compared to 39-weeks-old wild types. In contrast, TTD mice, which 
seemed to have higher BV/TV at all ages, showed a 24% decrease up to 65 weeks of age, 
but a tendency to increase thereafter (Figure 2A). In line with this, the number of trabeculae 
showed a gradual decrease in wild type mice reaching a 23% decline in 78-week-old wild 
types while in TTD mice the initial decline was followed by a subsequent increase in the 
number of trabeculae at 78 weeks of age (Figure 2B). Over all ages the number of trabeculae 
was significantly higher in TTD mice compared to wild type mice (Figure 2B). Following the 
changes in BV/TV and trabecular number, wild type mice showed a gradual increase in 2D 
trabecular spacing with aging whereas TTD mice showed an initial increase up to 65 weeks 
and a decrease thereafter (Figure 2C). Interestingly, the mean trabecular thickness was higher 
in TTD mice over all ages; albeit this did not reach statistical significance (Figure 2D). The 
Structure Model Index (SMI) suggested that TTD mice have a more plate-like structure (lower 
width
total volume
Figure 1
Figure 1: Area of interest for micro-computed tomography analyses.
The bone parameters were measured in the vertebral body. The line represents the width of the vertebra. The ellipse area depicts the total 
endocortical volume (TV) in which trabecular bone volume (BV) was determined. 
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SMI value) of the bone compared to wild type mice (Figure 2E). Wild type vertebrae showed 
a significant increase in width with aging (Figure 2F). In contrast, TTD mice had significantly 
wider vertebrae at 39 weeks and showed no increase in width with ageing (Figure 2F). In 
line with this observation total cortical volume showed an increase in aging wild type mice 
whereas this was not observed in TTD mice (data not shown). 
To study the difference in trabecular thickness in more detail, we anayzed the thickness dis-
tribution of vertebral trabeculae in wild type and TTD mice. Wild type mice showed a highly 
dynamic pattern in trabecular thickness distribution with aging. This was most prominent 
for the thinnest trabeculae, i.e. between 20 and 40 µm. However, this dynamic pattern is also 
observed for the thicker trabeculae, i.e. between 40 and 100 µm, albeit that the differences 
between the various ages are smaller (Figure 3A). The age-related changes in the TTD mice 
are clearly less dynamic although there was no stepwise age-related change in trabecular 
thickness distribution in TTD mice either (compare Figures 3A and B). At 39 weeks of age the 
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Figure 2: Bone parameters.
Bone parameters in aging wild type mice (solid bars) and TTD mice (open bars): trabecular bone volume fraction (A), trabecular number (B), 
trabecular thickness; over all ages TTD mice have significantly thicker trabeculae (C), trabecular spacing (D), SMI (E) and width of vertebrae (F). 
TTD mice compared to wild type animals: # p<0.05; TTD mice and wild type animals compared to their 39 week time point: ** p<0.01; error 
bars represent SEM.
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number of trabeculae is highest, at 52 weeks of age the number of trabeculae has decreased 
substantially, whereas the number of trabebuale subsequently increased showing an inter-
mediate number at 65 and 78 weeks of age (Figure 3B). Age-matched comparison of wild 
type and TTD mice showed that at 39 and 65 weeks of age TTD have clearly thicker trabeculae 
than wild type mice (Figures 3C and E). While, there were also thicker trabeculae in TTD mice 
at 78 weeks of age, there were also thinner trabeculae in TTD mice than in wild type mice 
showing a greater heterogeneity in trabecular bone thickness in TTD mice compared to wild 
type mice (Figure 3F). At 52 weeks of age, TTD mice showed a completely different pattern 
with lower volume density than wild type mice except for the trabeculae over 80 µm (Figure 
3D). These dynamics and the fact that TTD mice in general have thicker trabeculae could 
not be observed from the mean BV/TV, trabecular number and trabecular thickness values 
shown in Figures 2A, B and D, in which the combination of the number of thinner and thicker 
trabeculae is not taken into account. 
10
15
-6 
mm
2)
w t 39
w t 52
w t 65
w t 78 10
15
-6 
mm
2) TTD 39
TTD 52
TTD 65
A B
0
5
0 20 40 60 80 100 120
trabecular thickness (microns)
vo
lum
e d
en
sit
y (
x1
0-  
0
5
0 20 40 60 80 100 120
trabecular thickness (microns)
vo
lum
e d
en
sit
y (
x1
0-  
TTD 78
C D
0
5
10
15
vo
lum
e d
en
sit
y (
x1
0-6
 m
m2
)
w t 39
TTD 39
0
5
10
15
vo
lum
e d
en
sit
y (
x1
0-6
 m
m2
) w t 52
TTD 52
0 20 40 60 80 100 120
trabecular thickness (microns)
0 20 40 60 80 100 120
trabecular thickness (microns)
10
15
(x1
0-6
 m
m2
) w t 65
TTD 65
10
15
(x1
0-6
 m
m2
) w t 78TTD 78
E F
0
5
0 20 40 60 80 100 120
trabecular thickness (microns)
vo
lum
e d
en
sit
y 
0
5
0 20 40 60 80 100 120
trabecular thickness (microns)
vo
lum
e d
en
sit
y 
Figure 3
Figure 3: Trabecular thickness distribution.
Trabecular thickness distribution in aging wild type females (A) and TTD females (B). Comparison of trabecular thickness distribution between 
wild type (solid line) and TTD females (dotted line) at 39 (C), 52 (D), 65 (E) and 78 (F) weeks of age. 
101
Increased bone mass in vertebrae of TTD mice
Histomorphometric analysis of vertebrae
Histomorphometric analysis of the vertebrae showed higher trabecular bone volume fraction 
(BV/TV) in TTD mice at all ages reaching statistical significance in 78-week old animals (Figure 
4A) thereby supporting the microCT analyses. In addition, the observed dynamics were 
similar; ie. wild type mice showed a gradual decrease in BV/TV whereas TTD mice exhibited a 
decrease at week 65 followed by an increase in BV/TV at old age (Figure 4A). 
Interestingly, TTD mice exhibited disorganized trabecular structures (illustrated in Figure 4B, 
panels 1-4), which may explain the greater heterogeneity in trabecular bone thickness, com-
pared to wild type mice (Figure 3F). These typical bone malformations increased with age. 
Histopathological analysis of the vertebral column of old TTD mice
TTD and wild type mice kept under different conditions (another location and receiving 
another diet) appeared to have a longer lifespan, allowing us to analyse animals at even a 
higher age. In line with our data, an increase in bone mass was observed in these old TTD 
mice. In transversal samples of the vertebrae of five 104-week-old TTD females a pronounced 
increase in bone mass (osteosclerosis) accompanied by a distinct reduction of medullary 
spaces in the thoracal and cervical vertebrae was observed (Figure 4C). Samples from five 
104-week-old wild type females did not show osteosclerosis and had normal-sized medullary 
spaces. These data are supported by results from a life-span study showing slight to moder-
ate osteosclerosis in transversal samples of vertebrae of 33 out of 36 aged TTD females and 
minimal osteosclerosis in only one out of 40 aged wild type females. In addition, osteone-
crosis (defined as empty osteocyte lacunae) was observed in the vertebrae of old TTD mice 
(Figure 4D). 
Discussion
To assess whether the skeletal phenotype in TTD mice truly reflects that observed in patients, 
ie. osteopenic long bones and osteosclerotic vertebrae, we analyzed the axial skeleton in age-
ing wild type and TTD females. In agreement with previous studies, wild type mice showed a 
decline in vertebral trabecular bone volume fraction and trabecular number with ageing (22). 
While TTD mice showed an initial decrease in trabecular bone volume fraction and trabecular 
number, they exhibited an increase in bone mass at 78 weeks. In addition, the thickness 
distribution data demonstrate that TTD mice contain thicker trabeculae than wild type mice 
and that the dynamics of vertebral trabecular bone turnover is different in wild type and TTD 
mice. Noteworthy, this telling data could not be observed from the mean microCT data, e.g. 
BV/TV, trabecular number and trabecular thickness, which are usually presented. 
It appears from the data on trabecular bone volume fraction, trabecular number and tra-
becular thickness distribution that already young TTD mice have more bone mass in their 
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Figure 4Figure 4: Histomorphometric and histopathological analysis of vertebrae. 
Trabecular bone volume fraction in aging wild type mice (solid bars) and TTD mice (open bars) (A), 2D histology (panel 1-4) images of vertebrae 
of aging TTD mice with the highest trabecular bone volume fraction; disorganized appearance indicated by arrow (B). Transversal section of 
vertebrae showing an increase in bone mass accompanied by a reduction of medullary spaces (indicated by arrows) in a 104-week old TTD 
mouse compared to a wild type mouse (C). Increased magnification showing empty osteocyte lacunae (indicated by arrows) in vertebrae of a 
104-week old TTD mouse compared to a wild type mouse (D). TTD mice compared to wild type mice: # p<0.02; error bars represent SEM. 
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vertebrae than wild type mice. As this increased bone mass is also observed in vertebrae of 
TTD patients, it is intrinsic to the XPD mutation and validates the XPD point mutant (TTD) 
mouse as a model for trichothiodystrophy. 
The higher bone mass in vertebrae does not represent a premature ageing phenotype. 
Wild type mice do not show such an extensive increase in bone mass nor is this observed 
in humans. Quantitative computed tomography studies in aging humans showed large de-
creases in volumetric bone mineral density (BMD) at several skeletal sites including the spine 
(23). This decrease in BMD is illustrated by the impression fractures in vertebrae observed in 
elderly people. 
Although, the increased bone mass in old TTD mice which can be observed as disorganized 
bone might represent a form of cancer, this is not likely to be the case. The analyzed vertebrae 
contain differentiated bone cells (personal communication, M. Amling) which is not typical 
of cancer. Furthermore, TTD mice develop less spontaneous cancer than wild type mice 
(18). However, hyperplasia of tissue, ie. atypical duodenal hyperplasia, has been reported in 
TTD mice (18). Interestingly, Paget’s disease which is a common condition characterised by 
increased and disorganised bone turnover shows similar bone lesions which can lead to eg. 
bone deformity. Although Paget’s disease was considered to be a disease of the osteoclast, 
there is evidence that stromal cell function and osteoblast function are also abnormal (24). 
Genetic factors play an important role in Paget’s disease, but environmental factors as e.g. 
viruses, mechanical loading and environmental toxins have also been implicated as possible 
disease triggers (24). However, other typical characteristics of Paget’s disease, e.g. fibrous 
replacement of the bone marrow, are not observed in TTD mice (R. Beems, unpublished 
results). 
The increase in trabecular bone volume fraction, which (partly) can be observed as an 
increase in the disorganized appearance of the vertebrae in old TTD mice might represent 
a local increase in the number or differentiation of osteogenic mesenchymal stem cells. It 
would be of interest to study mesenchymal stem cells derived specifically from murine verte-
brae. However, this is technically very challenging. We have studied mesenchymal stem cells 
derived from murine femora (Diderich et al., Chapter 2), but it has been shown that differ-
ences between mesenchymal stem cells derived from femora and vertebrae exist (25). Over 
all ages, TTD mice have significantly lower levels of estradiol compared to wild type mice 
(our unpublished results). It has been shown that vertebrae of ovariectomized rats exhibit a 
higher rate of bone formation compared to sham-treated animals (26). Thus, systemic factors 
may influence the phenotype in TTD vertebrae. 
In addition, TTD mice may show reduced mechanical adaptation. TTD vertebrae seem to 
exhibit less osteocytes (data RIVM,) which are thought to be the mechanosensors in bone 
(27). Furthermore, TTD vertebral trabeculae have a disorganized appearance which could be 
due to lack of alignment of trabeculae. Alignment of trabeculae was observed in tibiae of 
ovariectomized rats and was thought to represent an acceleration of normal bone adapta-
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tion (28). The observed increase in the number of trabeculae as well as the disorganized 
appearance may result from the decrease in osteocytes followed by a decrease in sclerostin 
expression. Sclerostin is a protein secreted by osteocytes, which inhibits bone formation 
and mineralization by osteoblasts (29). When osteocytes are absent or their numbers are 
decreased, it can be expected that (disorganized) bone formation is increased. 
As TTD mice exhibit osteosclerotic vertebrae, kyphosis in TTD mice is not due to osteopo-
rosis of the vertebrae as previously hypothesized and discussed (16,30,31), but may rather be 
related to deformation of the osteosclerotic vertebrae. Interestingly, TTD vertebrae showed 
no increase in width. TTD mice also showed a lack of increase in cortical thickness in tibiae 
which was due to a lack of periosteal apposition (Diderich et al., Chapter 2). 
In conclusion, similar to TTD patients TTD mice exhibit increased bone mass in their 
vertebrae. The bone phenotype in mice thus closely resembles the bone phenotype in TTD 
patients showing osteosclerotic vertebrae and validates the XPD knockout as a bonafide 
model for trichothiodystrophy. Furthermore, it shows the importance of proper DNA repair 
for optimal bone formation in vertebrae and for bone metabolism in general and thus further 
supports the significance of proper DNA repair in normal aging. 
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Abstract
Previously, we reported that trichothiodystrophy (TTD) mice show accelerated bone loss and 
lack of periosteal apposition with aging. In addition, the data suggested that the observed 
accelerated skeletal aging was the result of a combination of accelerated decline in the 
number of osteogenic stem cells and altered systemic influences. In this study we analyzed 
bodyweight, several bone metabolism-related serum parameters, i.e. calcium, parathyroid 
hormone, vitamin D, alkaline phosphatase, osteocalcin, TRAP, estradiol, testosterone, leptin 
and corticosterone levels as well as histology of the adrenals and ovaries in aging wild type 
and TTD mice to assess whether differences in these parameters are related to the previously 
observed bone phenotype. Aging TTD mice exhibit low estradiol levels which are the result 
of a lack of fat-mass rather than ovarian dysfunction. In addition, TTD mice showed low levels 
of parathyroid hormone and 25-hydroxyvitamin D3 while bone turnover markers showed 
no significant differences and 1,25-dihydroxyvitamin D3 levels were higher in aging TTD 
females. Analysis of adrenals suggests less effective steroidogenesis in TTD mice. In conclu-
sion, TTD mice show differences in circulating levels of hormones known to control bone 
metabolism as well as calcium homeostasis. These changes did not result in altered serum 
calcium but may constitute the systemic influences contributing to the bone phenotype in 
prematurely aging trichothiodystrophy mice. Following this, the observed bone phenotype 
may be important to maintain stable serum calcium with aging.
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Introduction 
Trichothiodystrophy (TTD) is a rare, autosomal recessive DNA repair disorder, in which pa-
tients present an array of symptoms, including photosensitivity, ichthyosis, brittle hair and 
nails, impaired intelligence, decreased fertility, short stature, an aged appearance, a reduced 
life span and skeletal abnormalities (1-12). Complementation analysis of UV-sensitive TTD 
patients revealed the involvement of three genes (XPB, XPD and TTDA), encoding subunits 
of the dual functional DNA repair/basal transcription factor TFIIH. TFIIH is a protein complex 
involved in the Nucleotide Excision Repair (NER) pathway, a repair mechanism which removes 
numerous types of helix-distorting and bulky lesions by a ‘cut and patch’-like mechanism 
anywhere in the genome (global genome NER) and also acts when damage blocks ongoing 
transcription (transcription-coupled repair) (13-17). In addition, TFIIH is implicated in tran-
scription initiation of RNA polymerases I and II (13,18). We have generated a mouse model in 
which we mimicked a causative point mutation identified in the XPD gene of a photosensitive 
TTD patient (TTD1Bel) (19). The phenotype of TTD mice very much resembles the symptoms 
of patients, including the presence of premature aging features (20,21). 
In previous studies, we examined in great detail the effects of aging on bone parameters 
of wild type mice as well as progeroid TTD mice (Diderich et al., Chapter 2; Nicolaije et al., 
Chapter 3). The systematic analysis uncovered the consequence of a defect in DNA repair and 
basal transcription on the velocity of age-related skeletal changes and assessed to which ex-
tent the skeletal abnormalities reflect normal bone aging. We showed that tibiae of TTD mice 
exhibited normal bone development and metabolism up to 39 weeks of age followed by an 
accelerated decrease in bone volume compared to wild type mice. In addition, we observed 
a different temporal pattern of change in bone phenotype in male wild types compared to 
female wild types. Furthermore, we found that aging TTD mice lack periosteal apposition 
leading to reduced bone strength compared to wild type mice. These data combined with 
bone marrow cultures and in vivo intermittent PTH treatment suggested that the accelerated 
decrease in bone mass was caused by a combination of accelerated decline in the number of 
osteogenic stem cells and altered systemic influences. The focus of the current study was to 
document changes in body-weight, serum parameters related to bone turnover, and endo-
crine factors known to affect bone metabolism in relation to the previously reported bone 
phenotype. For this, the aging cohorts of both female and male wild type mice as well as the 
prematurely aging TTD mice were investigated.
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Material & Methods 
Mice 
We generated a cohort of wild type and TTD mice including 8 mice per sex per age group per 
genotype. Wild type mice were held up to 104 weeks while TTD mice die at around 78 weeks 
of age. Mice were sacrificed at 6, 13, 26, 39, 52, 65 and 78 weeks (wild type and TTD mice) and 
91 and 104 weeks of age (wild type mice). All mice were in a C57Bl/6 background, maintained 
on a 12:12 h light-dark cycle and fed ad libitum with a standard rodent diet (0.5% Calcium and 
0.3% Phosphate). The animals were weighed 10 days before sacrifice. Blood was collected by 
an orbital puncture under isoflurane anesthesia and the mice were subsequently killed by 
cervical dislocation. Organs were isolated and either snap-frozen and stored at –80˚C or fixed. 
Blood was stored on ice during the procedure after which it was centrifuged at 6000rpm for 
10 minutes. Serum was taken off and stored at -20˚C. As required by Dutch law, formal per-
mission to generate and use genetically modified animals was obtained from the responsible 
local and national authorities. All animal studies were approved by an independent Animal 
Ethical Committee (Dutch equivalent of the IACUC).
Serum parameters
Calcium levels were colorimetrically determined at 595 nm (Packard Spectra Count) after 
addition of 1M ethanolamine buffer (pH 10.6) containing 0.35 mM o-cresolphtalein complex-
one, 19.8 mM 8-hydroxy-quinoline, and 0.6 mM hydrochloric acid. Results were adjusted for 
DNA content of the corresponding cell lysates. 
Parathyroid hormone was measured as decribed by the manufactures using the mouse intact 
PTH ELISA kit purchased from Lucron Bioproducts (Gennep, The Netherlands; produced by 
Immutopics Inc., San Clemente, USA). 25-hydroxyvitamin D3 was measured by a 125I radioim-
munoassay purchased from DiaSorin (Minnesota, USA). 1,25-dihydroxyvitamin D3 was mea-
sured by a 125I radioimmunoassay using the IDS Gamma-B kit purchased from Immunodiag-
nostic Systems (Tyne and Wear, UK). Serum levels of osteoocalcin were measured using an in 
house assay with antibodies generously supplied by prof. R. Bouillon (Leuven, Belgium). The 
levels of alkaline phosphatase were assayed by determining the release of para-nitrophenol 
from paranitrophenylphosphate (20 mM in 1 M diethanolamin buffer supplemented with 1 
mM MgCl2 at pH 9.8) in the serum for 10 min at 37°C (27). Adding 0.1 M NaOH stopped the re-
action and absorption was measured at 405 nm using a Packard Spectra Count. Results were 
adjusted for DNA content of the serum. Serum tartrate resistant acid phosphatase (TRAP) 
levels were measured as decribed by the manufactures, using the TRAP assay purchased from 
SBA Sciences (Turku, Finland). Serum levels of estradiol were estimated in duplicate using 
the ultrasensitive radioimmuno assay (RIA) purchased from Diagnostic Systems Laboratories 
(Webster, TX, USA). Serum levels of testosterone were measured by coated tube RIA obtained 
from Siemens DPC (Los Angeles, USA). Serum levels of leptin were measured, as decribed by 
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the manufactures, using an ELISA assay purchased from R&D Systems (UK). Serum levels of 
corticosterone were estimated using enzyme immunoassays provided by Diagnostic Systems 
Laboratories.
Ovarian histology and follicle counting
Three mice were randomly selected from each age group. Ovaries were isolated, fixed in 
Bouin (15 picric acid: 5 formaldehyde 37%: 1 acetic acid) overnight, placed in 70% ethanol 
and stored at 4˚C. Follicle count was performed as described previously (22) using one ovary 
per animal. Follicles were counted in every 10th section. 
Analysis of aromatase expression 
Fat from the abdomen was snap frozen and stored at –80˚C. RNA was isolated using Trizol 
according to the manufacturer’s guidelines. RNA was isolated from fat and ovaries using an 
adapted RNAzolB procedure. cDNA was made and the PCR product visualized by gelelectro-
phoresis.
Oil-Red-O staining
Cryosections of male liver were stained with Oil-Red-O to detect triglycerides. All histology 
images were acquired at 40x objective magnification on an Olympus BX40 microscope (Lon-
don, United Kingdom), equipped with a CCD camera.
Light microscopy and electron microscopy of adrenals 
Adrenals from 13- and 78-week old, male and female, wild type and TTD mice (4 mice per 
group) were isolated. For light microscopy adrenals were fixed in 3.7% formalin in phosphate 
buffer for 24-36 hours at roomtemperature. Subsequently, the adrenals were dehydrated in 
increasing grades of ethanol and embedded in paraffin.
For electron microscopy pieces of adrenals were fixed in glutaraldehyde 2.5% in 0.1 M sodium 
cacodylate buffer, pH 7.2 at 4ºC, for 2 hours and rinsed in 7% sucrose in 0.1 M sodium cacodyl-
ate buffer, pH 7.2 (same buffer as above) at 4ºC, overnight.
Subsequently, the pieces of adrenals were post-fixed in osmium tetroxide 1% in veronal 
acetate buffer, pH 7.3, 2 hours at 4ºC, dehydrated in ethanol and embedded in Epon.
Statistics
For comparisons in time (significance compared to 6 or 26 weeks of age), between sexes and 
genotype comparisons of the weight and serum parameters one-way ANOVAs with Tukey 
post hoc test and unpaired T-tests were performed using Graph Pad InStat version 3.05 for 
Windows 95, Graph Pad Software, San Diego California, USA, www.graphpad.com. A univari-
ate General Linear Model (SPSS 15.0) was used to analyze the effect of age in the different 
genotypes as wells as the effect of genotype over all ages for the serum parameters. 
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Results
Bodyweight  
Bodyweight can influence bone volume by the weight bearing effect. We measured the 
bodyweight of wild type and TTD mice (Figure 1). At 6 weeks of age TTD and wild type mice 
on average weighed 11 and 14-15 grams, respectively. From 13 weeks of age onwards male 
mice were heavier compared to female mice (compare Figures 1A and B). From 26 and 39 
weeks on the weight of respectively male and female wild type mice started to increase 
whereas TTD mice showed a stable weight during most of their late adult life span. As a result, 
significant differences in weight between wild type and TTD mice were observed from 52 
weeks of age onwards. In parallel with the increase in bodyweight in wild type mice, we 
observed accumulation of an increase of fat in the abdominal cavity (Figure 1C). In TTD mice 
this accumulation of fat was not observed (Figure 1C). At the end of their lifespan a decrease 
in weight was observed in both sexes of wild type and TTD mice, after 78 and 65 weeks, 
respectively (Figures 1A and B). Thus, TTD mice have a lower weight after 39 weeks of age 
compared to wild type mice and lack accumulation of fat in the abdomen. These data are in 
line with findings reported for other TTD cohort studies (20,21). 
Calcium, PTH and vitamin D 
Given their importance for bone metabolism, the levels of calcium, parathyroid hormone 
(PTH), 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 were measured in serum col-
lected from the aging mice. In both wild type and TTD mice calcium levels were maintained 
around 2,5-3 mM throughout life with no significant differences between wild type and TTD 
mice (Figures 2A, B). Over all ages, PTH levels in wild type mice were significantly higher than 
in TTD mice of similar sex (Figures 2C, D). While 25-hydroxyvitamin D3 levels only showed a 
significant increase with age in female mice, both male and female wild type mice had sig-
nificantly higher levels of 25-hydroxyvitamin D3 over all ages compared to TTD mice (Figures 
2E, F). Over all ages, 1,25-dihydroxyvitamin D3 levels were significantly higher in TTD females 
with a clear increase at 39 weeks and onwards (Figure 2G). In contrast, both wild type and TTD 
males showed a significant increase in 1,25-dihydroxyvitamin D3 levels with age (Figure 2H). 
Bone formation markers 
In addition, we measured two key markers of bone formation, alkaline phosphatase (ALP) 
and osteocalcin. As expected the ALP levels were significantly higher in young mice (Figures 
3A, B). In adulthood wild type mice seemed to show higher levels of ALP compared to TTD 
mice. However, this did not reach statistical significance. At 78 weeks of age ALP levels in 
wild type and TTD mice were similar after which an increase was observed in wild type mice 
which reached significance in 104-week-old males (Figures 3A, B). Similarly, osteocalcin 
levels were significantly higher in young animals (Figures 3C, D). Between 6 and 26 weeks 
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of age osteocalcin levels decreased and subsequently remained at a more or less constant 
level (Figures 3C, D). Overall, male wild type mice showed significantly higher osteocalcin 
levels compared to TTD mice (Figure 3D). Between 52 and 65 weeks of age and at the age 
of 65 weeks the curves of the wild type and TTD mice crossed for the female and male mice, 
respectively (Figures 3C, D). 
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Figure 1: Bodyweight and abdominal cavity in wild type and TTD mice.
Bodyweight in wild type (closed symbols) and TTD mice (open symbols); (A) females and (B) males. Error bars represent SEM; significance 
compared to 26 w: *= p<0.05, **= p< 0.01, ***= p< 0.001 and significance compared between genotypes: ##= p< 0.01, ###= p< 0.001. 
(C) abdominal cavity showing (lack of) fat mass in a wild type mouse and a TTD mouse. 
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Figure 2
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Figure 2: Calcium, PTH and vitamin D in wild type and TTD mice. 
Serum parameters in wild type (closed symbols) and TTD mice (open symbols). Levels of calcium in (A) female and (B) male mice, parathyroid 
hormone in (C) female and (D) male mice, 25-hydroxyvitamin D3 in (E) female and (F) male mice and 1,25-dihydroxyvitamin D3 in (G) female 
and (H) male mice. Error bars represent SEM; significance compared to 6 w: *= p<0.05, **= p< 0.01, ***= p< 0.001 and significance 
compared between genotypes: #= p<0.05. Over all ages wild type mice had significantly higher levels of parathyroid hormone and 
25-hydroxyvitamin D3. Over all ages female TTD mice had significantly higher levels of 1,25-dihydroxyvitamin D3. Female mice showed a 
significant increase in 25-hydroxyvitamin D3 with age. Male mice showed a significant increase in with age. 
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Bone resorption 
The levels of tartrate resistant acid phosphatase (TRAP) were measured in serum of female 
mice to assess possible differences in bone resorption. Albeit bone resorption seemed to 
be higher at 78 weeks of age, it did not significantly change upon aging and no significant 
difference between wild type and TTD mice was observed (Figure 3E). 
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Figure 3: Bone formation markers in wild type and TTD mice. 
Serum parameters in wild type (closed symbols) and TTD mice (open symbols). Levels of alkaline phosphatase in (A) female and (B) male mice, 
osteocalcin in (C) female and (D) male mice and TRAP in female mice (E). Error bars represent SEM; significance compared to 26 w: **= p< 0.01, 
***= p< 0.001, significance compared between genotypes: ###= p< 0.001. Young mice had significantly higher levels of alkaline phosphatase 
and osteocalcin. Over all ages male wild type mice had significantly higher levels of osteocalcin.
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Estradiol and testosterone 
Over all ages, TTD females had significantly lower estradiol levels compared to wild type mice 
(Figure 4A). In addition, we measured testosterone levels in aging male mice. However, as 
expected the testosterone levels showed large variation precluding any significant conclu-
sion about genotype or aging effects (Figure 4B). 
Ovarian histology and follicle counting 
Next, we went on to see whether the lower estradiol levels in TTD females are caused by a 
defect in the ovaries. It is known that the primordial follicle pool consists of a set of follicles 
of which some are selected to grow during initial recruitment. As a result, the size of the 
primordial follicle pool decreases. During cyclic recruitment a number of these growing fol-
licles is selected to form ovulatory follicles. The granulosa cells in these ovulatory follicles 
form estradiol. 
In both wild type and TTD females, the number of growing follicles gradually decreased from 
13 weeks of age onwards (Figure 4C). Up to 39 weeks of age about 50 to 150 growing fol-
licles were detected per ovary. After that the ovaries exhibited a clear drop in follicle number 
0
25
50
75
100
6 13 26 39 52 65 78
age (w eeks)
17
be
ta
 E
st
ra
di
ol
 (p
m
ol
/ll)
0
5
10
15
20
25
30
35
40
45
26 52 78
age (weeks)
te
st
os
te
ro
ne
 (n
m
ol
/L
)
B
A
0
2
4
6
8
0 13 26 39 52 65 78
age (w eeks)
nr
. o
f o
vu
la
to
ry
 fo
lli
cl
es
0
40
80
120
160
0 13 26 39 52 65 78
age (w eeks)
nr
. o
fg
ro
w
in
g 
fo
lli
cl
es
D
C
Figure 4
Figure 4: Estradiol, testosterone and ovarian follicles in wild type and TTD mice.
Serum parameters and numbers of growing and ovulatory ovarian follicles in wild type (closed symbols) and TTD mice (open symbols). (A) 
estradiol levels in female mice; over all ages wild type mice had significantly higher levels of estradiol, (B) testosterone levels in male mice, 
number of (C) growing and (D) ovulatory follicles. Error bars represent SEM.
Chapter 5
118
reaching follicle numbers between 0 and 42 per ovary (Figure 4C). In contrast, the number of 
ovulatory follicles showed no evident change with aging (Figure 4D). For none of the ovarian 
follicle parameters a significant difference between wild type and TTD mice was observed. 
Thus, wild type and TTD mice have similar numbers of growing and ovulatory follicles.
Aromatase expression 
Estrogen levels were lower in TTD mice in spite of a normal number of pre-ovulatory follicles. 
However, TTD mice lacked accumulation of abdominal fat. We analysed aromatase expres-
sion in abdominal fat of wild type mice using RT-PCR to investigate whether this fat could 
be the source of the additional estrogen that was measured in wild type mice. In abdominal 
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Figure 5: Aromatase expression, Oil-Red-O staining and leptin levels in wild type and TTD mice.
(A) aromatase expression in fat of wild type mice. (B) Oil-Red-O staining on livers from a 78-week-old male wild type and TTD mouse. Staining 
of triglycerides indicated by arrows. Pictures were taken at 100x magnification. Serum leptin levels in wild type (closed symbols) and TTD mice 
(open symbols); (C) female and (D) male mice. Error bars represent SEM. 
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fat from 6, 12 and 18 month old male and female wild type mice aromatase expression was 
detected (Figure 5A). 
Fat staining 
In order to see if the lack of fat is a more generalized phenomenon, we performed Oil-Red-O 
stainings on liver sections from wild type and TTD males. In 18-month-old male wild type 
mice abundant staining was present in liver (Figure 5B). In contrast, livers of 18-month-old 
male TTD mice showed no evident staining (Figure 5B). Thus, TTD mice have less fat accumu-
lation in liver as well as in the abdominal cavity. 
Serum leptin 
As leptin is produced in fat and plays a role in bone metabolism, we measured leptin levels 
in wild type and TTD males and females. In line with the increase in abdominal fat, wild type 
mice showed higher leptin levels at 52 weeks of age (Figures 5C, D). However, at the age of 
78 weeks both female and male wild types showed a decrease in leptin levels (Figures 5C, 
D) while no significant decrease in weight was observed. In contrast, TTD mice showed low 
leptin levels throughout life (Figures 5C, D). Thus, in agreement with the lower bodyweight 
and lack of abundant fat, TTD mice have lower leptin levels compared to wild type mice; 
particularly in the period in which wild type mice show an increase in visceral fat. 
Corticosterone levels and microscopy of adrenals 
Glucocorticoids (i.e. in mice corticosterone) may affect bone metabolism; in particular 
in mice high levels of glucocorticoids have a negative effect on bone mass. High levels of 
glucocorticoids reduce numbers of both osteoblast and osteoclast precursors in mice, but 
the number of osteoclasts does not decrease as does osteoblast number due to the ability of 
glucocorticoids to promote osteoclast life span (23). 
Serum corticosterone levels were significantly higher in wild type females compared to TTD 
females (Figure 6A). In male mice a large variation was observed, especially in 78-week-old 
TTD males, and no significant differences were observed with aging or between genotypes 
(Figure 6B). 
The adrenal cortex consists of the zona reticularis, the zona fasciculata and the zona glomeru-
losa. Glucocorticoids are secreted from the zona fasciculata and to a lesser extent from the 
zona reticularis. The zona glomerulosa secretes mineralocorticoids. The X-zone is a zone that 
can be distuinguished from the zona fasciculate in young mice. The X-zone is characterised 
by whorls of smooth endoplasmic reticulum and peculiar complexes of mitochondria and 
smooth endoplasmic reticulum (24). More whorls are observed when the X-zone regresses 
in old mice. 
We visualised the zona fasciculata and the zona reticularis by light microscopy. Old TTD mice 
exhibited a larger cell volume in the zona fasciculata compared to wild type mice as well 
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as younger TTD mice (Figures 6C, D). Electron microscopy revealed more mitochondria and 
fewer lipid droplets in the zona fasciculata in old TTD mice compared to wild type mice as 
well as younger TTD mice (Figures 6E, F). In addition, young TTD females showed more whorls 
than wild type mice (Figure 6E). Thus, on basis of cell volume and the amount of mitochondria 
and lipids one would predict highest glucocorticoid synthesis in old TTD mice in contrast to 
the observed corticosterone data in female TTD mice. 
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Figure 6 : Serum corticosterone levels and microscopical analysis of adrenals in wild type and TTD 
mice. 
Corticosterone in (A) female and (B) male wild type (closed symbols) and TTD mice (open symbols). Over all ages wild type mice had 
significantly higher levels of corticosterone. Parenchymal cell volume of (C) female and (D) male adrenals, number of organelles in the 
zona fasciculata of (E) female and (F) male adrenals. Abbreviations: wt= wild type, fasc= zona fasciculata, retic= zona reticularis, mito= 
mitochondria, retic= reticulocytes, hialopl= hialoplasma, lyso= lysosomes. Error bars represent SEM; significance compared between 
genotypes: ##= p< 0.01. 
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Discussion 
Previously, we have shown -by micro-computed tomography analysis- that TTD mice have 
an accelerated decrease in bone volume in tibiae compared to wild type mice and that they 
lack an increase in bone perimeter (Diderich et al., Chapter 2). Using double labeling stud-
ies, we confirmed that TTD mice lack periosteal apposition and thus have no compensatory 
mechanism to maintain bone strength (Diderich et al., Chapter 2). Indeed, mechanical testing 
showed a decrease in bone strength in TTD mice compared to wild type mice (Diderich et 
al., Chapter 2). In vitro bone marrow cell cultures showed that TTD osteoprogenitors retain 
the capacity to differentiate into osteoblasts, but show decreased bone nodules after 13-26 
weeks of age (Diderich et al., Chapter 2). In addition, after intermittent PTH treatment TTD 
females demonstrated an increase in cortical thickness implicating that there are still enough 
stem cells/osteoblasts to maintain the bone phenotype at wild type level (Diderich et al., 
Chapter 2). The accelerated skeletal aging in TTD mice is likely the result of a combination of 
an accelerated decline in the number of osteogenic stem cells together with altered systemic 
influences. Indeed various DNA repair deficient mouse models exhibiting premature aging 
show a sytemic downregulation of various key hormonal axes, including estrogen (25), which 
may also contribute to the observed loss of osteoprogenitors. To analyze these systemic influ-
ences in more detail, we measured several endocrine parameters as well as bodyweight of 
wild type and TTD mice. In both aging wild type and TTD mice serum levels of calcium, para-
thyroid hormone, 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3, alkaline phosphatase, 
osteocalcin, TRAP, estradiol, testosterone, leptin, and corticosterone were measured; several 
of these parameters have not been documented in aging mice before. 
Calcium, PTH and vitamin D3 levels
PTH and 25-hydroxyvitamin D3 levels were significantly lower in TTD mice whereas 1,25-di-
hydroxyvitamin D3 levels were significantly higher in female TTD mice. It is known that 
a decrease in serum calcium leads to an increase of PTH levels resulting in an increase in 
1,25-dihydroxyvitamin D3 levels. 1,25-dihydroxyvitamin D3 is synthesized mainly in the 
kidney by 25-hydroxy-vitaminD-1α-hydroxylase which is stimulated by PTH (26). 1,25-di-
hydroxyvitamin D3 then increases intestinal calcium absorption and renal reabsorption of 
calcium to restore serum calcium levels (27). In a negative feedback loop the increased level 
of 1,25-dihydroxyvitamin D3 leads to an inhibition of it’s own production by 1α-hydroxylase 
and also leads to an inhibition of PTH production and secretion leading to reduction of serum 
PTH levels (26). 
We hypothesize that TTD mice have decreased intestinal calcium absorption and/or 
increased renal calcium loss while maintaining serum calcium (see Figures 2A and B). To 
maintain this crucial stable level of serum calcium, PTH levels had to increase followed by an 
increase in 1,25-dihydroxyvitamin D3. The increased levels of 1,25-dihydroxyvitamin D3 will 
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then repress PTH secretion. Remarkable, the 25-hydroxyvitamin D3 levels were significantly 
lower in TTD mice. This could be the effect of decreased synthesis in the skin or the liver of 
TTD mice. TTD mice are known to have specific skin lesions as well as more hepatocellular 
atrophy compared to wild type mice (21). 
Previous studies, including biochemical analysis of aminoacids in serum of TTD mice, 
showed no indications of malabsorption in TTD mice (20), while just a small number of TTD 
mice exhibited atypical hyperplasia of the duodenum (21). If, however, there is an imbalance 
in the absorption and loss of calcium, one would expect to see high levels of 1,25-dihydroxyvi-
tamin D3 and low levels of PTH in addition to normal levels of serum calcium. This is exactly 
what we observed in TTD mice. Interestingly, long-term administration of 1,25-dihydroxyvi-
tamin D3 has been shown to result in a decrease in bone volume in mice (28). Furthermore, in 
TRPV5_/_ mice which exhibit increased levels of 1,25-dihydroxyvitamin D3 a decrease in bone 
volume was observed (29). In female TTD mice the 1,25-dihydroxyvitamin D3 levels increase 
just before the change in bone phenotype is observed. 
Interesting, but yet unexplainable are the difference in 1,25-dihydroxyvitamin D3 levels in 
female and male TTD mice. It is tempting to attribute this to differential effects of estrogens 
and testosterone. 
Estradiol
In addition to the decrease in bone volume that might be caused by increased levels of 
1,25-dihydroxyvitamin D3 in TTD mice, the low estradiol levels may result in impaired inhibi-
tion of bone resorption as well as in impaired bone formation. Estradiol plays an important 
role in bone metabolism by controling bone resorption, by inhibiting osteoclast formation 
and by decreasing their life-span. In addition estradiol has been shown to have an anabolic 
effect on bone in mice (30). 
The lower levels of estradiol in TTD females do not seem to be caused by ovarian dysfunction 
as wild type and TTD females have similar numbers of growing and ovulatory follicles. This is 
in contrast to the previously observed heterogeneous ovarian dysfunction in 6-months-old 
female TTD mice in a mixed genetic background (20). The pure C57Bl/6 background in our 
TTD mice, which allows the TTD mice to become older as well, thus alleviates several of the 
symptoms that were reported for TTD mice in a mixed background. Since the lower estradiol 
levels are not caused by ovarian dysfunction, we next analysed the abundant fat in wild type 
mice for aromatase expression. Indeed, aromatase expression is present in fat from wild type 
females. In men and postmenopausal women, extragonadal aromatase expression plays a 
key role in estrogen production (31). Recent work has suggested that aromatase expression 
in adipose tissue of male mice may play an important role in their estrogen biosynthesis 
(31). Is is possible that aromatase expression in adipose tissue present in wild type mice may 
contribute to the higher levels of estradiol in old wild type females. On the other hand, it is 
possible that the breakdown of estrogen is increased in TTD mice. 
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Much is known about the role of estrogen on bone metabolism. Together with biomechani-
cal strain, estrogen is an important player in bone mass conservation (32). Most importantly, 
estrogen inhibits bone resorption by inhibiting osteoclastogenesis and osteoclast function 
and favouring osteoclast apoptosis (33,34). In addition, estrogen promotes the development 
of osteoblasts from the osteoblast-adipocyte-precursor, and increases the production of a 
number of osteoblast proteins as e.g. IGF-1 (30,35,36) Thus, a decrease in estrogen due to 
menopause or ovariectomy results in increased bone loss and adipocyte formation (37). The 
lower levels of estradiol in TTD mice can thus play a role in the accelerated bone loss resulting 
in enhanced differences between wild type and TTD mice.
Recently, it was found that estrogens also decrease osteoblast apoptosis (32). In addition, 
estrogens, like androgens, may be involved in regulation of periosteal apposition. Although 
estrogens were believed to have a negative effect on periosteal bone formation (32,38,39), 
recent studies have shown that estrogens may stimulate periosteal apposition (40-42). It is 
therefore possible that the lower levels of estradiol could have some contribution to the 
decline in periosteal appostion as observed in TTD mice. 
Bone turnover 
Total alkaline phosphatase was high in young animals in line with data in other species (43). 
The measured alkaline phosphatase is not bone-specific, but in dogs it was shown that at 
young age bone-specific alkaline phosphatase made up 96% of total alkaline phosphatase 
(43). High bone-specific alkaline phosphatase correlates with increased bone formation (43). 
Between 13 and 78 weeks of age, total alkaline phosphatase was higher in wild type mice. 
Higher levels of total alkaline phosphatase are observed in hyperparathyreoidie and when 
corticosteroid levels are higher (43) suggesting that the lower levels of parathyroidhormone 
and corticosterone in female and young male TTD mice may have had an effect on the levels 
of alkaline phosphatase. At old age, the percentage of total alkaline phosphatase that is 
induced by corticosteroids increases (43). However, the majority of alkaline phosphatase 
is liver-specific alkaline phosphatase (43). The increase in alkaline phosphatase in old mice 
could thus be a result of liver-associated problems which have been reported in wild type 
mice (21). In addition, the strong increase in alkaline phosphatase in wild type females may 
partly result from the increase in corticosterone. However, osteocalcin levels showed an iden-
tical pattern as total alkaline phosphatase with aging indicating that the observed changes in 
alkaline phosphatase reflect changes in bone metabolism with aging.
In spite of the increased levels of 1,25-dihydroxyvitamin D3 which could increase osteo-
clastogenesis, the accelerated decrease in bone strength observed in TTD mice does not 
appear to be due to increased bone resorption as assessed by measurement of serum TRAP.
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Bodyweight
Adult wild type mice gain weight from 26-39 weeks of age onwards. Macroscopically, this 
increase is mainly due to accumulation of fat in the abdominal cavity. In contrast, TTD mice 
do not increase in weight and lack accumulation of fat in the abdominal cavity as well as in 
for example liver. Remarkably, with aging a fatty liver can be observed in other DNA repair 
deficient mouse models; e.g. CSB/XPA double mutants show a fatty liver (25). As TTD mesen-
chymal stem cells were shown to be able to form adipocytes in vitro (Diderich et al., Chapter 
2), systemic effects are likely to cause the lack of fat tissue in TTD mice. Whereas the total lean 
body mass has not been investigated in TTD mice or patients, it is known that TTD mice have 
a lower relative heart mass and aortic sarcopenia (21). We may thus assume that the lower 
bodyweight is not only due to the lack of fat accumulation. 
The lower weight in TTD mice could influence bone volume by decreased mechanical load-
ing leading to e.g. decreased periosteal apposition (44) or a decrease in estradiol or leptin. 
Whether bone formation is influenced by muscle mass or fat mass is under debate ((45) and 
references therein). The effect of weight on bone volume is most likely a combination of lean 
body mass and fat mass. Positive correlations have been reported for the relation between 
lean body mass and bone mineral density (BMD), as well as for fat mass and BMD in post-
menopausal women (46,47). An increase in fat mass after the menopause decreases bone 
resorption without a corresponding decrease in bone formation (48). Even moderate obesity 
can play a protective role on postmenopausal bone loss (49). Normal mechanical loading 
maintains bone mass whereas increased mechanical loading stimulates bone formation and 
decreased mechanical loading is associated with bone loss (50). Two studies, in respectively 
men and women, compared the relative contribution of lean body mass versus fat mass on 
bone mineral density and both concluded that lean body mass has a greater effect on bone 
mineral density (51,52). The lower bodyweight in TTD mice may thus contribute to the ac-
celerated bone loss irrespective whether this predominantly due to lack of fat accumulation, 
a decrease in lean body mass or a combination of the two. However, we could not detect an 
obvious correlation between bodyweight and perimeter (our unpublished results). Moreover, 
in contrast to humans, in mice a relationship between bodyweight and femur, vertebral and 
phalangeal bone parameters has not been found (46-49,53).
Leptin
An alternative link between altered fat mass and bone metabolism can be leptin. Leptin is 
a protein hormone that is primarily secreted by white adipose tissue. It seems to be able to 
modulate the reciprocal differentiation of stromal cells between osteoblast and adipocyte 
pathways and of inhibiting osteoclastogenesis (54). The lower leptin levels correlate with the 
lower amount of fat in TTD mice to a certain extent. Whether the somewhat lower leptin 
levels contribute to the bone phenotype in TTD mice is unknown. In addition, possible effects 
are not straightforward as correlation studies do not give unequivocal results and it consti-
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tutes a complex system also involving central regulatory pathways of bone metabolism (55). 
The complexity is further demonstrated by the fact that leptin deficient mice are the only 
hypogonadal animal model with a high bone mass while the high bone mass was unrelated 
to the increased fat mass (55). Several studies concluded that leptin is not a direct deter-
minant of BMD (56-59) whereas others showed a negative correlation (60-65) or a positive 
correlation between leptin and BMD (66-68). These differences cannot only be explained by 
sex or menopausal status as some studies proposed (69-72). Interestingly, aging wild type 
mice show a drop in leptin levels before the decrease in bodyweight. It has been shown that 
body fat content correlates with plasma leptin in young males and females, whereas this 
relationship is disrupted in elderly people (73). For example, anorexia nervosa patients or 
amenorrhoeic athletes have low leptin levels (33). 
Adrenals and corticosterone
Old TTD mice exhibit high steroidgenic activity as assesed by cell volume and the amount of 
mitochondria and lipids in the adrenal gland while corticosterone levels are relatively high in 
old male TTD, but not in female TTD mice. Firstly, steroidogenesis might be less effective in 
TTD mice. Secondly, the break-down-rate of corticosterone in TTD mice might be more rapid 
leading to a higher production, more stimulation and larger cells in the zona fasciculata. It 
would be of interest to measure (break-down products of ) corticosterone levels in urine. 
Thirdly, it is possible that 11ß-hydroxysteroid dehydrogenase I, which regenerates active 
glucocorticoids from their inactive 11-keto derivatives, is less active and thus less corticos-
terone is formed (74,75). Interestingly, it was found that expression of 11ß-hydroxysteroid 
dehydrogenase I was reduced in another DNA repair deficient mouse model (25). 
Noteworthy, overall the corticosterone levels are higher in female mice compared to 
male mice. It has been reported that corticosterone levels as well as levels of corticosteroid-
binding globulin are higher in stressed female rats compared to stressed male rats (76). Aging 
C57Bl/6 female mice also showed significantly higher levels of corticosterone compared to 
male mice (77). 
Interestingly, young TTD females showed more whorls, ie. regression of the X-zone, than 
wild type females. This might be due to the lower levels of estradiol in TTD mice as regression 
of the X-zone is also delayed in castrated wild type females. 
In conclusion, the calciotropic hormone analyses indicate an altered calcium intake and/
or increased calcium loss in TTD mice. However, TTD mice are able to adjust their calcium 
regulatory mechanism of vitamin D and PTH to maintain stable levels of serum calcium up 
to at least 78 weeks of age. A consequence of these altered levels of PTH and vitamin D3 
will be an altered bone metabolism which may lead to a negative effect on bone volume. 
In addition, the lower bodyweight in TTD mice results in lower levels of serum estradiol 
which may contribute to the change in bone phenotype in female TTD mice. Furthermore, 
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microscopy of adrenals suggested that old TTD mice exhibit high, but possibly less effective 
steroidgenic activity. Further studies are required to fully understand the full contribution 
of endocrine parameters to the bone phenotype in prematurely aging DNA repair deficient 
trichothiodystrophy mice. 
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TTD mice display features of premature aging in many organs and tissues (1,2) although 
the progeroid symptoms do not affect all tissues to the same extent. In fact, paradoxically, 
a detailed, systematic large cohort analysis revealed that some organs and tissues even 
exhibit features resembling caloric restriction and delayed aging. For instance, the 
occurrence of cataract in the eyes in TTD mice was found to be significantly less compared 
to the isogenic wild type control mice kept under the same conditions (2). This extends 
the notion that all human progeroid syndromes are segmental (3), i.e. that multiple organs 
suffer from rapid aging, yet others seem relatively unaffected and as shown by TTD mice 
may even age slower than wild type controls. Microarray expression analysis of various 
accelerated aging mice revealed a strong parallel with expression profiles of normal aging 
(4). To examine at the level of physiology, whether TTD mice are indeed a bona fide model 
for aging and to rule out that it is a developmental disorder, we carried out a detailed 
comparison of the effect of aging on bone parameters of progeroid TTD females with wild 
type controls. This systematic analysis uncovered the consequence of a defect in DNA repair 
and basal transcription on the velocity of age-related skeletal changes and assessed to 
which extent the skeletal abnormalities reflect normal bone aging.
Bone develops normally in TTD mice, i.e. bone volume, cortical thickness and perimeter 
in tibiae are similar in wild type and TTD mice up to 39 weeks of age. In addition, similar 
numbers of osteoblasts and osteoclasts were observed in early bone marrow cultures and 
periosteal apposition was present in tibiae up to at least 13-weeks of age. This observation 
excludes a developmental defect as explanation for the TTD phenotype and is in line with 
other studies on TTD mice (2). 
After 39 weeks of age profound accelerated decrease in bone volume is observed in tibiae 
of TTD mice. The decrease in bone volume is almost 40 weeks ahead of that in wild type 
mice. In parallel with the decrease in bone volume, an accelerated decrease in bone strength 
is observed in TTD mice after 26 weeks of age. This accelerated form of natural bone aging 
strongly underlines the premature aging phenotype of TTD mice, which implies that the 
other aging-like features in TTD mice and patients may also represent bona fide premature 
aging symptoms and which in a broader context substantiates the importance of DNA repair 
in healthy aging. 
An important mechanism underlying the accelerated decrease in bone strength is that in 
TTD mice the larger endocortical volume is not fully compensated by periosteal apposition 
and a subsequent increase in perimeter as seen in wild type mice. In fact, TTD mice show a 
significant decrease in periosteal apposition between 13 and 39 weeks of age. 
The accelerated decrease in bone volume is preceded by an accelerated decrease in bone 
nodule formation in ex vivo osteogenic bone marrow cultures. These data implicate an ac-
celerated reduction in the number of mesenchymal stem cells but also imply that they still 
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can differentiate into osteoblasts. The adipocyte cultures support the fact that the intrinsic 
differentiation capacity of mesenchymal stem cells is not significantly affected. Whereas TTD 
mice lack fat accumulation in vivo, normal adipocyte differentiation is observed in vitro. We 
hypothesize that DNA damage levels in TTD mice reach a critical threshold in (mesenchymal) 
stem cells between 13 and 26 weeks, which triggers apoptosis and cellular senescence 
and translates into reduced numbers of differentiated osteoblasts and a bone phenotype 
between 39 and 52 weeks of age. 
Although there is an accelerated decrease in bone nodule formation, TTD bone marrow 
mesenchymal stem cells retain bone forming capacity. In addition to the data from the bone 
marrow cultures, this is shown by the effect of intermittent PTH administration on long bones 
of TTD mice. After intermittent PTH administration TTD mice demonstrated an increase in 
cortical thickness implicating that the stem cells/osteoblasts can still be stimulated to form 
bone. Considering the above mentioned relationship between DNA repair and apoptosis, it is 
interesting to note that PTH has been reported to inhibit osteoblast apoptosis (5,6). 
The accelerated skeletal aging in TTD mice is likely the result of a combination of an ac-
celerated decline in the number of osteogenic stem cells together with altered systemic influ-
ences. Indeed, various DNA repair deficient mouse models exhibiting premature aging show 
a systemic downregulation of various key hormonal axes, including for example the growth 
hormone--insulin-like growth factor 1 axis (4), which may also contribute to the observed 
loss of osteoprogenitors. Although these systemic factors have not been fully identified in 
TTD mice, we observed several changes in TTD mice suggesting that systemic factors influ-
ence the phenotype. For example, TTD females exhibit significantly lower levels of estradiol 
which may contribute to the accelerated bone loss observed in TTD mice. The lower levels of 
estradiol in TTD mice are not likely due to ovarian dysfunction as wild type and TTD females 
have similar numbers of growing and ovulatory follicles. Rather, estradiol levels are higher 
in wild type females as additional estrogen is produced by aromatase in the fat mass that 
is strongly reduced in TTD mutants. As TTD mesenchymal stem cells were shown to form 
adipocytes, systemic effects are likely to cause the lack of fat tissue in TTD mice.
In contrast to the osteopenic phenotype observed in long bones of TTD mice, 78-week-old 
TTD mutants exhibit significantly increased bone mass in their vertebrae. It appears from 
the data on trabecular bone volume fraction, trabecular number and trabecular thickness 
distribution that already young TTD mice have more bone mass in their vertebrae than wild 
type mice. As increased bone mass is also observed in vertebrae of TTD patients, it is intrinsic 
to the XPD mutation. The increase in trabecular bone volume fraction, which (partly) can be 
observed as an increase in the disorganized appearance of the vertebrae in old TTD mice 
might represent a local increase in the number or differentiation of osteogenic mesenchymal 
stem cells. On the other hand, the observed increase in the number of trabeculae may result 
from a decrease in the number of osteocytes followed by a decrease in sclerostin expression, 
i.e in contrast to TTD tibiae, TTD vertebrae seem to exhibit less osteocytes which are thought 
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to be the mechanosensors in bone. Osteocytes secrete sclerostin, which inhibits bone forma-
tion and mineralization by osteoblasts. When osteocytes are absent or their numbers are 
decreased, it can thus be expected that bone formation is increased. 
The bone phenotype in mice closely resembles the bone phenotype in TTD patients 
showing osteosclerotic vertebrae and osteopenic long bones and validates the XPD point 
mutant (TTD) mouse as a bona fide model for trichothiodystrophy. Whereas TTD mice exhibit 
a premature aging phenotype in long bones, the higher bone mass in vertebrae does not 
represent a premature aging phenotype as wild type mice do not show such an extensive 
increase in bone mass nor is this observed in humans. TTD mice thus exhibit segmental aging 
even within the skeleton. 
While answering our first questions, many other questions came up during our study. The 
lack of effective periosteal apposition in adult TTD mice is intriguing as it is a localized phe-
nomenon. While intermittent PTH administration to TTD mice demonstrated an increase in 
cortical thickness, no increase in perimeter was observed. Thus, the PTH effect on cortical 
thickness in TTD mice appears to be the result of increased endosteal bone formation and 
not periosteal apposition. Interestingly, a recent study showed differences in mechanism by 
which intermittent PTH treatment increases bone formation at the endosteal and at the peri-
osteal surface (7). The increase in endocortical osteoblasts after intermittent PTH treatment is 
predominantly due to attenuated osteoblast apoptosis (7). In periosteal bone where the rate 
of osteoblast apoptosis is low, PTH does not increase the number of osteoblasts by attenuat-
ing apoptosis, but by exerting pro-differentiating effects on post-mitotic pre-osteoblasts (7). 
While we observe no difference in endosteal bone formation between aging wild type and 
TTD mice, endosteal bone formation does show a declining trend with aging. It would be 
of interest to treat wild type mice with intermittent PTH and assess whether wild type mice 
show a lower, similar or more pronounced increase in cortical thickness compared to TTD 
mice and whether they show an increase in periosteal bone formation as well. 
A decrease in the number of osteogenic cells was shown in bone marrow cultures from 
TTD mice. However, in vivo TTD mice do not show a decrease in endosteal bone formation 
compared to wild type mice whereas they do show a significant decrease in periosteal bone 
formation. It seems that in addition to the decrease in osteogenic stem cells, other factors, 
e.g. systemic factors and/or mechanical loading, play a major role in periosteal bone forma-
tion. TTD mice provide an excellent tool to study periosteal apposition and to analyze the 
different age-related mechanisms at the endosteal and periosteal level.
Furthermore, while we hypothesize that DNA damage levels in TTD mice reach a critical 
threshold in (mesenchymal) stem cells, which triggers cell death and cellular senescence 
and translates into reduced numbers of differentiated osteoblasts, this remains to be proven 
definitely. At this moment, it is not possible to measure DNA damage in mesenchymal stem 
cells and to relate this to (altered) gene-expression in bone marrow of TTD mice of different 
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ages. Alternatively, one could assess the impact of DNA damage induced by oxygen radicals 
on the development of mesenchymal stem cells. It is possible to culture mesenchymal stem 
cells at different percentages of oxygen. One expects less DNA damage when culturing cells 
at a low oxygen percentage (2-3%) compared to the most commonly used (unphysiological) 
20% oxygen. It would be interesting to see whether the difference in osteogenic cell numbers 
is smaller between wild type and TTD mice when cultured at low oxygen. On the other hand, 
one could culture the cells at a higher oxygen percentage and assess whether the number 
of osteogenic cells is even lower in TTD mice. In addition, one could isolate DNA from the 
cultured cells and analyze differences in the number of oxidatively induced lesions by gas 
chromatography or mass spectrometry (8). In parallel, one could perform micro-array analy-
sis and assess changes in gene-expression in bone marrow cells. Ideally, mesenchymal stem 
cells should be isolated for this purpose, but at this moment mesenchymal stem cell-specific 
antibodies are not available. In vivo, transplantations of wild type bone marrow to TTD mice 
may reduce the decline in bone volume that is observed in TTD mice arguing for the role of 
diminished osteogenic stem cells in TTD mice.
Next to the osteopenic phenotype in long bones, TTD mice displayed a high bone mass 
phenotype in their vertebrae. It would be of great interest to study mesenchymal stem cells 
derived specifically from murine vertebrae. However, this is technically very challenging. To 
analyze the difference between long bones and vertebrae in greater detail, one could as-
sess the effect of intermittent PTH treatment on the phenotype in vertebrae. Furthermore, 
it would be of interest to exactly measure the number of osteocytes in vertebrae. As we hy-
pothesize that decreased expression of sclerostin by osteocytes might contribute to the high 
bone mass phenotype in TTD mice, it would also be of interest to measure the expression of 
sclerostin in long bones and vertebrae (by in situ hybridisation, RT-PCR or high throughput 
sequencing). 
In addition to sclerostin measurement, other systemic factors that may contribute to the 
(bone) phenotype in TTD mice could be analysed; e.g. expression of genes related to calcium 
homeostasis such as 1α-hydroxylase in kidney samples. Another possibility to study systemic 
factors is to perform intervention studies with e.g. estrogen suppletion or to assess the im-
pact of bone resorption inhibition by bone resorption inhibitors like bisphosphonates.
In conclusion, the TTD mouse mutant constitutes a valid model for bone aging in long 
bones and is an excellent tool to study periosteal apposition as well as age-related differences 
between long bones and vertebrae. Furthermore, proper DNA repair, notably transcription-
coupled repair, is required to maintain optimal bone characteristics and strength as long as 
possible. 
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Summary 
Trichothiodystrophy (TTD) is a rare, autosomal recessive Nucleotide Excision Repair (NER) 
disorder caused by mutations in components of the dual functional NER/basal transcription 
factor TFIIH. TTD mice, carrying a patient-based point mutation in the Xpd gene, strikingly 
resemble many features of the human syndrome and exhibit signs of segmental premature 
aging. For example, TTD patients exhibit skeletal abnormalities like thoracic kyphosis, axial 
osteosclerosis, and peripheral osteoporosis while radiographs of 14-month-old TTD mice 
revealed prominent kyphosis, generalized reduction in radio-density of the skeleton, but 
higher radio-density in the skull. In this thesis we performed an extensive analysis of the 
bone phenotype in aging TTD mice to gain insight in the premature aging phenotype of TTD 
mice. 
We showed that female TTD mice exhibit accelerated bone aging from 39 weeks onwards 
as well as lack of periosteal apposition leading to reduced bone strength. Prior to 39 weeks 
long bones of wild type and TTD mice are identical excluding a developmental defect. Albeit 
that bone formation is decreased, osteoblasts in TTD mice retain bone-forming capacity as in 
vivo PTH treatment leads to increased cortical thickness. In vitro bone marrow cell cultures 
showed that TTD osteoprogenitors retain the capacity to differentiate into osteoblasts. 
However, after 13 weeks of age TTD females show decreased bone nodule formation. No dif-
ferences in osteoclasts or bone resorption were detected. We hypothesize that DNA damage 
levels in TTD mice reach a critical threshold in (mesenchymal) stem cells between 13 and 26 
weeks, which triggers apoptosis and cellular senescence and translates into reduced num-
bers of differentiated osteoblasts and a bone phenotype between 39 and 52 weeks of age. 
Next we showed that male TTD mice also display accelerated bone aging. Long bones of 
TTD males exhibit a rapid 90% decrease in periosteal apposition at 78 weeks and an overall 
decline in bone strength of about 25% compared to wild type males. After 42 weeks of 
development, mesenchymal differentiation potential towards the osteoblast lineage was 
significantly decreased in TTD males. In contrast, mineralization of osteoblast colonies and 
adipocyte and osteoclast differentiation were not impaired. In comparison with their female 
counterparts, TTD males are not as strongly affected and the dynamics of their accelerated 
skeletal aging seem to be slightly different. 
In contrast to the decline in bone volume in long bones of TTD mice, we showed that 
vertebrae of TTD mice exhibit increased bone mass compared to wild type mice. This os-
teosclerotic phenotype in vertebrae is strikingly similar to the phenotype observed in TTD 
patients. The bone phenotype in mice thus closely resembles the bone phenotype in TTD 
patients showing osteopenic long bones and osteosclerotic vertebrae. Whereas TTD mice 
exhibit a premature aging phenotype in long bones, the higher bone mass in vertebrae does 
not represent a premature aging phenotype as wild type mice do not show such an extensive 
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increase in bone mass nor is this observed in humans. TTD mice thus exhibit segmental aging 
even within the skeleton.
We hypothesized that altered systemic influences contribute to the observed bone 
phenotype in TTD mice and analyzed bodyweight, several bone metabolism-related serum 
parameters as well as histology of the adrenals and ovaries in aging wild type and TTD mice. 
Aging TTD females exhibit significantly lower levels of estradiol which may contribute to the 
accelerated bone loss observed in TTD females. In addition, TTD mice showed low levels of 
parathyroid hormone and 25-hydroxyvitamin D3 while bone turnover markers showed no 
significant differences and 1,25-dihydroxyvitamin D3 levels were higher in aging TTD females. 
Analysis of adrenals suggests less effective steroidogenesis in TTD mice. In conclusion, TTD 
mice show differences in circulating levels of hormones known to control bone metabolism 
as well as calcium homeostasis. These changes did not result in altered serum calcium but 
may constitute the systemic influences contributing to the bone phenotype in prematurely 
aging trichothiodystrophy mice. 
TTD mice thus provide an excellent tool to study bone aging in long bones, periosteal 
apposition, the different age-related mechanisms at the endosteal and periosteal level as 
well as age-related differences between long bones and vertebrae. Furthermore, proper DNA 
repair, notably transcription-coupled repair, is required to maintain optimal bone character-
istics and strength as long as possible. 
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Samenvatting
Vrijwel elke cel in ons lichaam bevat het erfelijk materiaal. Dit erfelijk materiaal, het DNA, 
is van groot belang voor het specifieke functioneren van de verschillende cellen. Het DNA 
wordt echter continu beschadigd door zowel externe factoren, zoals zonlicht en sigaret-
tenrook, als interne factoren, zoals zuurstofradikalen die ontstaan bij de stofwisseling. Deze 
schade aan het DNA kan ernstige gevolgen hebben. Bij het kopiëren van beschadigd DNA 
kunnen permamente veranderingen (mutaties) in de genetische code ontstaan waardoor 
cellen bijvoorbeeld ongeremd kunnen gaan delen en uiteindelijk kanker kunnen veroorza-
ken. DNA schade kan ook resulteren in het stoppen van de celdeling of in celdood waardoor 
(vroegtijdige) veroudering kan optreden. Gelukkig bestaan er verschillende DNA herstelme-
chanismen die beschadigingen in het DNA verwijderen. 
Trichothiodystrofie (TTD) is een zeer zeldzame, autosomaal recessief overervende stoor-
nis in het DNA-schade herstelmechanisme. In het verleden werd een muismodel gemaakt 
met een mutatie in het XPD gen, één van de erfelijke factoren die samen het eiwitcomplex 
TFIIH vormen. TFIIH is betrokken bij zowel DNA-schade herstel als basale transcriptie. TTD 
muizen vertonen vele symptomen die overeenkomen met problemen zoals deze bij TTD 
patiënten worden gezien. Daarnaast vertonen zij kenmerken van vroegtijdige veroudering. 
Bij TTD patiënten zijn afwijkingen van het skelet, zoals een thoracale kyphose, sclerose van 
de wervelkolom en osteoporose van de lange pijpbeenderen, beschreven. Bij 14 maanden 
oude TTD muizen werd op röntgenfoto’s een opvallende kyphose, een algeheel verminderde 
botdichtheid en sclerose van de schedel gezien. In dit proefschrift beschrijven we een uit-
voerige analyze van het botfenotype in TTD muizen met als doel het verkrijgen van inzicht 
in de vroegtijdige veroudering van TTD muizen en in het verlengde daarvan TTD patiënten. 
In hoofdstuk 2 laten we zien dat TTD vrouwtjes vanaf de leeftijd van 39 weken een ver-
snelde botveroudering tonen met daarbij een verminderde botvorming aan de buitenzijde 
van het bot (periosteale appositie) en toenemende zwakte van de botten. Voor de leeftijd 
van 39 weken vonden wij geen verschil tussen de lange pijpbeenderen van wild type en 
TTD muizen; er zijn dus geen aanwijzingen voor een stoornis in de ontwikkeling van de 
lange pijpbeenderen. Hoewel de botvorming is verminderd, hebben TTD muizen nog wel de 
capaciteit om bot te vormen; dit wordt geillustreerd door de toename in corticale dikte bij 
met parathyroïd hormoon (PTH) behandelde TTD muizen. PTH wordt door de bijschildklieren 
geproduceerd en stimuleert botafbraak. Bij intermitterende toediening van PTH is er echter 
met name sprake van botaanmaak. Ook de celkweken tonen aan dat stamcellen van TTD 
muizen zich nog kunnen ontwikkelen tot osteoblasten. Na de leeftijd van 13 weken laten 
celkweken van TTD vrouwtjes in vergelijking met wild type vrouwtjes een afname in de 
hoeveelheid botvormende cellen zien terwijl de osteoclasten geen verschil tonen. Onze hy-
pothese is dat de hoeveelheid DNA schade in stamcellen van TTD muizen tussen de 13 en 26 
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weken een kritische drempel overschrijdt waardoor celdood en celveroudering optreedt en 
minder osteoblasten worden gevormd met het hiervoor beschreven botfenotype als gevolg. 
In hoofdstuk 3 laten we zien dat ook TTD mannetjes versnelde botveroudering, sterk ver-
minderde periosteale appositie en zwakte van de botten tonen. Vergeleken met de vrouwtjes 
is het effect bij de mannetjes echter minder groot, hetgeen ook bij de mens het geval is. 
In hoofdstuk 4 wordt beschreven dat wervels van TTD muizen -in tegenstelling tot het 
verminderd botvolume in de lange pijpbeenderen- een toename van botmassa tonen. Het 
beeld in de wervels van TTD muizen vertoont grote gelijkenis met het beeld bij TTD patiën-
ten, maar wijkt in dit opzicht af van het beeld bij normale veroudering. Het botfenotype van 
zowel de lange pijpbeenderen als de wervels vertoont grote gelijkenis tussen TTD muizen en 
TTD patiënten, hetgeen de parallellen tussen het ziektebeeld bij de mens en het muismodel 
versterkt. 
In hoofdstuk 5 beschrijven we de analyze van verschillende endocriene parameters die 
betrokken zouden kunnen zijn bij het verandere botfenotype in TTD muizen. Oude TTD 
vrouwtjes hebben significant minder circulerend oestrogeen wat kan bijdrage aan de 
afname van bot. Daarnaast werd in het bloed van TTD muizen een lagere concentratie van 
PTH en 25-hydroxyvitamine D3 gemeten. Bij de oude TTD vrouwtjes was de concentratie van 
1,25-dihydroxyvitamine D3 hoger. Deze hormonen hebben een effect op botmeta-bolisme 
zowel als calciumconcentratie welke strikt gereguleerd moet worden. Mogelijk spelen deze 
systemische factoren een rol in het botfenotype van vroegtijdig verouderende TTD muizen. 
Concluderend is het TTD muismodel een goed middel om botveroudering, periosteale 
appositie, verschillen tussen endosteale en periosteale appositie en de afwijkingen aan het 
skelet bij TTD te bestuderen. Daarnaast is het goed functioneren van het DNA herstel-
mechanisme van belang voor een optimale structuur en stevigheid van het bot. 
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Accelerated aging pathology in ad libitum fed XpdTTD mice is 
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Abstract
Trichothiodystrophy (TTD) patients with a mutation in the XPD gene of nucleotide excision 
repair (NER) have a short life span and show various features of premature aging, thereby 
linking DNA damage to the aging process. XpdTTD mutant mice share many features with TTD 
patients, including a shorter life span, accompanied by a segmental progeroid phenotype. 
Here we report new pathology features supportive to the premature aging phenotype of 
XpdTTD mice. Strikingly, accelerated aging pathology is accompanied by signs suggestive of 
caloric restriction (CR), a condition usually linked to retardation of age-related pathology and 
life extension. Accelerated aging symptoms in XpdTTD mice are most likely due to accumula-
tion of endogenously generated DNA damage and compromised transcription leading to cell 
death, whereas CR symptoms may reflect the need of XpdTTD mice to reduce metabolism (ROS 
production) in an attempt to extend their life span. Our current findings in XpdTTD mice further 
strengthen the link between DNA damage, repair and aging.
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Introduction
Aging is a progressive, time-dependent deterioration in the capacity of an organism to prop-
erly function and respond adaptively to environmental challenges resulting in an increased 
vulnerability to death [1]. Within this process, cellular macromolecules like DNA, lipids and 
proteins accumulate damage leading to the malfunctioning of cellular organelles (like mito-
chondria) and cellular processes. In addition, damaged macromolecules may cause necrosis 
and apoptosis of cells resulting in tissue and organismal dysfunction and therefore can be 
considered as the ultimate driver of aging (reviewed in [2]). Damage to the genome leads 
to essentially irreversible loss of genetic information and therefore will be more deleterious 
than damage to RNA, proteins or lipids that can be replaced [3]. A main source of spontane-
ous somatic DNA damage likely involves reactive oxygen species (ROS), natural by- products 
of normal oxidative energy metabolism [4, 5]. More than 100 different types of oxidative DNA 
lesions have been described, ranging from base modifications to single- and double-strand 
DNA breaks and interstrand cross-links, DNA-protein crosslinks as well as damage to the 
phosphate-sugar backbone [6, 7]. Oxidative DNA lesions might disrupt vital processes like 
transcription and replication, resulting in cell death or (transient or permanent) growth arrest 
or may induce mutations or chromosome aberrations that lead to cancer. 
To counteract the effects of (oxidative) DNA damage, an intricate network of DNA repair 
pathways has evolved, each focusing on a different class of lesions. One major DNA repair 
pathway is nucleotide excision repair (NER), which removes a broad range of bulky lesions 
including UV-induced damage, chemical adducts as well as some forms of oxidative dam-
age [7, 8]. NER entails a complex ‘cut and patch’-type reaction involving over 30 proteins. 
Important core components are the XPB and XPD helicases, which are subunits of the TFIIH 
complex implicated as DNA helix opener in both NER and in basal transcription initiation [9, 
10]. The multi-functionality of the XPD (and XPB) protein is further illustrated by the complex 
genotype-phenotype relationship in human NER patients with a mutation in XPD. Site-
specific XPD mutations can lead to a variety of syndromes; xeroderma pigmentosum (XP), XP 
combined with Cockayne syndrome (CS), or trichothiodystrophy (TTD). XP patients are highly 
predisposed to (skin) cancer, CS and TTD patients show various features of premature aging 
whereas XP-CS patients display both [11, 12]. 
The connection between NER deficiency and aging can be extended to several other DNA 
damage repair and response systems. Human segmental progeroid syndromes are frequently 
caused by genetic alterations that partially or wholly inactivate proteins that sense or repair 
DNA damage, like in the case of ataxia telangiectasia (AT), Bloom syndrome (BS) and Werner 
Syndrome (WS) [13]. Hence, accelerated aging symptoms in both humans and mice with 
genetic defects in genome maintenance, strongly suggest that a wide-spread, strong con-
nection exists between genome care-taking and accelerated aging [14].
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In order to further investigate the causes and mechanisms that underlie the aging process 
and the influence of genome instability on this process, we are currently performing com-
plete lifespan studies of various NER-deficient mouse strains, all defective in one or both 
sub-pathways of the NER repair system (i.e. Xpa, Csb, Xpc and XpdTTD mice)(reviewed in [15]). 
For these studies, the mouse mutants were backcrossed over 10 generations into a homoge-
neous C57BL/6 background and their survival was compared to wild type C57BL/6 controls 
under strict specific pathogen-free (SPF) conditions. 
In this report, we focus on the previously described XpdTTD mouse model and its segmental 
progeroid phenotype. The results obtained in the present study confirm and significantly 
extend the previous observations on this mouse model [16]. Here we report many new 
features not reported before in XpdTTD females. While most of the new features involve ad-
ditional symptoms of premature aging, we also report phenotypes, consistent with what is 
normally observed in mice during dietary / caloric restriction, an intervention that signifi-
cantly increases lifespan and retards aging-related pathology [17]. This observed dichotomy 
in pathology of aging XpdTTD female mice might be related to the complex roles of the Xpd 
gene in both DNA repair and transcription. 
Material and methods
Mice
To perform longevity studies with extensive cohorts of homozygous mutant XpdTTD mice and 
C57BL/6 controls (Harlan), mice were passed through different rounds of breeding. XpdTTD 
mice used in this study carry a R722W mutation at the mouse Xpd gene. Generation of XpdTTD 
mice by targeting of the XpdR722W allele has been described previously [18]. To get a geneti-
cally homogenous background, XpdTTD mice were back-crossed over 10 times into a C57BL/6 
background. To offer the future possibility to monitor genomic instability, heterozygous Xpd 
mutant mice as well as C57BL/6 controls were crossed with pUR288-lacZ C57BL/6 transgenic 
mice line 30, homozygous for lacZ integration on chromosome 11 [19], carrying 21±1 copies 
of the pUR288-lacZ plasmid per haploid genome. In the second round of breeding, double 
heterozygous mice were intercrossed to obtain XpdTTD homozygous mice carrying one locus 
of the integrated copies of the lacZ marker, used in the third breeding round to generate 
the experimental animals for the aging (and interim) cohorts as described below. Mice were 
genotyped by a standard PCR reaction using DNA isolated from tail tips. Primers to amplify 
the wild type and targeted Xpd allele, as well as primer sequences for lacZ determination 
have been described previously [18, 19]. 
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Experimental design 
Mice were marked and randomized at the day of birth in 9 different groups; i.e. the longevity 
cohort, or one of the interim cohorts in which the mice were sacrificed at a fixed age of 2, 6, 13, 
26, 52, 78, 91, 104, 117 or 130 weeks, respectively (scheduled sacrifice). The interim cohorts 
consisted of 15 XpdTTD mice, as well as 15 C57BL/6 control animals per sex per time point. In the 
longevity cohort, a total of 45 XpdTTD and 45 C57BL/6 controls per sex were monitored during 
their entire life span. Additionally, a sub-cohort of 30 wild type XpdTTD littermate controls was 
examined in a parallel longevity study to compare survival, pathology and body weight with 
the true C57BL/6 cohort. In the present study, only the findings of female XpdTTD and C57BL/6 
animals are reported because data obtained with female XpdTTD wild type littermates were 
very similar to those from female C57BL/6 mice (data not shown). Furthermore, results from 
Figure 1: Age-matched XpdTTD and C57BL/6 mice of ~90 wks old.
Picture of two female mice of ~90 weeks old. On the left, a C57BL/6 mouse and right a XpdTTD mouse which is much smaller and tinier. Also 
brittle hair and skin lesions are clearly visible. 
Figure 2: Body weights of XpdTTD and C57BL/6 female mice.
Body weight curves of female mice during life. Weights of XpdTTD females are depicted in blue, weights of C57BL/6 control females in red.
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Figure 3: Survival curves of XpdTTD and C57BL/6 female mice.
Survival curves of XpdTTD (blue) and C57BL/6 (red) female mice. A statistical significant difference was determined using Kaplan Meier survival 
statistics with Log Rank test: p-value =0.0163.
male XpdTTD and C57BL/6 mice were comparable to those from females (data not shown). 
The health state of the mice was checked daily, beginning at the day of weaning. Individual 
animals were weighed biweekly to determine live weights. All animals were kept during their 
entire life span in the same and stringently controlled environment, fed ad libitum under a 
normal day/night rhythm. The microbiological status of the cohorts was monitored every 3 
months during the entire study. Food intake was determined in a subgroup of 10 individual 
animals per genotype. Animals from the longevity cohort were removed from the study only 
when found dead or moribund. Complete autopsy was performed on animals of all cohorts; 
a total of 45 different tissues was isolated from each animal and stored for further analysis. 
Total animal weights as well as various organ weights were determined at time of death. 
Pathology
Organ samples (40 organs and tissues) of intact animals and dissected for histopathology, 
were preserved in a neutral aqueous phosphate-buffered 4% solution of formaldehyde (10% 
neutral buffered formalin). In addition, samples of 17 different organs were snap-frozen in 
liquid nitrogen for further molecular biological analyses (to be published elsewhere). Tis-
sues required for microscopic examination were embedded in paraffin wax, sectioned at 5 
µm and stained with haematoxylin and eosin. Kidneys were also stained with Periodic Acid 
Schiff (PAS) and unstained slides were prepared of liver, brain, adrenal, ovaries and heart for 
lipofuscin UV-fluorescence determination. Other staining methods were used incidentally 
if necessary. Detailed microscopic examination was performed on all organs and tissues of 
all female XpdTTD and C57BL/6 control mice. Histopathological abnormalities were recorded 
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using the PATHOS pathology data acquisition software and if possible, a cause of death was 
established for each animal.
Statistical evaluation
Statistical analyses of mortality curves included calculation of Kaplan-Meyer distributions of 
survival of the two different genotypes and comparison by a two-sided log rank test (SPSS, 
vs 11). Also cause of death (COD) was analyzed using the Kaplan-Meier survival statistics. 
Incidences of lesions and tumors were analyzed with the Fisher’s exact test and with the 
method of Peto, respectively [20]. 
Results
Body weights and food intake 
XpdTTD mice have a remarkable phenotype that clearly mimics a segmental progeroid syn-
drome (Fig. 1) [16]. One striking hallmark of adult XpdTTD mice is a reduced bodyweight. In 
order to get more knowledge on bodyweight kinetics during life, we determined biweekly 
the bodyweights of XpdTTD and control C57BL/6 female mice. Results of individual animals 
(live weights) are plotted in Fig. 2. From this graph it is clear that at early age, growth char-
acteristics for the XpdTTD females were quite similar to those of C57BL/6 control females. 
However, when female mice reached the age of 13 weeks, striking differences in body weight 
gain became apparent between XpdTTD and C57BL/6 females, which persisted during the rest 
of their lives. In general, C57BL/6 females gained weight until the age of 86-90 weeks with a 
mean weight of 39.0 ± 6.2 gr. After the age of 90 weeks, the majority of the wild type animals 
started to loose weight to a mean weight of about 32.0 gr. at the time of death. Body weights 
of female XpdTTD wild type littermates were comparable to those of the C57BL/6 controls (data 
not shown). XpdTTD females however, remained low in weight during their entire life span. The 
mean weight was about 25 gr. from the age of 36 wks until 90 wks, showing a remarkable 
tight distribution for over a 1.5-2 year period. Also XpdTTD female body weights displayed a 
tendency to decline in the final weeks of their life and as can be expected from mice with a 
lower body weight and diminished fat reserves; this drop was not as pronounced as observed 
Table 1: Survival curve summary female mice.
  C57BL/6 XpdTTD
50% survivala 103 93
20% survivalb 121 115
oldest survivorc 133 121
amedian survival in weeks (first week of 50% mortality)
bthe average of the longest-lived 20% of a cohort in weeks 
cage in weeks
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Figure 4: Organ weights at time of schedules sacrifice.
(A) Absolute brain weight in grams. Relative weights (as % of total weight) of thymus (B), spleen (C), kidney (D), heart (E), and liver (F). Organ 
weights of XpdTTD females are depicted in blue, organ weights of C57BL/6 control females in red.
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in C57BL/6 mice. Average weight at the time of death in XpdTTD females was 23.3 ± 2.5 gr. 
Importantly, the difference in body weight between XpdTTD and C57BL/6 mice could not be 
explained by a difference in food intake as determined in a sub-cohort of female mice during 
the first 26 weeks of life. Both XpdTTD females and C57BL/6 control mice consumed 30-35 
grams of food per week during this period (data not shown).
Survival of XpdTTD and C57BL/6 female mice
The survival curves for the aging cohorts of female XpdTTD as well as C57BL/6 mice as presented 
in Fig. 3 are based on 45 animals per genotype. All animals were removed from the cohort 
when found dead or when they appeared moribund. In Table 1, the age of each group at 
50% survival (median survival) and maximal survival (mean age of the oldest 20%) are sum-
marized, and the age of the oldest survivor of each genotype is listed. The median survival 
of XpdTTD females (93 wks) appeared significantly reduced (p=0.0163, Kaplan Meier with Log 
rank test) compared to the median survival of the C57BL/6 wild type controls (103 wks). Also 
the average of the longest-lived 20% of the XpdTTD cohort was lower than in C57BL/6 females, 
as well as the age of the oldest survivor (Table 1). Again, survival curves of XpdTTD wild type 
littermates were comparable to those of C57BL/6 controls (data not shown).
Organ weights 
Analysis of organ weights in groups of animals with considerably different growth and 
terminal body weights is complicated. Absolute and relative organ weights should be evalu-
ated together and in conjunction with body weights. Presented are the organ weights of 
scheduled interim sacrifices, since these weights give a good impression of the trends in 
organ weights in time in relatively healthy animals not suffering from terminal diseases. The 
absolute brain weight (Fig. 4A) was within a narrow range and was only slightly lower in 
XpdTTD mice compared to C57BL/6 control females. In contrast to the relatively stable brain 
weight, the other organs weights determined (heart, kidney, liver, spleen and thymus) are 
known to be influenced by variations in growth, diet, physiology, or health status. Therefore, 
relative weights are more informative for these organs (Fig. 4B-F). Evaluation of the lymphoid 
organs revealed a considerable decrease in relative (and absolute) thymus weights during 
life in WT mice as expected and consistent with aging, but this decline was distinctly more 
pronounced in XpdTTD females (Fig. 4B). The relative spleen weights of both genotypes (Fig. 
4C) tended to increase in time and were higher in XpdTTD than in C57BL/6 mice up to 78 weeks 
but decreased afterwards in XpdTTD mice only. The XpdTTD females showed a higher variation 
in splenic weight, which is probably due to increased extramedullary hematopoiesis in many 
animals, whereas others showed lymphoid depletion. The kidney increased in weight over 
the whole lifespan in both genotypes and relative kidney weights were higher in XpdTTD than 
in C57BL/6 mice (Fig. 4D). This implies that the kidney weight stays high while the overall 
body weight declines, due to loss of subcutaneous and abdominal fat by XpdTTD females (see 
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below). The heart weights of all mice increased over the whole experimental period and 
surprisingly not only the relative but also the absolute heart weights were higher in XpdTTD 
mice when compared to the C57BL/6 controls, despite the low body weights (Fig. 4E). Liver 
weights in female mice increased in C57BL/6 mice during aging, whereas the liver weights 
remained more or less the same in XpdTTD mice over time (Fig. 4F). In summary, the weights 
of heart, kidney and spleen appeared to be higher and thymus weights were lower in XpdTTD 
females when compared to C57BL/6 controls.
Hematological findings
In keeping with our previous findings [16], XpdTTD mice showed reduced red blood cell counts 
(RBC) during their whole life span. For instance, RBC values were 7.4, 6.4 and 7.6 x1012 cells/l 
for XpdTTD mice and 8.6, 8.4 and 8.3 x1012 cells/l for C57BL/6 controls at the age of 52, 78 and 
104 weeks, respectively. This RBC decrease in mutant mice was associated with decreased 
hemoglobin and hematocrit values. However, the mean cellular hemoglobin concentration 
(MCHC) as well as mean corpuscular volume (MCV) was not altered in XpdTTD mice versus the 
C57BL/6 controls (data not shown), pointing to a mild normochrome anemia in XpdTTD mice. 
Platelets increased initially in both genotypes and were relatively high in XpdTTD females but 
decreased after the age of 78 weeks (from 1392 to 1151 at the age of 104 weeks). The amount 
of white blood cells showed a considerable variation over the whole experimental period in 
both genotypes (data not shown). 
Causes of death
In Table 2, the causes of death are listed for both XpdTTD and C57BL/6 control mice as deter-
mined by combined gross and microscopic pathology. It is clear from this table that striking 
differences exist between the two genotypes. While in C57BL/6 control females most of the 
mice died of neoplasms (35%) and (skin) inflammation (50%), these numbers were much 
Table 2: Causes of death in XpdTTD and C57BL/6 mice. 
  C57BL/6 XpdTTD
  n=40 % n=35 %
Neoplasms 14 35 7 20
Inflammation 20 50 2 6*
Multiple pathology 0 0 2 6
Prolaps 0 0 12 34**
Circulatory disorders 2 5 0 0
Conditional decline 3 8 11 31**
Other 1 3 1 3
N.B. A cause of death was only given when complete autopsy and full histopathology was 
performed. Autolysed mice were excluded. 
Statistically significant difference using Kaplan-Meier survival statistics
* p<0.01 and **p<0.001
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lower in the Xpd mutant mice (20% and 6%, respectively). In contrast, the most common 
cause of death in XpdTTD mice was anorectal prolapse (34%) or a general conditional decline 
without major pathological conditions that could be designated as a primary cause of death 
or a reason for the moribund state (31%). These phenomena were hardly found in the wild 
type controls (0% and 8% respectively). Using the Kaplan-Meier survival statistics, both 
decrease in (skin) inflammation (p<0.01) and increase in anorectal prolapse or conditional 
decline (p<0.001) were statistically significant. However, the decrease of neoplasms as a 
Table 3: Tumor development in XpdTTD and C57BL/6 mice at the time of death.
a. Tumor summary in female mice 
  C57BL/6 XpdTTD
  n=40 % n=35 %
Number of benign tumors 24   12  
Number of malignant tumors 18   10  
Total number of tumors 42   22  
Mean number of tumors per mouse 1.1   0.6  
Number of tumor bearing animals 30 75.0 19* 54.3
Number of multiple tumor bearers 12 30.0 3 8.6
Median latency (50% percentile)a 788   699  
Mean age at time of death for the mice analyzed is 99,6 wks for C57BL/6 and 90,8 wks for XpdTTD mice 
aMedian tumor latency in days
* p=0.10 (Fisher exact test 2-sided) and not significant with the Peto method
B. Individual tumor types
    C57BL/6 XpdTTD
    n=40 n=35
Adrenal pheochromocytoma (benign) 0 3
Bone osteosarcoma 2 0
Head squamous cell carcinoma 0 1
Harderian gland adenoma 1 0
Lymphatic system lymphoma 10 3*
  histiocytic sarcoma 3 3
Liver hepatocellular carcinoma 0 1
  sarcoma 1 0
Lung bronchiolo-alveolar carcinoma 0 1
Pituitary pars distalis adenoma 20 3**
Small intestines leiomyosarcoma 1 0
Skin melanoma (benign) 0 1
Thyroid follicular cell adenoma 1 2
Vascular system hemangioma 2 3
  hemangiosarcoma 1 1
Mean age at time of death for the mice analyzed is 99,6 wks for C57BL/6 and 90,8 wks for XpdTTD mice 
Statistically significant difference using Fisher’s exact test
* p<0.05 and **p<0.001
Statistically significant difference using method of Peto
**p=0.002
Incidences of all other tumors are too low to reveal statistically significant differences
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Table 4: Histopathology differences in XpdTTD and C57BL/6 mice at the time of death.
A. Differences consistent with accelerated aging
  C57BL/6 (n=40) XpdTTD (n=35)
  incidence severity incidence severity
Osteoporosis femur 88.2 3.3 97.1 4.1
Hepatic lipofuscin accumulation 85.0 1.6 97.1 3.1
Hepatic intranuclear inclusions 10.0 0.1 28.6 0.5
Hepatocellular atrophy 5.0 0.1 34.3 0.5
Renal karyomegaly 17.9 0.2 38.2 0.7
Renal tubular dilatation 30.8 0.5 85.3 2.2
Renal hyaline glomerulopathy 15.4 0.3  52.9 1.1
Aortic sarcopenia 5.6 0.1 87.9 2.0
Lymphoid depletion spleen 30.8 0.4 85.7 2.0
Lymphoid depletion thymus 82.8 2.6 100 3.7
Skin reduced hypodermal fat 18.9 0.5  85.7 2.9
Heart lipofuscin accumulation 100 1.9 100 2.3
B. Trichothiodystrophy-specific differences
  C57BL/6 (n=40) XpdTTD (n=35)
  incidence severity incidence severity
Anorectal prolapse 0 n.a. 51.4 n.d.
Duodenal atypical hyperplasia 0 n.a. 17.6 0.5
Skin ulcerative dermatitis 45.9 1.5 8.6 0.3
TTD skin lesionsa 0 n.a. increased n.d.
C. Differences consistent with dietary restriction
  C57BL/6 (n=40) XpdTTD (n=35)
  incidence severity incidence severity
Skin ulcerative dermatitis 45.9 1.5 8.6 0.3
Skin reduced hypodermal fat 18.9 0.5 85.7 2.9
Cataract of eye lens 42.1 0.7 9.1 0.1
Nerve demyelination 59.0 1.1 11.8 0.1
Pituitary adenoma 51.3 n.a. 8.6 n.a.
Thyroid follicular cell hyperplasia 21.6 0.4 5.9 0.1
Thyroid follicular distension (“cold follicles) 94.6 2.6 85.7 1.9
Inflammation in various organs     Decreased  
Lacrimal gland lipofuscin accumulationb 94.3 1.7 46.9 0.5
Lacrimal gland Harderian type acinib 57.1 1.3 21.9 0.4
Adrenal extramedul hematopoiesisb 45.0 1.0 34.3 0.6
Brain eosinophilic inclusions thalamusb 55.0 1.0 34.0 0.6
Incidences are determined at the time of death and given in %, severity in a score (scale 1-5), mean severity is calculated per group
Mean age at time of death for the mice analyzed is 99,6 wks for C57BL/6 and 90,8 wks for XpdTTD mice 
n.a. not applicable, n.d. not determined
aTTD skin lesions is an assembly of acanthosis, hyperkeratosis, sebaceous hyperplasia, mast cell infiltration, extra-cellular melanin and follicular 
distention. No quantitative grade of severity is depicted for the separate features
bpossibly consistent with dietary restriction (not found in literature)
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cause of death observed in the XpdTTD mice did not reach the level of statistical significance 
(see also next section).
Tumor development during aging 
A summary of tumor incidence in old female C57BL/6 wild types and XpdTTD mice at the time 
of death is shown in Table 3A. From Table 2 it becomes clear that wild type mice mostly died 
of neoplasia (fatal tumors) while for XpdTTD mice other diseases were more life threatening 
(see above). However, mice of both genotypes showed occult tumors that were not the 
actual cause of death, but were found incidentally in mice dying of another cause (incidental 
tumors). In Table 3, when XpdTTD females were compared with C57BL/6 control mice at the 
time of death, both the total number of benign and malignant tumors appeared to be lower 
in XpdTTD mice. This indicates that there is no difference in tumor progression between the 
two genotypes. The percentage of tumor-bearing animals (54.3% versus 75%) and the mean 
number of tumors per mouse (0.6 versus 1.0) appeared to be lower in XpdTTD mice when com-
pared to wild type controls. Also, as XpdTTD mice live shorter, the tumors were found earlier 
than in wild type controls (mean latency time of 699 and 788 days, respectively). However, 
although there is a clear trend for lower tumor frequencies in XpdTTD mice, at present no firm 
conclusion on significant differences in cancer proneness between genotypes can be drawn. 
For that, further pathology analyses on cross sectional kills are needed. 
Incidences of the individual tumor types at the time of death are summarized in Table 3B. All 
tumors belonged to the spectrum normally observed in aging C57BL/6 mice. The incidences 
of the majority of these tumors were too low (less than 5%) to reveal any significant differ-
ences between the genotypes. As expected, only lymphomas and pituitary pars distalis ad-
enomas had a relatively high incidence in C57BL/6 females and appeared to have a distinctly 
lower incidence in XpdTTD mice (Table 3B). These differences were statistically significant for 
both lymphomas (p=0.05) and pituitary adenomas (p<0.001, Fisher’s exact test). However, 
when the data were corrected for differences in survival, using the Peto method [20], only the 
incidence of pituitary adenomas, but not lymphomas, was statistically significantly decreased 
in XpdTTD mice (p=0.002 and p=0.26 two-sided, respectively).
Non-neoplastic pathology
In addition to tumors, both C57BL/6 and XpdTTD mice showed a large variety of non-neoplastic 
pathological abnormalities in several organ systems: inflammatory, proliferative, degenera-
tive or regressive. Many of these abnormalities are known to increase with age in C57BL/6 
wild type mice. Most of these lesions occurred to about the same degree and incidence in 
both genotypes and will not be discussed here any further. In addition, pathology features in 
XpdTTD wild type littermates were found to be comparable to those in C57BL/6 females (data 
not shown). Several abnormalities showed biological (and statistical) relevant differences 
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Figure 5: Examples of pathology differences between XpdTTD and C57BL/6 female mice.
Histopathology differences between XpdTTD and C57BL/6 female mice. Examples of age-related (A-I, II, III), TTD-specific (B-IV), and caloric-
restriction-related differences (B-V, VI) are depicted. The upper picture of every set is of an XpdTTD mouse, the lower picture of a C57BL/6 
mouse. 
Age-related pathology differences: I. Aortic sarcopenia in an XpdTTD female (644 days) and C57BL/6 mouse (662 days). Note the scarcity of 
nuclei between the elastic fibers in the XpdTTD aorta. II. Kidney hyaline glomerulopathy in an XpdTTD female (497 days) and C57BL/6 mouse 
(722 days). PAS-positive purple stained deposits (negative for amyloid) within glomeruli of the XpdTTD kidney, that were absent in the C57BL/6 
control kidney. III. Lipofuscin fluorescence (UV) in the liver of an XpdTTD mouse (735 days), which was distinctly less in a C57BL/6 female (855 
days). IV: TTD-specific atypical epithelial hyperplasia of the duodenum at the gastroduodenal junction. Note the crowding of nuclei and the 
disorganized aspect in the XpdTTD duodenum (735 days). Normal duodenum of a C57BL/6 mouse (624 days) is shown for a clear comparison. 
Dietary restriction-related pathology differences: V. Cataract of the eye lens of a C57BL/6 mouse (722 days), note the swollen and vacuolated 
lenticular fibers. The lens of the XpdTTD female (659 days) is relatively normal. VI. Thyroid with distended follicles in a C57BL/6 female (764 
days) and normal-sized follicles in a XpdTTD female (609 days).
Pictures were obtained using HE staining (I, IV, V, VI) or PAS-staining (II). For III, unstained slides were used. Magnification bars shown represent 
0.1 mm in all pictures (except the thyroid (VI): 1 mm). Upper and lower picture in one panel show the same magnification. Objectives used were 
5x (VI), 20x (III, IV) or 40x (I, II, V).
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in incidence and/or severity between XpdTTD and C57BL/6 mice. These differences can be 
subdivided into various categories as pointed out below (see also Table 4). 
Accelerated aging features: Histopathological features of this category were consistent with 
and added on the earlier described premature aging phenotype of the XpdTTD mice [16]. Age-
related pathology at the time of death was found to be most overt in liver, kidney, bone as 
well as lymphoid tissues (Table 4A, Fig. 5A). Lipofuscin accumulation in the liver was distinctly 
most severe in XpdTTD females (Fig.5A-III). The age-related pigment was present mainly in 
Kupffer cells, but also in hepatocytes. A similar trend was present in the heart of XpdTTD mice, 
although to a lesser extent. Eosinophilic or ‘empty’ hepatic intra-nuclear inclusions occurred 
to a higher extent in XpdTTD than in C57BL/6 mice. Hepatic intra-nuclear inclusions increase 
with age and are generally considered to be invaginations of the nuclear membrane con-
taining cytoplasm [21]. Renal karyomegaly, seen as large, frequently bean-shaped nuclei in 
epithelial cells of the pars recta of the proximal renal tubules was slightly more pronounced 
in XpdTTD mice. Furthermore, the renal tubules were frequently dilated, which might be the 
cause of the high relative kidney weights of XpdTTD mice. Renal hyaline glomerulopathy oc-
curred generally to a mild degree in C57BL/6 mice, but was much more pronounced in XpdTTD 
females (Fig.5A-II). Evidence for the occurrence of osteoporosis of the femur, characterized by 
loss of trabecular bone, as well as kyphosis (although not quantified) was found in XpdTTD mice 
(Table 4, K. Diderich et al, in preparation). The increase of lymphoid depletion of the spleen 
in XpdTTD females was characterized by a decreased lymphocytic density and a smaller extent 
of the splenic white pulp area. This may provide an explanation for the decline in spleen 
weight observed later in life for the XpdTTD mutant mice. The normal age-related involution 
(lymphoid atrophy) of the thymus, with loss of organoid structure and decrease in size, was 
more pronounced in XpdTTD than in C57BL/6 mice and correlated with the decreased organ 
weights. Aortic sarcopenia was defined as loss of muscle cells in the tunica media, a condition 
that occurred almost exclusively in XpdTTD mice (Fig.5A-I). Since the number of muscle cells in 
aortas of 3 and 6 months old XpdTTD mice did not differ from those of age-matched C57Bl/6 
controls (data not shown), aortic sarcopenia should be considered as a real aging-related 
phenomenon. Another conspicuous feature, specifically present in aging XpdTTD mice, was re-
duced or absent hypodermal fat as compared to C57BL/6 mice of the same age. This explains 
the consistent lower body weights of the XpdTTD animals.
XpdTTD-specific features: The second category of pathology differences consisted of differ-
ences specifically for the TTD phenotype that manifest during the whole lifespan (Table 4B, 
Fig.5B). One of the most striking hallmarks of TTD patients is the brittleness of hair as was also 
found in XpdTTD mice. In more detail, XpdTTD mice showed acanthosis, hyperkeratosis, seba-
ceous gland hyperplasia, mast cell infiltration, extra-cellular melanin and follicular distention 
in the skin (mentioned as TTD skin lesions in Table 4B). Duodenal epithelial hyperplasia just 
near the gastro-duodenal junction occurred mainly in XpdTTD mice (Fig.5B-IV). However, no 
intestinal tumors were observed in this area in any of the mice. A striking feature of XpdTTD 
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mice in our study was anorectal prolapse, a condition in which a part of the rectum protrudes 
through the anus. Since this change was followed by perianal inflammation and ulceration 
it was a frequent cause of death of XpdTTD mice (see above). The non- protruding part of 
the rectal mucosa of affected animals appeared not to be altered, however. No evidence of 
inflammation of the large intestines was found, a condition that has been associated before 
with rectal prolapse [22]. In conclusion, the observed anorectal prolapse in XpdTTD mice is 
probably associated with the prolonged cachectic state of the mice or with XpdTTD-specific 
changes in the perianal musculature and as such there is no relationship with aging per se. 
Signs of caloric restriction: Apart from the aging-related changes and XpdTTD-specific 
changes, we found a third unexpected category of altered (reduced) pathology in XpdTTD mice 
at the time of death, consistent with a phenotype associated with dietary / caloric restriction 
(CR)(Table 4C, Fig. 5B). These features include a considerably lower incidence and/or severity 
in XpdTTD mice of the following symptoms: de-myelination of the peripheral nerve, cataract 
(Fig.5B-V), thyroid follicular distension (Fig.5B-VI), pituitary adenomas, ulcerative dermatitis, 
etc. (see for further details Table 4C). Most of these abnormalities are known to increase dur-
ing aging, but under conditions of CR they have been reported to occur with lower incidence 
and severity [23]. Also age-associated reduction of hypo-dermal fat has been related to CR 
in rodents [23, 24]. 
Discussion
Aging is poorly defined at the mechanistic level, because aging is pleiotropic and segmental 
in its nature. It is a complex process with concurrence of multiple diseases or disabilities on 
a background of increasing functional decline and failure of homeostasis, associated with 
reduced stress resistance and an increased risk of dying. The universal driver of the aging 
process, across species, is likely the accumulation of somatic damage in cellular macromol-
ecules, such as DNA, with ROS as the prime suspect for being the main damage-inducing 
agent. In view of the importance of DNA as the ultimate template and the discovery that 
heritable mutations in DNA maintenance genes underlie almost all known human segmental 
progeroid syndromes, maintenance of genome integrity has now emerged as a major factor 
in longevity and cell viability. Mice are good model systems to investigate the molecular basis 
of (accelerated) aging, because of their powerful genetics and the similarity of genomes and 
genome maintenance systems between mice and man. Many mouse mutants defective in 
genome maintenance display, like their human counterparts, segmental progeria [14]. 
In order to further understand the causal relationship between the aging process and 
genome maintenance, we are currently performing complete life span studies with various 
mouse models harboring defects in one or both sub-pathways of the NER system (i.e. Xpa, 
Csb, Xpc and XpdTTD mice). In the present study, we focused on the XpdTTD mouse mutant, 
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previously shown to display a segmental premature aging phenotype [16] that in retrospect 
could also be recognized in human trichothiodystrophy (TTD) patients [12]. A cohort of fe-
male XpdTTD mice was compared under strict SPF conditions to control mice having the same 
C57BL/6 genetic background. Such a side-by-side comparison with the normal aging process 
is the only valid way of identifying genuine symptoms of premature aging [3].
TTD is a segmental progeroid disorder
From present and previous results, it appears that the XpdTTD mice, just like the TTD patients, 
display wide-spread, premature segmental multi-system aging. XpdTTD mice show accelerated 
aging for a large number of known aging parameters (Table 4A) and as such they are excellent 
to study various (not all) premature aging phenotypes. When assumed that the underlying 
mechanism of aging in XpdTTD mice is similar as that in normal aging, this mouse model could 
be of potential use in future intervention studies. 
Although a statistically significant difference in life span between XpdTTD mice and C57BL/6 
control mice was observed, XpdTTD mice in the present study lived significantly longer than 
reported initially [16]. The major differences between these two studies were differences in 
genetic background and housing conditions. Either one of these can have impact on the 
ultimate outcome of longevity studies and underline that genuine comparison of the life 
span of different strains can only be reliably done under such strict conditions. An important 
cause of death in XpdTTD mice, and not in C57BL/6 controls, was a general conditional decline 
(including cachexia), also found in TTD patients [12]. Perhaps this state of conditional decline 
should be considered as a failure of the organism to maintain homeostasis. Additional causes 
of death were anorectal prolapse in XpdTTD mice and inflammation (mainly ulcerative derma-
titis) in C57BL/6 mice, which was also reported by others [25, 26]. 
In TTD patients, a specific form of anemia (thalassaemia, trait) has been described [27] that 
has been related to reduced levels of transcription of the β-globin gene. Although the type 
of anemia observed in XpdTTD mice (normochrome) appears to be slightly different from that 
in TTD patients, a similar etiology may be postulated. Pronounced kyphosis and evidence for 
osteoporosis were found in aging XpdTTD mice, pointing to age-related skeletal abnormalities 
as were also found in TTD patients [12]. In addition to these known age-related features, 
the detailed systematic analysis performed in the present study revealed new (histo-) 
pathological parameters of aging in various organs and tissues of XpdTTD females. Especially 
lipofuscin accumulation in liver (and heart) cells was a very interesting observation since 
the accumulation of this pigment can be associated with oxidative damage [28], underlining 
the theory that defects in genome maintenance may be directly related to accumulating 
aging features. However, as the XPD protein functions both in DNA repair and transcription 
(initiation), it needs to be established whether the observed lipofuscin accumulation is due 
to defects in global genome NER, damage-induced interference of transcription by TCR or 
inactivated or constitutive transcription initiation of RNA polymerase I and II promoters. Also 
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renal karyomegaly has been associated with accumulation of DNA damage (M. Luijten et al, 
in preparation). One of the most pronounced age-related pathological differences between 
old XpdTTD and control females was aortic sarcopenia. This loss of aortic muscle cells was 
particularly enhanced in old mice. This loss together with the age-related growth retarda-
tion and skeletal abnormalities in XpdTTD mice, underlines the hypothesis that TTD is not a 
developmental disorder, but is truly due to early onset of specific aging-related symptoms. 
Besides these genuine progeroid features of XpdTTD mice, we also found (TTD-related) 
features that do not meet age-related criteria. These are, i) the TTD-specific aberrant brittle 
hair and skin abnormalities; ii) increase of duodenal atypical hyperplasia and iii) anorectal 
prolapse probably as a consequence of the cachectic state of the mice. It is our hypothesis 
that these TTD-specific features are caused by a transcriptional deficit rather than by a defect 
in the DNA repair function of the XPD protein. 
XpdTTD mice show signs of caloric restriction
A striking finding in the present study, purely based on pathological findings, was the iden-
tification of CR features in XpdTTD mice. Pronounced effects of CR on a variety of pathological 
abnormalities as well as mean and maximum life span in mammalian species are well docu-
mented [29, 30]. In C57BL/6 mice on a restricted diet, the frequency of pituitary adenomas as 
well as dermatitis, other inflammatory changes and cataract appears considerably reduced 
[23]. The following observations in XpdTTD mice are in line with this CR hypothesis: i) a low 
body weight accompanied by low hypodermal fat mass and absence of abdominal fat; ii) 
reduced tumor development; iii) low frequency of inflammation and cataract. 
Strikingly however, food intake of XpdTTD mice was comparable to that of the wild type 
C57BL/6 mice, indicating that the CR phenotypes may be due to metabolic problems in XpdTTD 
mice owing to mild transcription failures. Supportive to this assumption are our preliminary 
data on mouse models with true NER defects like Xpa and Xpc, which lack such an apparent 
CR phenotype (to be published elsewhere). Definite proof that XpdTTD mice go into a state of 
metabolic restriction should come from more dedicated studies like biochemical analyses 
(for instance glucose, insulin, IGF-1), studies that were not possible to combine with our cur-
rent longevity experiment. Still though, preliminary micro-array analyses further support our 
CR hypothesis (Suh et al, manuscript in preparation).
In conclusion, it is conceivable to assume that inefficient energy uptake is advantageous 
to XpdTTD mice. Under such conditions, production of harmful metabolic side products (like 
ROS) will be decreased which is in favor of DNA-repair deficient XpdTTD mice, and clearly more 
general to all living organisms when survival is considered. 
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Abstract
Mutations in the XPD subunit of TFIIH give rise to human genetic disorders initially deﬁned 
as DNA repair syndromes. Nevertheless, xeroderma pigmentosum (XP) group D (XP-D) pa-
tients develop clinical features such as hypoplasia of the adipose tissue, implying a putative 
transcriptional defect. Knowing that peroxisome proliferator-activated receptors (PPARs) 
are implicated in lipid metabolism, we investigated the expression of PPAR target genes in 
the adipose tissues and the livers of XPD-deﬁcient mice and found that (i) some genes are 
abnormally overexpressed in a ligand-independent manner which parallels an increase in 
the recruitment of RNA polymerase (pol) II but not PPARs on their promoter and (ii) upon 
treatment with PPAR ligands, other genes are much less induced compared to the wild type, 
which is due to a lower recruitment of both PPARs and RNA pol II. The defect in transactiva-
tion by PPARs is likely attributable to their weaker phosphorylation by the cdk7 kinase of 
TFIIH. Having identiﬁed the phosphorylated residues in PPAR isotypes, we demonstrate how 
their transactivation defect in XPD-deﬁcient cells can be circumvented by overexpression of 
either a wild-type XPD or a constitutively phosphorylated PPAR S/E. This work emphasizes 
that underphosphorylation of PPARs affects their transactivation and consequently the ex-
pression of PPAR target genes, thus contributing in part to the XP-D phenotype. 
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Introduction
XPD mutations cause the rare autosomal recessive disorder xeroderma pigmentosum (XP), 
primarily deﬁned as a DNA repair defect, which is sometimes associated with Cockayne syn-
drome, as well as trichothiodystrophy (TTD) (29, 47). Be sides the potential for carcinogenesis 
caused by photosensitiv ity, these patients exhibit a large spectrum of clinical abnor malities, 
such as immature sexual development, mental retardation, skeletal abnormalities, and 
dwarﬁsm. The princi pal hallmark of TTD patients is brittle hair and nails, caused by a reduc-
tion in cysteine-rich matrix proteins. Some TTD pa tients have ichthyotic skin and an unusual 
face that appears aged due to the lack of subcutaneous fatty tissue (15, 21). In women, the 
breast tissue may be completely absent in spite of normal development of the nipples. Obvi-
ously, these various clinical features cannot solely be explained by DNA repair defects (5). 
While one cannot exclude the biological effects due to the damage itself (that can in some 
cases prevent one of the ongoing cellular mechanism such as replication or transcrip tion), 
it however has to be pointed out that the product of the XPD gene belongs to the TFIIH 
complex, which is involved in the DNA repair as well as in the transcription process. 
TFIIH can be resolved into two subcomplexes: the core-TFIIH (containing in particular the 
XPB helicase) and the cdk-activating kinase (CAK) complex containing the cyclin dependent 
kinase cdk7 (40). The core-TFIIH and CAK sub-complexes are bridged by the XPD helicase 
subunit, which interacts with p44 on the one side and MAT1 on the other side (9, 41). In the 
nucleotide excision reaction, TFIIH, once re cruited on the damaged DNA already recognized 
by the XPC HR23B factor, unwinds the DNA around the lesion upon ad dition of ATP to allow 
the recruitment of XPA, RPA, XPG, and XPF/ERCC1 repair factors (37). When XPD is mutated 
in the C-terminal end, its interaction with its regulatory partner p44 is weakened (9). In that 
case, the XPD helicase is no longer upregulated by p44 and cannot optimally operate in the 
nucleotide excision repair process (49). In the transcription process, TFIIH together with TFIIA, 
-B, -D, -E, and -F basal transcription factors and RNA polymerase (pol) II, partici pates in the 
initiation of RNA synthesis by opening the pro moter around the start site via its XPB helicase 
(18) and by phosphorylating via its cdk7 kinase the carboxy-terminal do main of the largest 
subunit of RNA pol II and some transcrip tional activators including nuclear receptors (7, 12, 
25, 32, 38). 
The peroxisome proliferator-activated receptors PPARα,-γ, and -δ are ligand-activated nuclear 
receptors which form het erodimers with the retinoid X receptor and bind to PPAR-responsive 
elements of numerous target genes (26). These transcription factors regulate lipid metabolism 
(3, 28) and are activated by fatty acids, their derivatives, and/or synthetic com pounds (11). 
PPARα enhances fatty acid combustion in the liver by upregulating genes encoding enzymes 
in the ß-oxida tion pathway and hence mediates the hypolipidemic effects of ﬁbrates (35). In 
contrast, PPARγ serves as an essential regu lator of adipocyte differentiation and promotes 
lipid storage in mature adipocytes (39). Two PPARγ isoforms (PPARγ1 and -2) are produced 
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by the differential use of three promoters and alternative splicing (reviewed in reference 11). 
Lastly, PPARδ regulates fat burning in peripheral tissues by coordinating fatty acid oxidation 
and energy expenditure (48). Besides their func tion in lipid metabolism, many potential roles 
for PPARs have been named in pathological states observed in XP group D (XP-D) patients, 
such as infertility and cancers (4). 
In order to evaluate whether a transcriptional defect takes part in the XP-D phenotype, 
we focused on a putative connec tion between the hypoplasia of adipose tissue observed 
in XP-D patients and a defect in transactivation by PPARs. Con trary to what was expected, 
we observed that the expression of PPARγ target genes is differently affected in the adipose 
tis sues from XPD/TTD-deﬁcient mice. Indeed, whereas some of these genes are abnormally 
overexpressed in a ligand-indepen dent manner, we also observed a lower induction of PPARγ 
target genes after treatment with a speciﬁc ligand. We found that the defect in transacti-
vation by PPARs in XPD-deﬁcient cells (isolated from both TTD mice and XP-D patients) is 
associated with a weaker phosphorylation of these nuclear receptors by cdk7. Having 
identiﬁed the phosphorylated resi dues in the PPAR isotypes, we demonstrate how their 
trans-activation defect in XP-D-deﬁcient cells can be circumvented upon the overexpression 
of either wild-type (WT) XPD or PPAR S/E, in which the glutamic acid mimics a constitutively 
phosphorylated residue. 
Materials and methods 
Animals and morphological studies. 
The generation of the TTD mouse line R722W has been described previously (10). Mice were 
fed standard chow with a 5% (wt/wt) fat content (R03 breeding diet; UAR, Villemoisson, 
France). Frag ments of adipose tissues and liver were ﬁxed in 4% formaldehyde for 48 h prior 
to parafﬁn embedding. Hematoxylin-and-eosin (H&E)-stained sections were 5 μm thick, while 
frozen sections for oil red-O staining were 15 μm thick. Apo ptosis was assessed by the termi-
nal deoxynucleotidyltransferase-mediated dUTP biotin nick end labeling (TUNEL) method us-
ing the ApopTag kit (Chemicon Int.). Brieﬂy, liver sections were deparafﬁnized, hydrated, and 
incubated for 15 min at room temperature in 20 mg/ml proteinase K. After being thoroughly 
washed in distilled water and immersed in terminal deoxynucleotidyltransferase (TDT) buffer 
for 10 min at room temperature, the sections were incubated in TDT buffer, digoxigenin dUTP, 
and TDT for 60 min in a humidiﬁed chamber at 37°C. The reaction was visualized by an immu-
nohistochemical technique using anti-digoxigenin-peroxidase antibodies. Cell regeneration 
was evaluated by im munohistochemical studies using antibody against the cell proliferation 
marker Ki67 according to the manufacturer’s instructions (Novocastra). Fragments of various 
tissues were also frozen for RNA and protein extraction. Three-month old mice were treated by 
oral gavage with rosiglitazone (10 mg/kg body weight for 3 days; GlaxoSmithKline), WY14643 
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(100 mg/kg body weight for 20 h; Calbiochem), or the corresponding vehicle (ethanol at 3 ml/
kg or dimethyl sulfoxide at 3 ml/kg, respectively). 
Retrotranscription and real-time quantitative PCR. 
RNAs were prepared with TRIzol (GIBCO-BRL) and treated with RQ1 DNase (Promega) accord-
ing to the manufacturer’s instructions. For reverse transcriptase PCR, total RNA (2 μg) was 
reverse transcribed with Moloney murine leukemia virus reverse tran scriptase (Invitrogen) 
using random hexanucleotides. Real-time quantitative PCR was done using the FastStart 
DNA Master SYBR Green kit and the LightCycler apparatus (Roche Diagnostic). The primer 
sequences and the PCR conditions for each target gene are available upon request. 
Chromatin immunoprecipitation (ChIP). 
Hepatic fragments were ﬁxed by adding 37% formaldehyde to a ﬁnal concentration of 1% 
and incubated for 15 min at room temperature and1hat 4°C. Fragments of white adipose tis-
sue (WAT) and brown adipose tissue (BAT) were pooled from tissues of two animals and ﬁxed 
as described above. Cross-linking was stopped by addition of glycine to a ﬁnal concentration 
of 0.125 M. Fragments were washed twice with cold phos phate-buffered saline and treated 
with sonicate buffer (50 mM HEPES [pH 7.9], 140 mM NaCl 1 mM EDTA, 1% Triton X-100, 
0.1% sodium dodecyl sulfate [SDS], 0.1% Na-deoxycholate) containing protease inhibitors. 
Fragments were homogenized, and cell lysates were then sheared extensively by sonication 
on ice to obtain fragments of 200 to 600 bp (as revealed by ethidium bromide staining of 
aliquots run on agarose gels). Samples were centrifuged to pellet debris, and an aliquot was 
taken for gel analysis and inputs. Soluble chromatins were pre treated for2hat4°C with protein 
G (previously saturated with 1 mg/ml of sonicated salmon sperm DNA and 1 mg/ml of bovine 
serum albumin). Samples were then incubated overnight at 4°C with antibodies of interest; 
protein G (previously saturated) was then added, and the mixture was incubated for2hat 4°C. 
Sepharose beads were washed twice for 10 min at 4°C with wash 1 (sonicate buffer with 500 
mM NaCl) and then with wash 2 (0.25 M LiCl, 0.5% NP-40, 0.5% sodium deoxycholate, 1 mM 
EDTA, 20 mM Tris-HCl [pH 8.0]), and ﬁnally with Tris-EDTA (TE; pH 8.0). Immune complexes 
were eluted from the beads with 1% SDS in TE (pH 8.0), and protein-DNA cross-links were 
reversed by adding 200 mM NaCl and heating for5hat 65°C. After treatment with proteinase 
K (2 h at 42°C), the samples were puriﬁed by phenol-chloroform-isoamyl alcohol extraction 
and precipitated with ethanol. One-ﬁfteenth of the immunoprecipi tated DNA and 1% of the 
input DNA were quantiﬁed by real-time quantitative PCR (see above). Results are expressed 
relative to the amount of input DNA per ChIP. 
Antibodies. 
Monoclonal antibodies against the TFIIH subunits, TATA box binding protein (TBP), and RNA 
pol II were produced by the Institut de Gé nétique et de Biologie Moléculaire et Cellulaire 
175
Dysregulation of the PPAR target genes by XPD mutations
facility. Polyclonal antibodies against VDR (sc-9164; Santa Cruz), PPARα (H-98; Santa Cruz), 
PPARα/S12 (PA1-820; ABR), and PPARδ (K-20; Santa Cruz) and monoclonal antibodies raised 
against PPARγ (E-8 for Western blotting [Santa Cruz], AB12409 for immunoprecipitation [AB 
Cam LTD]) or phosphorylated S84/S112 PPARγ1/2 (1F5; Euromedex) were purchased. 
Coimmunoprecipitation assays. 
PPARα and PPARγ2 cDNAs were inserted into the pVL1392 vector, and the resulting vectors 
were recombined with bacu lovirus DNA (Baculogold; Pharmingen) as previously described 
(13). Sf9 cells were infected with combinations of baculoviruses encoding the subunits of 
TFIIH (45) and either VDR (31), PPARα, or PPARγ2. Whole-cell extracts were incubated with 
an antibody directed against either the p44 subunit of TFIIH, VDR, or the corresponding 
PPAR isotype. After extensive washing (300 mM KCl), bound proteins were resolved by SDS-
polyacrylamide gel electrophoresis (PAGE) and revealed by immunoblotting. 
Plasmids and construction of PPAR mutants. 
Speciﬁc PCR products including the entire coding sequence, the truncated form without the 
A/B domain, or the A/B domain alone for each PPAR isotype were inserted into the NdeI clon-
ing site of the prokaryotic pET15b expression vector (Novagen). Serine residue changes to 
alanine or glutamic acid were introduced using the QuikChange site-directed mutagenesis 
kit (Stratagene). 
In vitro kinase assays. 
His fusion proteins were produced into Escherichia coli strain BL21 and puriﬁed on Ni-
nitrilotriacetic acid agarose (Qiagen). Equal amounts (1 μg) of recombinant proteins were 
incubated with puriﬁed recombi nant CAK complex (40) or highly puriﬁed TFIIH in the pres-
ence of [‘-32P]ATP (0.14 μm). 
Mass spectrometry. 
PPAR A/B domains were in vitro phosphorylated by CAK, puriﬁed by SDS-PAGE, and in gel 
digested with Staphylococcus aureus V8 protease (for PPARα and -γ) or Asp-N endoprotein-
ase (for PPARδ). Peptide extracts (0.5 ml) were mixed with an equal volume of saturated 
2,5-dihydroxy benzoic acid, dissolved in 20% acetonitrile, and applied to the target. Mass 
measurements were carried out on a Bruker Reﬂex IV matrix-assisted laser desorption ion-
ization–time of ﬂight mass spectrometer in the positive-ion reﬂec tor mode. Mono-isotopic 
peptide masses were assigned using the Bruker X-TOF software. Potential phosphorylation 
sites were searched using the FindMod tool (http://us.expasy.org/tools/ﬁndmod/) with the 
following parameters: PPAR A/B domains as user-entered sequences, V8 or Asp-N digestion 
in phosphate buffer, two missed cleavages allowed, cysteines modiﬁed by carbamidometh-
ylation, me thionine oxidation, and a mass tolerance of 75 ppm. 
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Cell culture and transient transfection assays. 
HeLa and HD2 cells were grown in Dulbecco’s modiﬁed Eagle medium (DMEM)-Ham F10 
containing 10% (vol/vol) fetal calf serum (FCS) and 40 μg/ml gentamicin and plated to ap-
proximately 50% conﬂuency (5 X 105 cells/35-mm plate) before transfection. Normal human 
ﬁbroblasts (GM03348D; Coriell Cell Repository), XPD-mutated ﬁbroblasts (XPJCLO) (44), 
TTD8PV, and TTD12PV (isolated from TTD pa tients bearing the R112H and R722 point muta-
tions, respectively [reviewed in reference 6]) were grown in DMEM (1 g glucose/liter; GIBCO-
BRL) supple mented with 10% FCS and 40 μg/ml gentamicin. TTD and WT mouse ﬁbroblasts 
were grown in DMEM (4.5 g glucose/liter; GIBCO-BRL) and supplemented with 15% FCS and 
40 μg/ml gentamicin. Human and mouse ﬁbroblasts were transiently transfected using the 
transfection reagent Fugene6 (Roche Diagnos tics). In all experiments, 1 μg of pPPAR-RE-Luc 
and 100 ng of each expression vector were used per well in the absence of serum. Control 
transfections were undertaken with corresponding void plasmids. To normalize transfection 
efﬁ ciencies, pCH110 (1 μg) was cotransfected. Following transfection for 7 h, the cells were 
treated with red phenol-free medium containing 10% charcoal-treated FCS–40 μg/ml gen-
tamicin. After 12 h of incubation, the appropriate ligand for each PPAR isotype was added 
and the mixture was incubated for 24 h. Fibro blasts extracts were analyzed for luciferase and 
f-galactosidase activities as previously described (25). The results are the mean of at least 
three independent experiments performed in triplicate. 
Statistical analysis. 
The number of mice for each group used in experiments is indicated in the ﬁgure legends. 
Values are presented as the mean ± the standard error of the mean. A two-tailed Student test 
was used to calculate P values. 
Results 
TTD mice exhibit hypoplasia of the adipose tissues. 
TTD mice bearing the XPD point mutation R722W were used in our study. These mice develop 
features similar to those observed in XP-D patients, such as brittle hair, developmental de-
fects, skeletal abnormalities, and cachexia (Fig. 1A; reviewed in ref erence 10). Indeed, weight 
differences between WT and TTD mice appear and become more pronounced a few months 
after birth (TTD mice have about 20% lower body weights at 3 months of age; Fig. 1B). The 
weight loss is not due to disrup tion of the daily food intake (3.8 ± 0.2 and 4.2 ± 0.2 g/animal/ 
day for WT and TTD mice, respectively). The appearance and fat composition of the feces of 
TTD mice are normal (data not shown), arguing against malabsorption as the cause of weight 
loss. 
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The weights of various tissues were then analyzed at differ ent ages (Fig. 1C). Whereas the 
TTD liver exhibits a weight similar to the WT, we observed a progressive mass reduction for 
the perivisceral WAT (48% and 32% of that observed in 3 and 6-month-old WT mice, respec-
tively; Fig. 1C and 2A, parts 1 and 2, arrows) and the interscapular BAT (67% and 52% of that 
observed in 3-and 6-month-old WT mice, respectively; Fig. 1C). Interestingly, the perivisceral 
WAT and the inter-scapular BAT are almost nonexistent in 18-month-old TTD mice (Fig. 2A). 
Histological analysis after standard H&E stain ing revealed that the adipocytes in the intra-
Figure 1: Lean phenotype in TTD mice. 
(A) Photographs of repre sentative 3-month-old XPD+/+ , XPDR722W/R722W and XPD+/R722W mice. (B) Body weights of male WT (n = 6) and 
TTD (n = 6) mice were monitored for 18 months. (C) Weights of the liver (Liv), intra peritoneal WAT, and interscapular BAT were normalized to 
body weight for 3-and 6-month-old male TTD mice (n = 6). The values are percentages relative to those observed for WT mice. 
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peritoneal WAT of 3-month-old TTD mice are reduced and heterogeneous in size, whereas 
they are homogeneous and uniform in the WAT of control littermates (Fig. 2B, parts 1 and 2). 
In parallel, oil red-O staining of TTD BAT cells reveals a decrease in the accumulation of lipid 
Figure 2: Expression of PPARγ target genes in TTD adipose tissues. 
(A) Ventral view of 3-, 6-, and 18-month-old WT (parts 1, 3, and 5) and TTD (parts 2, 4, and 6) mice. Note the progressive loss of visceral fat 
pads in TTD mice (arrows). (B) H&E-stained sections of intraperitoneal WAT and interscapular BAT of 3-month-old WT and TTD mice. BAT was 
also stained with lipid-speciﬁc oil red-O dye. Magniﬁcation is indicated at the bottom left of each part. (C) Gene expression in WAT and BAT of 
3-month-old WT (dark boxes, n = 4) and TTD (open boxes, n = 4) mice on standard chow (-) or supplemented with rosiglitazone, a speciﬁc 
PPARγ ligand (+ Rosi; 10 mg/kg body weight for 3 days). The values were normalized relative to 18S RNA expression. The full names of the 
genes are given in the text. The recruitment of PPARγ and RNA pol II on the corresponding promoters was also analyzed by ChIP assays in 
WT (dark boxes) and TTD (open boxes) adipose tissues. Immunoprecipitated DNA was quantiﬁed by real-time quantitative PCR. Results are 
expressed as n-fold recruitment relative to nontreated WT mice. 
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droplets (Fig. 2B, parts 5 and 6), which explains the decrease in the intracytoplasmic vacuoles 
ob served in the H&E staining (parts 3 and 4). Similar histological observations were found in 
TTD mice at different ages (data not shown). 
Dysregulation of PPARγ-responsive genes in the adipose tissues. 
We were wondering whether the morphological alter ations of the TTD mouse adipose 
tissues could be associated with dysregulation of some genes. Knowing that PPARs play a 
preponderant role in these tissues (46, 48), we analyzed the expression of genes known to be 
controlled by PPARs and/or involved in various pathways of lipid metabolism (Fig. 2C). 
WT and TTD mice were thus treated by gavage with rosigli tazone (10 mg/kg body weight 
for 3 days), a speciﬁc ligand of PPARγ (30). In WT BAT, the rosiglitazone ligand stimulated 
the expression of UCP-1 and -3 (uncoupling proteins 1 and 3, involved in the uncoupling 
of oxidative phosphorylation), mCPT1 (the muscle form of carnitine palmitoyltransferase 
1, involved in fatty acid ß-oxidation), and aP2 (a fatty acid bind ing protein) (Fig. 2C). More 
importantly, we observed that the induction of these genes was 50% lower in TTD BAT than 
in WT BAT. A similar reduction was observed by transfection assays in XPD-deﬁcient cells (see 
Fig. 5B and C). We also found in TTD WAT an unexpected ligand-independent over-expression 
of UCP-1 (10-fold), mCPT1 (3.5-fold) (two genes usually expressed in BAT), and aP2 (4.5-fold). 
Note that PGC1c, a coactivator that regulates the expression of genes involved in biological 
programs linked to energy homeostasis (such as thermal regulation), is also overexpressed in 
both TTD BAT and WAT (about twofold). Finally, under both standard and gavage conditions, 
no signiﬁcant changes be tween WT and TTD mice were observed in the expression of some 
genes, such as PPARγ, PPARδ, the very long chain acyl coenzyme A (CoA) synthetase (involved 
in fatty acid ß-oxida tion), UCP-2, the lipoprotein lipase (involved in triglyceride hydrolysis), 
Spot 14 (involved in lipogenesis), and the acyl-CoA binding protein (involved in fatty acid 
trafﬁcking) (Fig. 2C and data not shown). 
To understand whether such dysregulations are due to PPARγ, we set up ChIP assays. The 
genomic DNA fragments bound to either PPARγ or RNA pol II were immunoprecipi tated with 
the corresponding antibodies and further analyzed by quantitative PCR. Upon rosiglitazone 
treatment, PPARγ was much less recruited on the promoters of UCP-1, UCP-3, mCPT1, and 
aP2 in TTD BAT (Fig. 2C). Therefore, it is not surprising that the occupancy on the respective 
promoters by RNA pol II parallels that of PPARγ, thus explaining the lower RNA synthesis level. 
In the case of the abnormal overexpression of aP2 in TTD WAT, we found that mRNA synthesis 
perfectly parallels RNA pol II recruitment whereas PPARγ is no longer recruited (Fig. 2C). We 
next hardly detected PPARγ recruitment on the promoters of UCP-1 and mCPT1 (masked in 
the background; data not shown). 
Altogether, our data underline a profound dysregulation of PPARγ-dependent genes in 
TTD adipose tissues. Whereas the basal dysregulation observed for some of these genes 
might occur in a PPARγ (and ligand)-independent manner, the lower response of genes to a 
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speciﬁc PPARγ treatment is associated with lower PPARγ recruitment and consequently of the 
transcription apparatus on their promoters. 
Dysregulation of PPARa-responsive genes in the livers of TTD mice. 
We next evaluated whether the transactivity of another PPAR isotype is affected in TTD mice. 
We focused our attention on PPARα, the major PPAR isotype in the liver (35). Macroscopic 
analysis ﬁrst showed that the livers of 3-, 6-, and 12-month-old TTD mice look normal, with 
a size, a form, a consistency, and a color similar to the WT (as illustrated for 3-month-old 
mice in Fig. 3A, parts 1 and 2). Histological anal ysis further reveals that there is no signiﬁcant 
difference in the architecture and structure of the hepatic parenchyma between WT and TTD 
mice at various ages (parts 3 to 6). A slight reduction of the intrahepatic lipid vacuoles is 
still observed in TTD mice compared to WT mice (Fig. 3A, parts 7 and 8). It is worth noting 
that we observed minimal necrotic lesions in the vicinity of the centrolobular and periportal 
areas of TTD mouse livers, which are associated with granular degeneration of hepatocytes 
having no or pyknotic nuclei (parts 4 and 6, arrows). Despite their persistence, no age-related 
accumula tion of these necrotic areas was observed in TTD mice. The presence of apoptosis 
in the 3-month-old TTD liver was as sessed by the TUNEL method (Fig. 3, parts 9 and 10). 
We observed a very slight (5%) increase in apoptosis in the livers of TTD mice compared 
to their control littermates. More importantly, the apoptotic areas were not colocalized to 
the necrotic areas. Immunodetection of the cell proliferation marker Ki67 revealed a slight 
increase in cell regeneration in the livers of WT mice compared to TTD mice (9%, parts 11 and 
12). Since neither necrosis accumulation nor other hepatic lesions have been observed, our 
results led us to suggest the aspeciﬁc and isolated status of these necroses. 
Although macroscopic and histological analyses did not re veal strong alterations of the TTD 
liver, we next analyzed the expression of hepatic genes known to be regulated by PPARα. 
Three-month-old WT and TTD mice were treated for 20 h with WY14643, a PPARα agonist, in 
order to measure the induction of hepatic genes known to be highly and quickly activated 
by PPARα (8). Under those conditions, the PPARα mRNA level remained unchanged in both 
WT and TTD livers (Fig. 3B). We also noted that the cellular concentrations of PPARα were 
similar in WT and TTD mice (see Fig. 5A, right part). Moreover, the expression of CD36 (encod-
ing a glycop rotein involved in the uptake of long-chain fatty acids), the acyl-CoA oxidase 
(the rate-limiting enzyme in peroxisomal ß-oxidation of fatty acids), or the mitochondrial 
3-hydroxy-3 methylglutaryl-CoA synthase (involved in ketogenesis) was similarly induced in 
WT and TTD mice (Fig. 3B and data not shown). On the contrary, pACOTH (peroxisomal acyl-
CoA thioesterase, involved in the hydrolysis of acyl-CoAs) and CYP4A1 (cytochrome P450 4A1, 
involved in the w-hydroxyla tion of fatty acids) are much less overexpressed in TTD mice (Fig. 
3B). ChIP assays next revealed that PPARα is much less recruited on the CYP4A1 promoter in 
TTD liver than in WT liver, while its recruitment on the CD36 promoter is similar in both livers 
(Fig. 3B). As expected, upon WY14643 treatment, we found that the recruitment of RNA pol 
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Figure 3: Expression of PPARα target genes in the TTD liver. 
(A) Macroscopic view (parts 1 and 2) of 3-month-old WT and TTD mouse livers. Parts 3 to 6: H&E-stained liver sections. Arrows indicate focal 
lesions corresponding to hepatic necrosis. Parts 7 and 8: oil red-O-dyed liver sections. Parts 9 and 10: in situ apoptosis detection in liver sections 
by TUNEL assay (see arrows). Parts 11 and 12: immunoperoxidase staining of liver sections for detection of the Ki67 antigen. Arrows indicate 
Ki67-positive nuclei. PV and CV, portal and centrolobular veins. Magniﬁcations are indicated. (B) Expression of PPARα target genes in the livers 
of 3-month-old WT (black boxes, n = 4) and TTD (open boxes, n = 4) mice treated for 20 h with WY14643 (100 mg/kg body weight). The results 
are presented as n-fold induction relative to nontreated mice. ChIP analyses were also performed on the CD36 and CYP4A1 promoters in the 
liver of WT (dark boxes) and TTD (open boxes) mice. Soluble chromatin was immunoprecipitated with antibodies raised against PPARα, RNA pol 
II, or TFIIH (XPB). Immunoprecipitated DNA was quantiﬁed by real-time quantitative PCR. Results are expressed as n-fold recruitment relative to 
nontreated mice. 
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II was much lower on the CYP4A1 promoter in TTD liver. Lastly, no signiﬁcant difference was 
observed between WT and TTD mice in the recruitment of TFIIH on the promoters of the 
CD36 and CYP4A1 genes (Fig. 3B). 
Altogether, these results demonstrate that TFIIH mutation inhibits the expression of some 
hepatic PPARα target genes in response to a speciﬁc agonist. This defect is associated with a 
weaker recruitment of PPARα and RNA pol II, two compo nents essential for their transcription. 
PPARs are phosphorylated by TFIIH via cdk7. 
Knowing that some nuclear receptors cooperate with TFIIH (7, 25, 38), we examined the 
physical and enzymatic connections between the PPAR nuclear receptors and basal tran-
scription factor TFIIH. Extracts from Sf9 insect cells coinfected with baculo viruses encoding 
the subunits of TFIIH and either PPARγ2or PPARα were incubated with Ab-p44, a monoclonal 
antibody directed against the p44 subunit of TFIIH (20). Ab-p44 immu noprecipitates either 
PPARγ2 or PPARα in addition to TFIIH (Fig. 4A, left and right parts, lanes 8), while it does not 
retain PPARs in the absence of TFIIH (lanes 6). The presence of a speciﬁc ligand does not affect 
the interaction between TFIIH and PPARs (data not shown). As a control, we observed that 
Ab-C, an unrelated antibody, does not immunoadsorb either of these components (lanes 9). 
As previously stated (12), no in teraction has been observed between TFIIH and the vitamin D 
nuclear receptor (VDR), demonstrating the speciﬁcity of the PPAR-TFIIH interactions (Fig. 4A, 
middle part, lane 8). To further determine which TFIIH subunit is targeted by PPARs, Sf9 insect 
cell extracts coinfected with baculoviruses encoding PPARα or PPARγ2 and either one of the 
subunits of TFIIH were incubated with the corresponding antibodies (Fig. 4B). Both PPARγ2 
and PPARα coimmunoprecipitated with XPB, p62, p44, and MAT1. 
We also investigated whether PPARs can be used as sub strates by cdk7. In vitro kinase assays 
show that both CAK and TFIIH phosphorylate recombinant PPARγ2 and PPARα (Fig. 4D, left 
and right parts, lanes 1 to 3) and more precisely their A/B domain (both parts, lanes 7 to 9). 
Indeed, PPAR lA/B, the truncated forms that lack the A/B domain, are not phos phorylated 
(both parts, lanes 4 to 6). Moreover, the A/B PPARs were not phosphorylated by rIIH-CKmut, 
a recombi nant TFIIH in which cdk7 was mutated in its ATP binding site (both parts, lanes 10 
to 12). The A/B PPAR motifs were next phosphorylated in vitro by CAK, resolved by SDS-PAGE, 
and digested for mass spectrometry analysis. Accordingly, and knowing that cdks are serine/
threonine kinases, each serine or threonine contained in the putative phosphorylated regions 
of PPARγ2 and PPARα was mutated to alanine. The mutated A/B proteins were produced in E. 
coli and further puriﬁed on a nickel chelate column before being tested in in vitro kinase as-
says. Having observed that some mutations of serine to ala nine prevent phosphorylation by 
either CAK or the entire TFIIH, we demonstrate that residue S112 of PPARγ2 (corre sponding 
to serine 84 of PPARγ1) is a target for cdk7 (Fig. 4E, left part, lanes 4 to 6 and 10 to 12). We 
also found that the A/B domain of PPARα contains two phosphorylation sites at posi tions 
S12 and S21 (Fig. 4E, right part). Indeed, A/B PPARα S12A/S21A, in which serines 12 and 21 
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were changed to ala nine, is no longer phosphorylated by TFIIH (Fig. 4E, right part, lanes 13 
to 16), whereas A/B PPARα-S12A or A/B PPARα-S21A is less phosphorylated (lanes 5 to 12), 
suggesting a synergistic effect of the phosphorylation of both serines 12 and 21. Additionally, 
Figure 4: Interaction between TFIIH and PPARs and determination of their cdk7 phosphorylation 
sites. 
(A) Sf9 cells were coinfected with baculoviruses encoding the subunits of TFIIH (rIIH wt) and PPARγ2 (left part), VDR (middle part), or PPARα 
(right part). Immunoprecipitation (IP) was done using an antibody directed against the TFIIH/p44 subunit (Ab-p44, lanes 5 to 8) or a control 
antibody (Ab-C, lanes 9). The bound proteins were analyzed by Western blotting using antibodies against subunits of TFIIH (XPD, p62 and 
cdk7), PPARγ2, VDR, or PPARα. (B) Sf9 cell extracts overexpressing each TFIIH subunit alone (-) or in combination with PPARγ2 or PPARα (as 
indicated) were incubated with antibodies directed against the corresponding PPAR isotype. Immunoprecipitated proteins were analyzed by 
Western blotting using antibodies against each subunit of TFIIH. The input lanes (IN) represent 10% of the total volume of extracts used in each 
immunoprecipitation. 
(C) Schematic representation of the truncated PPAR proteins with a histidine tag (dark box). The different domains (A to F) of PPARγ2 and PPARα 
and the cdk7 phosphorylation sites are depicted. Serine 112 in PPARγ2 corresponds to serine 84 in the PPARγ1 isoform. (D) Puriﬁed PPAR, 
PPARlA/B, and A/B PPAR were incubated in the absence (lanes 1, 4, 7, and 10) or presence of either free CAK (lanes 2, 5, and 8), TFIIH isolated 
from HeLa cells (lanes 3, 6, and 9), recombinant TFIIH (rIIH wt, lanes 11), or recombinant TFIIH mutated in the cdk7 ATP binding site (rIIH CKmut, 
lanes 12). Coomassie blue-stained gels (top parts) and autoradiography (Autoradio; bottom parts) of the incubated fractions are shown. (E) 
Left part: A/B PPARγ1-wt, A/B PPARγ2-wt, A/B PPARγ1 S84A, and A/B PPARγ2 S112A were incubated with CAK or TFIIH in the presence of 0.14 
μm[‘-32P]ATP. Right part: puriﬁed A/B PPARα-wt, S12A, S21A, and S12A/S21A were incubated with CAK and increasing concentrations of [‘-32P]
ATP (0.07, 0.14, 0.42, and 0.70 μm). 
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preliminary mass spectral data strongly  suggest that the PPARΔ A/B domain is phosphory-
lated by cdk7 between residues 44 and 55 (DLSQNSSPSSLL; data not shown). 
Phosphorylation of PPARs is crucial for their transactivation. 
We next questioned whether a default in the phosphorylation of PPARs might explain their 
lower ability to transac tivate their target genes in XPD-mutated cells. Nuclear extracts of 
WAT, BAT, and liver isolated from 3-month-old WT and TTD mice were resolved by SDS-PAGE, 
followed by Western blot analysis (Fig. 5A). We found that the cellular concentrations of 
PPARγ1/2 and PPARα are similar in both WT and TTD mice (left and right parts). Nevertheless, 
using an antibody speciﬁcally designed for either phosphorylated S84/S112 of PPARγ1/2 (Ab 
PPARγ-P) or phosphorylated S12 of PPARα (Ab PPARα/S12), we observed that PPARγ1/2 and 
PPARα are signiﬁcantly less phosphorylated in the adipose tissues and liver isolated from TTD 
mice. 
We next designed PPAR expression vectors in which the serine residues phosphorylated 
by cdk7 were changed to either alanine or glutamic acid, which mimics a constitutively 
phos phorylated serine residue. Wild-type and TTD mouse ﬁbro blasts were cotransfected 
with these expression vectors in as sociation with pPPAR-RE-Luc (Fig. 5B). First, we observed 
that luciferase gene expression was stimulated in WT ﬁbro blasts by PPARγ1 (3.3-fold), PPARγ2 
(4.8-fold), and PPARα (4.4-fold) following the addition of their corresponding ligands (Fig. 
5B, each part, lanes 3 and 4, dark boxes). In contrast, the transactivation directed by PPARγ1, 
PPARγ2, or PPARα was approximately 50% lower in TTD ﬁbroblasts than in WT cells (lanes 3 
and 4, open boxes). Control experiments showed that reporter gene activation requires both 
PPAR overexpression and the presence of the ligand (lanes 1 to 3). Interestingly, the transfec-
tion of PPARγ1-S84E, PPARγ2-S112E, and PPARα S12E/S21E expression vectors circumvents 
the transactivation defect observed in TTD ﬁbroblasts (Fig. 5B, compare lane 6 to lane 4, open 
boxes). Moreover, the overexpression in WT ﬁ broblasts of PPARγ1-S84A, PPARγ2-S112A, and 
PPARα S12A/S21A gives reduced luciferase activity similar to what is usually obtained in TTD 
cells (compare lane 5 to lane 4, dark boxes). 
Finally, we investigated in XPD-mutated cells whether WT XPD would restore the transac-
tivation by PPARs (Fig. 5C) and secondly whether this effect would be correlated with their 
phosphorylation status (Fig. 5A, middle part). For conve nience, we used the established cell 
line HD2 (22), resulting from the fusion between human ﬁbroblasts harboring the XPD point 
mutation R683W (an other XPD mutation affecting transactivation by PPARs; see below) and 
HeLa cells. HD2 and HeLa cells (used as a control) were cotransfected with pPPAR-RE-Luc (a 
construct containing the luciferase re porter gene placed under the control of three DR1-type 
PPAR-responsive elements) and expression vectors encoding WT XPD and either PPARα or 
PPARγ2 (Fig. 5C). Upon addition of the corresponding ligand, the transactivation di rected 
by any PPAR was approximately 50% lower in HD2 than in HeLa cells, as previously observed 
for PPAR target genes in TTD mice (Fig. 5C, each part, lanes 1, open boxes). Interestingly, 
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overexpression of WT XPD fully restores trans-activation by PPARγ1, PPARγ2, and PPARα in 
HD2 cells (both parts, lanes 2, open boxes). These results clearly dem onstrate that the defect 
in transactivation by PPARs in XPD-deﬁcient cells is due to the XPD mutation itself. In parallel, 
the phosphorylation status of PPARγ2 was evaluated by Western blotting in HD2 cells. WT 
Figure 5: Phosphorylation of PPARs is crucial for their transactivation.
(A) Left part: Western blotting analysis of PPARγ1 and -2 (Ab PPARγ) and their phosphorylated status on serines 84 and 112 (Ab PPARγ-P) in WAT 
(10 μg, lanes 1 and 2) and BAT (25 μg, lanes 3 and 4) nuclear extracts from 3-month-old WT and TTD mice. TBP (Ab TBP) was used as an internal 
control. Middle part: detection of PPARγ2 (PPARγ), its phosphorylated status on serine 112 (Ab PPAR-P) and XPD (Ab XPD) in crude extracts (100 
μg) from HeLa and HD2 (bearing XPD point mutation R683W) cells overexpressing PPARγ2 (lanes 1 to 4) and WT XPD (+ XPD, lanes 3 and 4). 
TBP (Ab TBP) was used as an internal control. Right part: detection of PPARα (Ab PPARα), phosphorylated S12 PPARα (Ab PPARα/S12), and TBP 
(Ab TBP) in hepatic nuclear extracts (25 μg) from 3-month-old WT and TTD mice. (B) WT (dark boxes) and TTD (open boxes) mouse ﬁbroblasts 
were cotransfected with pPPAR-RE-Luc (1 μg), pCH110 (1 μg), and either PPARγ1-wt, PPARγ2-wt, PPARγ1S84A, PPARγ1S84E, PPARγ2S112A, 
PPARγ2S112E, pSG5-PPARα-wt, PPARα S12A/S21A, or PPARαS12E/S21E(100 ng). The cells were next treated with a speciﬁc ligand for PPARγ1/2 
(rosigli tazone, 0.5 μm) or PPARα (WY14643, 1 μm). Luciferase (Luc) activity was measured 24 h later and normalized relative to f-galactosidase 
activity. Note that the f-galactosidase values were similar in WT and TTD ﬁbroblasts. (C) HeLa (dark boxes) and HD2 (open boxes) cells were 
transfected with pPPAR-RE-Luc (1 μg), pCH110 (1 μg), pSG5-PPARγ1 (100 ng), pSG5-PPARγ2 (100 ng), pSG5-PPARα (100 ng), and either 
pcDNA-XPDwt (XPDwt) or empty pcDNA. Cells were then treated with the corresponding ligand, as mentioned for panel B. The values are 
presented as percentages, 100% being the level of transactivation obtained in HeLa cells overexpressing each PPAR isotype in the presence of 
the corresponding ligand. Rosi, rosiglitazone. 
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and HD2 cells were transfected with expression vectors encoding WT XPD and PPARγ2 (Fig. 
5A, middle part). Whereas PPARγ2 is signiﬁcantly less phosphor ylated in HD2 cells than in 
HeLa cells (compare lanes 1 and 2), WT XPD overexpression restores the phosphorylation 
status of PPARγ2 in XPD-mutated cells (compare lanes 2 and 4). 
Altogether, these results demonstrate unambiguously that an XPD C-terminal mutation af-
fects the phosphorylation of PPARs and consequently their transactivation efﬁciency. 
Other XPD mutations affect transactivation by PPARs. 
We then examined whether different XPD mutations alter trans-activation by PPARs. TTD8PV 
(R112H), XPJCLO (R683W), and TTD12PV (R722W) human primary ﬁbroblasts isolated from 
XP or TTD patients (44) (http://www.xpmutations.org/) and normal human ﬁbroblasts 
(GM03348D) were transfected with pPPAR-RE-Luc and the expression vector pSG5 PPARα, 
pSG5 PPARγ1, or pSG5 PPARγ2-wt (Table 1). In the pres ence of ligand, we observed that lu-
ciferase gene expression was reduced in cells bearing XPD C-terminal mutations R683W and 
R722W, while it was normal in TTD8PV cells harboring the N-terminal mutation R112H. These 
results demonstrate that transactivation by PPARs is altered in ﬁbroblasts from XP or TTD 
patients and suggest that this deﬁciency is associated with the position of the XPD mutation 
rather than with the nature of the disorder. 
Discussion
This work is part of a study aiming to better understand the involvement of TFIIH in the trans-
activation process. We ana lyzed how a mutation in its XPD subunit affects this process, which 
in ﬁne might explain the emergence of some clinical features observed in XP-D patients. We 
thus found that the adipose tissues and livers of TTD mice (bearing the XPD R722W mutation) 
have a defect in the regulation of their PPAR-responsive genes. We demonstrate that lower 
PPAR phosphorylation by the cdk7 kinase of TFIIH contributes to the dysregulation of these 
genes. 
Table 1: Transactivation by PPARs in XPD-deﬁcient human ﬁbroblastsa 
Cell line XPD mutation Phenotype PPARγ1 PPARγ2 PPARα
TTD8PV R112H TTD 100 ± 8 97 ± 5 105 ± 5
XPJCLO R683W XP 64 ± 3 65 ± 7 61 ± 3
TTD12PV R722W TTD 63 ± 5 66 ± 3  63 ± 1
a TTD8PV, XPJCLO, and TTD12PV human primary ﬁbroblasts were trans fected with pPPAR-RE-Luc (1 μg), pCH110 (1 μg), and PPAR expression 
vectors (100 ng) and subsequently treated with a speciﬁc ligand for each PPAR as described Fig. 5B. The transactivation values are indicated 
as percentages, 100% being the level of transactivation obtained in normal ﬁbroblasts (GM03448D) overexpressing each PPAR isotype in the 
presence of the appro priate ligand. 
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PPAR phosphorylation by cdk7. 
Our results demonstrate that the activity of PPAR nuclear receptors depends on their ability 
to be phosphorylated by the DNA repair-transcription factor TFIIH. Mass spectral analysis 
and mutagenesis show that the phosphorylation sites are located in their A/B domain, also 
called the AF1 domain, in a serine/proline consensus site, namely, at positions S12 and S21 
for PPARα and S84 and S112 for PPARγ1 and -2, respectively. Interestingly, the sites of PPAR 
phosphorylation by the cdk7 kinase are also targeted by the mitogen-activated protein (MAP) 
kinases (19, 23). This observation is not restricted to PPARs, since other nuclear receptors are 
also phosphorylated on the same residue by cdk7 and/or MAP kinases, such as retinoic acid 
receptor c (38) and estrogen receptor c (7, 24). How do we reconcile that the same residue 
could be phosphorylated by different kinases? MAP kinases and cdk7 are involved in different 
signaling pathways, and their actions might occur at different times in cellular life. Whereas 
PPARs (and in extenso other nuclear receptors) would be phosphorylated in response to 
some mitogenic signal that activates the MAP kinase pathway, their phosphorylation by 
cdk7 would occur together with the formation of the trans-activation complex that puts 
TFIIH (within the preinitiation complex) and PPARs in very close proximity. Consequently, the 
same phosphorylation performed by various kinases differ ently affects the activity of the 
target factor. Along this line, it was demonstrated that serine 5 from the carboxy-terminal 
do main of RNA pol II could be phosphorylated by both cdk7 and cdk8 kinases with adverse 
consequences for the transcription process. While phosphorylation by cdk8 (which occurs 
outside the preinitiation complex) prevents the recruitment of RNA pol II on the promoter, 
modiﬁcation of serine 5 by cdk7 (which occurs inside the preinitiation complex) promotes 
initiation of transcription by facilitating promoter escape (2, 17, 36). 
Interestingly, PPAR nuclear receptors are much less phos phorylated by cdk7 in cells bearing 
an XPD C-terminal muta tion, as shown in cells isolated from XP-D R683W patients, as well as 
in tissues of TTD R722W mice. In these cells, the PPAR underphosphorylation is due to the 
XPD mutation it self, since overexpression of WT XPD restores PPAR phos phorylation to the 
normal level. How can one explain that any mutation in the C-terminal end of XPD affects 
PPAR phos phorylation? XPD C-terminal mutations weaken the interac tion between XPD and 
the p44 subunit, and consequently the anchoring of the CAK to the core-TFIIH (9). This might 
ex plain why these mutations not only prevent the regulation of the XPD helicase by p44 
to allow elimination of DNA damage (13) but also the ability of cdk7 to phosphorylate the 
nuclear receptors, such as PPARs. 
Incidence of PPAR underphosphorylation. 
In the adipose tissues and livers of TTD mice, the XPD mutation R722W affects the phos-
phorylation of PPARγ1/2 and PPARα and consequently the expression of PPAR target genes. 
In some cases, the transactivation by underphosphorylated PPARs is maintained after 
treatment with a speciﬁc ligand, although the PPAR-responsive genes are induced to a much 
Appendix II
188
lower level than in the WT ones, as shown for aP2 (in WAT), UCP-1, UCP-3 and mCPT1 (in BAT), 
and CYP4A1 and pACOTH (in the liver) (Fig. 2C and 3B). Additional ChIP experiments clearly 
demonstrate that the slight induction of these genes in TTD tissues is consistent with the 
lower recruit ment of PPARs, as well as RNA pol II, on their promoters. Their expression defect 
is not due to a dysfunction of TFIIH in the basal transcription process, since (i) TFIIH is nor-
mally recruited on their promoters and (ii) a TFIIH complex that carries an XPD C-terminal end 
mutation is able to normally promote RNA synthesis in in vitro transcription assays (9, 25). 
The expression defect (that was also observed in our transient transfection assays) is rather 
due to the inability of TFIIH to accurately phosphorylate PPARγ or PPARα. Indeed, overex-
pression of WT XPD restores not only transactivation by PPARs but also their phosphorylation 
in XPD-mutated cells (Fig. 5A, middle part, and C). Moreover, overexpression of the PPAR 
S-to-E-mutated forms (in which the glutamic acid mim ics a constitutively phosphorylated 
residue) allows normal ex pression of PPAR-dependent genes even in XPD-mutated cells (Fig. 
5B). It remains to be determined whether lower phosphorylation prevents the recruitment of 
accurate cofactors which are required for the PPAR transactivation process. 
In other cases, the expression of PPAR target genes is un expectedly increased in a tissue-
speciﬁc manner, as observed for UCP-1, mCPT1, and aP2 in TTD WAT. Since such over-
expression occurs independently of the presence of a speciﬁc ligand, it is not surprising that 
PPARs are no longer recruited on their corresponding promoters, while the recruitment of 
RNA pol II is consistent with the expression level (as illus trated for aP2 in Fig. 2C). Knowing 
that the expression of any gene requires a subtle combination of several DNA binding factors 
(14), a defect in the function of one of them might completely reprogram the transcription 
process. Since PPARs cannot be correctly phosphorylated, one cannot exclude the possibility 
that their transactivation function is diminished to a such level that they are supplanted by 
other tissue-speciﬁc factors. Further investigations should be undertaken to under stand why 
underphosphorylated PPARs are no longer re cruited, giving rise to other regulatory path-
ways. Altogether, our results show that PPAR target genes are speciﬁcally aff ected by PPAR 
underphosphorylation in a tissue speciﬁc man ner. This differential effect can thus explain 
the apparent dis crepancies between our results and data showing that the S112A mutation 
in PPARγ2 increases the expression of re sponsive genes (1, 19). In the latter case, it is likely 
that the nonphosphorylated PPAR S112A might be either assisted or supplanted by another 
transcriptional factor. 
Contribution of PPAR defects to the TTD phenotype. 
The reduction of adipose mass in TTD mice may occur by a dis ruption of adipogenesis and/
or elevated energy dissipation. Defects in adipogenesis typically result in irregular metabolic 
features, such as fatty liver, hypertriglyceridemia, and insulin resistance (34, 43). However, in 
TTD mice, no apparent ab normal fat accumulation was observed in the liver, and the circu-
lating glucose and total triglyceride levels are normal (data not shown). Subtle adipogenic 
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defects cannot be ex cluded, since the adipose tissues disappear with age (Fig. 2A) and TTD 
mouse embryonic ﬁbroblasts have a reduced capa bility to differentiate into adipocytes in the 
presence of pros taglandin PGJ2, a PPARγ ligand known to induce adipocyte differentiation 
(data not shown). Besides adipogenic dysfunc tion, we also observed in TTD mice elevated 
energy dissipation by indirect calorimetric analysis (1.4 ± 0.06 and 1.6 ± 0.07 kcal/h in WT and 
TTD mice, respectively; P 0.05; data not shown), as well as the aberrant overexpression in TTD 
WAT of BAT-speciﬁc genes involved in fatty acid catabolism, such as PGC1c and UCP-1 (33, 
42). The overexpression of these genes could contribute to the higher energy expenditure in 
TTD mice, as previously found in transgenic mice overexpressing UCP-1 in WAT (27). 
Therefore, the hypoplasia of the adipose tissues observed within the TTD mice might be 
due at least partially to a dysfunction of the PPAR nuclear receptors, which are essential in 
the lipid metabolism and both differentiation (46) and in vivo survival of the adipocytes (16). 
However, it seems also clear that the overall pleiotropic nature of the XP-D pheno type might 
result from the defect of various transcriptional factors, such as other nuclear receptors (12, 
25). By using diverse treatments, XPD-deﬁcient mice could provide excel lent models to eluci-
date the contribution of a defect of differ ent nuclear receptors, such as the estrogen receptor 
or the thyroid receptor, in various physiological pathways. 
Our in vivo results underline the crucial role of phosphory lation by TFIIH for the transactiva-
tion process. Moreover, we demonstrate that a defect in phosphorylating nuclear receptors 
might simply result in a drop in their transactivation capacity that could (as a function of 
the tissue and the environmental situation) lead to their being opportunistically replaced by 
other factors. The major challenge for the future will be to understand how phosphorylation 
by TFIIH directs the integra tion of nuclear receptors in the transactivation complex. 
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Abstract
Cockayne syndrome (CS) is a photosensitive, DNA repair disorder associated with progeria 
caused by a defect in the transcription-coupled repair (TCR) subpathway of nucleotide 
excision repair (NER). Here, complete inactivation of NER in Csbm/m/Xpa-/- mutants causes a 
phenotype that reliably mimics the human progeroid CS syndrome. Newborn Csbm/m/Xpa-/- 
mice display attenuated growth, progressive neurological dysfunction, retinal degeneration, 
cachexia, kyphosis and die before weaning. Mouse liver transcriptome analysis and several 
physiological endpoints revealed systemic suppression of the Growth Hormone/ 
Insulin-like Growth Factor 1 (GH/IGF1) somatotroph axis and oxidative metabolism, 
increased antioxidant responses, hypoglycemia together with hepatic glycogen and fat ac-
cumulation. Broad genome-wide parallels between Csbm/m/Xpa-/- and naturally aged mouse 
liver transcriptomes suggested that these changes are intrinsic to natural aging and the 
DNA repair-deficient mice. Importantly, wild type (wt) mice exposed to a low dose of chronic 
genotoxic stress recapitulated this response, thereby pointing to a novel link between ge-
nome instability and the age-related decline of the somatotroph axis. 
Appendix III
198
Introduction
A prevailing hypothesis to explain the molecular basis of aging is Harman’s “free-radical 
theory of aging”, which states that endogenous reactive oxygen species (ROS), resulting from 
cellular metabolism, continually damage biomolecules [1]. In line with this hypothesis, it 
has been shown that increased resistance to oxidative stress (e.g. by improved antioxidant 
defense) extends the life span of C. elegans, Drosophila, and rodents [2-4], whereas oppo-
sitely, hypersensitivity to oxygen considerably reduces the life span of nematodes [5]. A key 
macromolecule at risk for ROS-mediated damage is nuclear DNA [1], as evident from the 
wide range of oxidative DNA lesions that accumulate gradually in rodents and humans with 
advancing age [6,7]. 
In humans, the causative role of DNA damage in aging is supported by a variety of 
progeroid disorders with defects in DNA repair pathways [8,9]. One such condition is 
Cockayne syndrome (CS; affected genes: CSA or CSB), a photosensitive disorder, originating 
from a defect in transcription-coupled repair (TCR), that specifically removes DNA lesions, 
which obstruct RNA polymerases, to allow resumption of transcription and promote cellular 
survival from DNA damage. TCR of helix-distorting DNA damage is a dedicated subpathway 
of the multi-step ‘cut-and-patch’ nucleotide excision repair (NER) system, and is designated 
Transcription-Coupled Nucleotide Excision Repair (TC-NER) [10] to distinguish it from the 
so-called global genome NER (GG-NER) subpathway that operates genome wide to elimi-
nate distorting damage. Available evidence suggests that CS cells are also defective in TCR 
of non-helix distorting, DNA lesions that block transcription such as transcription-blocking 
oxidative DNA lesions [11,12], which are normally genome-wide removed by base excision 
repair. We will use TCR, when referring to transcription-coupled repair in general. CS patients 
present with growth failure (cachectic dwarfism), progressive neurological abnormalities 
(including delayed psychomotor development, mental retardation, microcephaly, gait ataxia, 
sensorineural hearing loss, retinal degeneration), along with impaired sexual development, 
kyphosis, osteoporosis and severely reduced life span (mean age of death: 12.5 years) [13,14]. 
A related yet distinct disorder is Trichothiodystrophy (TTD; affected genes: XPB, XPD or TTDA). 
TTD patients are partially defective in TCR, as well as in the global genome repair subpathway 
of NER, and share the symptoms associated with CS. In addition, these patients have a partial 
defect in transcription itself, causing additional symptoms such as ichthyosis and brittle hair 
and nails [15]. Many of the CS and TTD features are progressive and resemble premature ag-
ing. As patients develop some but not all aspects of normal aging in an accelerated manner, 
CS and TTD are considered “segmental progeroid syndromes” [8] 
Mouse mutants for CS-A and CS-B reliably mimic the UV-sensitivity of CS patients and 
show accelerated photoreceptor loss, reduced body weight, and mild neurologic abnormali-
ties [16,17]. Similarly, mice homozygous for a causative TTD point mutation in the Xpd gene 
faithfully mirror the symptoms in TTD patients [9] whereas complete inactivation of NER (by 
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concurrent inactivation of the Xpa gene) dramatically aggravates the CS features of partially 
NER-defective TTD mice [9]. These observations, together with the notion that DNA lesions 
can provoke a permanent cell cycle arrest or apoptosis, led us to propose that aging can re-
sult from (oxidative) DNA lesions that interfere with transcription and/or replication causing 
cell death or cellular senescence, ultimately leading to loss of tissue homeostasis and onset 
of age-related diseases [18-20]. 
Here, we report that mice with engineered mutations in both Csb and Xpa genes display 
many CS features in a dramatic form, including postnatal growth attenuation, progressive 
kyphosis, ataxia, retinal degeneration, motor dysfunction and premature death. Importantly, 
full genome transcriptome analysis of the Csbm/m/Xpa-/- mouse liver at the age of 15 days un-
covered a systemic response seen also in wt mice exposed to chronic oxidative stress. These 
findings disclose a novel link between DNA damage, compromised genome maintenance 
and the somatotrophic axis that determines life span and shed new light on the etiology of 
Cockayne syndrome and natural aging.
Methods
Animals 
The generation and characterization of NER-deficient Xpa-/-, Xpc-/-, and Csbm/m mice has been 
previously described [16,22,64,65] p53-/- mice [66] were kindly provided by Dr. T. Jacks (MIT, 
Cambridge, MA). Unless stated otherwise, all mice were kept in a C57BL/6J genetic back-
ground. In the DEHP exposure study, 4-week old male wt mice (C57BL/6J; n=6) were put on 
a di(2-ethylhexyl)phthalate (DEHP; 1500 ppm; Sigma) containing diet or on a regular diet 
for 9 weeks. Animals were daily screened for discomfort and weighed once a week. Food 
consumption was registered by weighing the food. In the ionizing irradiation exposure study, 
19-day old Csbm/m/Xpa-/- and littermate control animals (n=4-6/genotype) were exposed to 10 
Gy, sacrificed 20 hours after exposure and eyes were further processed. Additional informa-
tion on the isolation and processing of the eyes is provided in the supplementary section. As 
required by Dutch law, all animal studies were approved by an independent Animal Ethical 
Committee (Dutch equivalent of the IACUC). Further information on mouse crossing, geno-
typing, housing and macroscopic examination is described in the supplementary section. 
Cellular sensitivity studies
UV sensitivity was determined as described [67]. Sparsely seeded Petri dish cultures were 
exposed to different doses of UV (254 nm, Philips TUV lamp). After 4 days, the number of 
proliferating cells was estimated from the amount of radioactivity incorporated during a 2 hr 
pulse with [3H] thymidine. Cell survival was expressed as the percentage of radioactivity in 
exposed cells in relation to the radioactivity in untreated cells. UV-induced global genome re-
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pair was assayed using the UDS method described by [68]. In brief, coverslip-grown cells were 
exposed to 16 J/m2 of 254 nm UV light and labeled with [3H] thymidine. Repair capacity was 
quantified by grain counting after autoradiography. RNA synthesis recovery was measured 
according to [69]. In short, coverslip-grown cells were exposed to 10 J/m2 of 254 nm UV light, 
allowed to recover for 16 hr, labeled with [3H] uridine, and processed for autoradiography. 
The relative rate of RNA synthesis was expressed as GUV/GC (percentage), where GUV and GC 
represent the number of grains over UV-exposed and non-exposed nuclei, respectively.
Ionizing radiation sensitivity of immortalized MEFs was determined using a colony assay. 
Cells were plated in 6-cm-diameter dishes at various densities. After 16 h, cells were exposed 
to a single dose of ionizing radiation (137Cs source; dose range of 0 to 8 Gy. Cells were grown 
for another 5 to 14 days, and after fixation and staining, colonies were counted. All experi-
ments were performed in triplicate. 
Immunohistological Examination and Blood Parameters
Detailed histopathological examination was performed on all organs and tissues. Paraffin-
embedded tissues were sectioned at 5 μm and stained with haematoxylin/eosin solution. 
Liver sections were stained with Periodic Acid Schiff (PAS) or Oil Red O (cryosections) to detect 
glycogen and triglycerides respectively. Detailed information on the immunohistochemical 
procedures is described on the supplementary section. Apoptotic cells were detected using 
a TdT-mediated dUTP Nick-End Labeling (TUNEL) assay as described by the manufacturer 
(Apoptag Plus Peroxidase In Situ Apoptosis Detection Kit, Chemicon). For retinal evaluation, 
eyes were marked nasally with Alcian blue (5% Alcian blue in 96% ethanol), enucleated, fixed 
in 4 % paraformaldehyde in 0.1M phosphate buffer, washed in PBS and embedded in paraf-
fin. Horizontal sections (5 μm thick) of the retina were cut and sections in the middle of the 
retina were selected by Alcian blue marking and proximity of the optic nerve. Sections were 
stained for degenerating cells by TdT-mediated dUTP Nick-End Labeling (TUNEL), according 
to the manufacturer’s instructions (Apoptag Plus Peroxidase In Situ Apoptosis Detection Kit, 
Chemicon). For quantification, the number of TUNEL-positive cells in the inner nuclear layer 
(INL) and outer nuclear layer (ONL) were counted in 6 whole sections per mouse. Differences 
between the genotypes were tested for statistical significance using multivariate analysis of 
variance (ANOVA), followed by a posthoc test of Student-Newman-Keuls (S-N-K). Significance 
was set at p<0.05. Serum IGF1 and GH levels were determined with the Active mouse/rat IGF1 
ELISA (Enzyme-Linked Immuno Sorbent Assay) and Active mouse/rat GH ELISA kits respec-
tively, as described by the manufacturer (Diagnostic Systems Laboratories Inc., Texas). Blood 
glucose was measured using a Freestyle mini blood glucose measurement device (Abbott 
Diabetes Care). 
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Radiography and Micro-computed Tomography 
Mice were anaesthetized by intraperitoneal injection of ketalin and rompun (120 and 7.5 
μg/g body weight). Lateral films were taken at 2x magnification using a CGR Senograph 500T 
X ray system operated at 30 kV and 32 mAS [9]. Formalin fixed tibiae from wt and mutant mice 
were scanned from proximal end to mid-diaphysis, using a SkyScan 1072 microtomograph 
(SkyScan, Antwerp, Belgium) with a foxel size of 8.82 μm. Scans were processed, and 2D im-
ages of the bones were obtained. 
Footprint Studies
Footprint analysis was performed by painting the hind and fore paws of the mice with differ-
ent colors of water-soluble non-toxic paints. Animals were allowed to walk along a 30 x 7 cm 
walled runway, lined with paper, into a darkened, enclosed space. Tests were performed in 
duplicate at day 15 and 19. Footprint patterns were analyzed for (1) stride length, measured 
as the average distance between each stride, (2) front base width and (3) hind base width, 
measured as the average distance between contralateral footprints [70].
Microarray Analysis and Q-PCR Evaluation
Standard procedures were used to obtain total RNA (Qiagen) from the liver of wt, Xpa-/-, 
Csbm/m, and Csbm/m/Xpa-/- mice (n=4) at postnatal day 15 and from the liver of 8-, 16-, 96- and 
130-week old mice (n=5). Synthesis of double stranded cDNA and biotin labeled cRNA was 
performed according to the instructions of the manufacturer (Affymetrix, USA). Fragmented 
cRNA preparations were hybridized to full mouse genome oligonucleotide arrays (430 V2.0; 
Affymetrix, USA). Q-PCR was performed with a DNA Engine Opticon device (MJ Research). 
Detailed information on microarray hybridization, microarray data analysis, gene ontol-
ogy classification, and analysis of overrepresented biological themes, as well as on Q-PCR 
data analysis and used primer pair sequences is described in the supplementary section. 
Microarrays complied with the Minimum Information for Microarray Experiments (MIAME, 
E-MEXP-835 and E-MEXP-839).
Supplementary methods
Animals 
Since Xpa-/-, Xpc-/- and Csbm/m mice are fertile, Csbm/m/Xpa-/-, Csbm/m/Xpa-/-and Xpa-/-/Xpc-/- mice 
were obtained from crossings between homozygous/heterozygous double mutant animals 
(e.g. Csbm/m/Xpa+/- x Csb+/m/Xpa-/-) to increase the expected proportion of double-mutant mice 
from 1:16 to 1:4. Csbm/m/Xpa-/-/p53-/- triple-mutant mice were obtained in a similar way after 
the Xpa and Csb mutant alleles had first been crossed into a p53-deficient background. Mice 
were genotyped by PCR using a three-primer mix that amplifies both the wt and targeted 
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allele in a single reaction (see supplementary section). Animals are housed at the Animal 
Resource Center (Erasmus University Medical Center) and the National Institute of Public 
Health and the Environment (RIVM), which operate in compliance with the “Animal Welfare 
Act” of the Dutch government, using the “Guide for the Care and Use of Laboratory Animals” 
as its standard. As required by Dutch law, formal permission to generate and use genetically 
modified animals was obtained from the responsible local and national authorities. All ani-
mal studies were approved by an independent Animal Ethical Committee (Dutch equivalent 
of the IACUC).
Exposure to Ionizing Irradiation 
For the ionizing irradiation study, 19-day old Csbm/m/Xpa-/- and littermate control animals (n=4-
6/genotype) were exposed with 10Gy. Animals were sacrificed 20 hours after exposure and 
eyes were processed for further analysis. For the isolation of the eyes, animals were anaesthe-
tized by CO2 inhalation, followed by cervical dislocation. Eyes were marked on the nasal side 
with Alcian blue (5% Alcian blue in 96% ethanol), subsequently enucleated and fixed in 4 % 
paraformaldehyde in 0.1 M phosphate buffer. Paraffinized sections of 5 μm thickness were 
subjected to TUNEL staining (see methods), eyes were fixed in 4 % paraformaldehyde in 0.1 
M phosphate buffer and embedded in paraffin. 
Macroscopic Examination / Blood Parameters
Newborn Csbm/m/Xpa-/- mice and their littermates were observed and weighed daily between 
11.00 and 13.00 hours. Animals were euthanized at defined time points (as indicated in the 
text) or when displaying evident worsening of health condition (indicative for imminent 
death). Internal organs were isolated and either fixed in 10% phosphate-buffered formalin 
and paraffin-embedded (histopathological analysis) or snap-frozen in liquid N2 (for transcrip-
tion profiling by microarray analysis or quantitative PCR). In some cases animals were given 
an intra-peritoneal injection with bromo-deoxy-uridine (BrdU; 50 μg/gram bodyweight) 45 
min. prior to euthanasia in order to measure cell proliferation.
Immunohistochemistry
Immunohistochemical procedures: Paraffin sections (5 μm) were dewaxed and rehydrated, 
followed by an antigen retrieval step, comprising 1 x 7 minute and 2 x 3 minute incubations 
of tissue sections with a 0.01M sodium citrate buffer in a 800 Watt microwave. Sections were 
washed in phosphate buffered saline (PBS) for 2 minutes. Endogenous peroxidase activity 
was blocked by incubating the sections for 30 minutes in PBS, containing 30% H2O2 and 
12.5% sodium azide. Sections were washed in PBS (1 x 2 minutes) and PBS, containing 0.5% 
milk powder, and 0.15% glycine (PBS+ buffer, 2 x 2 minutes). 
Immunohistochemical staining was performed by incubating sections with primary anti-
bodies against PCNA (PC10, Abcam, dilution 1:1000) or BrdU (Bu20a, DAKO, dilution 1:100) in 
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PBS+ (16 hr; 4 oC). In case of BrdU, sections were first covered with 0.1M HCl for 60 minutes at 
37 oC and rinsed with PBS, prior to incubation with the primary antibody. Next, sections were 
washed in PBS+ (3 x 5 minutes) and incubated for 1 hour at room temperature with rat-anti-
mouse Immunoglobulins antibody (1:1000) coupled to horseradish peroxidase (DAKO). After 
sections were washed in PBS+ (3 X 5 minutes) and PBS 1 x 2 minutes), color was developed 
for 8 minutes in 3, 3’-diaminobenzidine solution (DAKO Liquid DAB substrate-chromogen 
system), all according to the instructions of the manufacturer. Sections were counterstained 
in haematoxylin before dehydration and mounting. All histology images were acquired at 
40x objective magnification on an Olympus BX40 microscope (London, United Kingdom), 
equipped with a CCD camera. 
Citrate Synthase Enzyme Activity
Frozen livers were transferred into ice-cold buffer (SHE) consisting of 250 mM sucrose, 10 mM 
HEPES, pH 7.4, and minced. Fresh SHE was added and homogenized by 12 passes in a tight-
fitting glass/Teflon power-driven Potter-Elvejehem homogenizer. Citrate synthase activity 
of the homogenate was measured by monitoring the CoA-coupled conversion of Ellman’s 
reagent into TNB at 412 nm at 37ºC in the presence of 0.005% (v/v) Lubrol-WX to solubilize 
the mitochondrial inner membrane and expressed in mU as nmol 5-thio-2-nitrobenzoate 
(TNB)/min per mg protein. Protein concentrations were determined by the Bio-Rad DC pro-
tein assay (Bio-Rad Laboratories, Inc., Veenendaal, the Netherlands) with BSA as a standard.
Microarray Analysis 
Standard procedures were used to obtain total RNA (Qiagen) from the liver of wt, Xpa-/-, 
Csbm/m, and Csbm/m/Xpa-/- mice (n=4) at postnatal day 15 and from the liver of 8-, 16-, 96- and 
130-week old mice (n=4). Synthesis of double stranded cDNA and biotin labeled cRNA was 
performed according to the instructions of the manufacturer (Affymetrix, USA). Fragmented 
cRNA preparations were hybridized to full mouse genome oligonucleotide arrays (Affymetrix, 
mouse expression 430 V2.0 arrays), using Affymetrix hybridization Oven 640 (Affymetrix, 
USA), washed, and subsequently scanned on a GeneChip Scanner 3000 (Affymetrix, USA). 
Initial data extraction and normalization within each array was performed by means of the 
GCOS software (Affymetrix). By implementing the R statistical package that is based on an 
open-sourced language, data intensities were log transformed and normalized within and/
or between groups of arrays by means of the quantile normalization method. For all 15-day 
old livers, normalization was performed within and between groups of mice based on the 
assumption that most genes do not change between the various genotypes (Csbm/m, Xpa-/-, 
Csbm/m/Xpa-/- and wt). We also took into account, however, that this assumption may not be 
true for expression data derived from very distinct groups of mice (e.g. 130-week old compared 
to 8-week old mice). In those cases, expression data were normalized within age groups. This 
approach was shown to minimize the variance within each group of mice, thereby increasing 
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the statistical power between groups of mice. The two normalization approaches used in this 
study (i.e. within and between groups or only within groups) did not affect the Spearman’s 
rank correlation measures (see below) on the categorical data. Based on the quality report 
files generated by the manufacturer (Affymetrix, USA), the threshold background noise was 
set at 40. For each probe set, signals were considered to be valid when they were marked as 
“Present” and exhibit a signal higher than 40 in at least one microarray experiment. All probe 
sets with a signal below 40 were set to be equal to 40. Where appropriate, two-tail, pair wise 
analysis or two-way analysis of variance was employed by means of the Spotfire Decision Site 
software package 7.2 v10.0 (Spotfire Inc., MA, USA) to extract the statistically significant data 
from each of the four individual microarrays obtained for each genotype (wt, Xpa-/-, Csbm/m, 
and Csbm/m/Xpa-/- livers) as well as from the four microarrays in each of the three groups of 
naturally aged mice (16-, 96- and 130-week old mice, n=4) as compared to 8-week old mice. 
The criteria for significance were set at p≤0.010 and a ≥ ±1.2-fold change with the exception 
of glycogenin 1 where after Q-PCR the difference in expression (1.26-fold up regulation) was 
considered to be significant despite the slightly deviant p-value of 0.012 (the cut-off was 
set at 0.010). All correlations were calculated by Spearman’s rank correlation coefficient, a 
non-parametric correlation method and were based on categorical values derived from all 
significant probe sets (see above). For all correlations, significance was set at p ≤ 0.001. 
Gene Ontology Classification and Overrepresentation of Biological Themes 
All significant gene entries were subjected to GO classification (http://www.geneontology.
org). Significant over-representation of GO-classified biological processes was assessed by 
comparing the number of pertinent genes in a given biological process to the total number 
of the relevant genes printed on the array for that particular biological process (Fisher exact 
test, p≤0.01, False discovery rate (FDR) ≤0.1) using the publicly accessible software Ease 
(Hosack et al. 2003).
Quantitative PCR Evaluation
Total RNA was isolated from liver, heart, kidney and spleen of wt, Xpa-/-, Csbm/m, Csbm/m/
Xpa-/- mice at postnatal day 15 using a Total RNA isolation kit (Qiagen) as described by the 
manufacturer. Quantitative PCR (Q-PCR) was performed with a DNA Engine Opticon device 
according to the instructions of the manufacturer (MJ Research). Primer pair designed to 
generate intron-spanning products of 180-210bp were as follows: Sod1: 5’-GGG ACA ATA CAC 
AAG GCT GT-3’ and 5’-GCC AAT GAT GGA ATG CTC TC-3’; Gsr1: 5’- CCG CCT GAA CAC CAT CTA T 
-3’ and 5’-TTC CCA TTG ACT TCC ACC G-3’; Ghr: 5’-ATT CAC CAA GTG TCG TTC CC-3’ and 5’-TCC 
ATT CCT GGG TCC ATT CA-3’; Igf1: 5’-TGC TTG CTC ACC TTC ACC A-3’ and 5’-CAA CAC TCA TCC 
ACA ATG CC-3’; Prlr: 5’-GCA TCT TTC CAC CAG TTC CG-3’ and 5’-GCT CGT CCT CAT TGT CAT CC-
3’; Gstt2: 5’-GCC CAA GTC CAC GAA TAC CT-3’ and 5’-CTC TGT TCC GTT CCA CCT TC-3’; Ephx1: 
5’-CAG CCA AAG AAG ATG AGA GCA-3’ and 5’-AGC CAT AGT GGA AGC GAC T-3’; Hmox1: 5’-AAC 
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Figure 1: Growth retardation, cachexia, and premature death in Csbm/m/Xpa-/- and Csbm/m/Xpc-/- mice. 
(A) UV repair characteristics of wild type, single mutant, and double mutant primary mouse embryonic fibroblasts (MEFs). UV-induced 
Unscheduled DNA Synthesis (UDS; left panel) and Recovery of RNA Synthesis (RRS, right panel) are indicative for GG-NER and TC-NER capacity, 
respectively. For a detailed explanation of the procedure, see Method section. Error bars indicate S.E.M. (B) Survival of primary MEFs exposed 
to increasing doses of UV-C light (254 nm), as determined using the with [3H]-thymidine incorporation assay. Error bars (in most cases smaller 
than symbols used) indicate S.E.M. (C) Photograph of a 14-day old Csbm/m/Xpa-/- mouse with an Xpa-/- littermate (hybrid 129Ola/C57BL/6J 
background). (D) Photograph of an 8-day old Csbm/m/Xpc-/- mouse with a Csbm/m littermate (hybrid 129Ola/C57BL/6J background). (E) 
Body weight curve of Csbm/m/Xpa-/- and Csbm/m/Xpc-/- mice (n=7) compared to those defective in a single NER gene (n=7) all in a hybrid 
129Ola/C57BL/6J background. The arrow indicates birth. Error bars (in most cases smaller than symbols used) indicate S.E.M. (F) Photographs 
of day 18.5 Csbm/m/Xpa-/- and Xpa-/- embryos (C57BL/6J). 
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ACT CTG GAG ATG ACA CCT-3’ and 5’-TGT GAG GGA CTC TGG TCT TTG-3’; ApoA4: 5’-CAC CGT 
TTC TTC TGA CTC CG-3’ and 5’-AAT CCC ACA CCA CAT TGG C-3’; Igfbp3: 5’-GTG ACC GAT TCC 
AAG TTC CA-3’ and 5’-TGT CCT CCA TTT CTC TGC GG-3’; Dio1: 5’-CCC TGG TGT TGA ACT TTG 
GC-3’ and 5’-TGA GGA AAT CGG CTG TGG A-3’. The generation of specific PCR products was 
confirmed by melting curve analysis (which measures product specificity by the decrease in 
fluorescence signal when the PCR product is denatured) and gel electrophoresis (using Roche 
Agarose MS for analyzing small PCR products). Each primer pair was tested with a logarithmic 
dilution of a cDNA mix to generate a linear standard curve (crossing point (CP) plotted versus 
log of template concentration), which was used to calculate the primer pair efficiency (E = 
10(-1/slope)). Hypoxanthine guanine phosphoribosyltransferase1 (Hprt-1) mRNA was used as an 
external standard. For data analysis, the second derivative maximum method was applied: 
(E1gene of interest D
CP (cDNA of wt mice - cDNA of Xpa-/- or Csbm/m or Csbm/m/Xpa-/-) gene of interest)/ (Ehprt-1 D
CP (cDNA wt mice- cDNA of Xpa-/- or 
Csbm/m or Csbm/m/Xpa-/-) hprt-1). All Q-PCR experiments were repeated at least three times. In case of the 
DEHP experiment, we also used the glyceraldehyde-3-phosphate dehydrogenase as an ad-
ditional housekeeping gene. P values (*) report the one-tail t-test probability that a gene has 
the same direction in the expression with that shown for the 15-day old Csbm/m/Xpa-/- mouse 
liver as compared to corresponding littermate controls. In addition, we also calculated the 
probability that all genes examined by Q-PCR demonstrate the same direction in the expres-
sion with those previously shown in the liver of Csbm/m/Xpa-/- mice by microarrays. Assuming 
these are independent events, the probability of each gene being up- or down regulated is 
0.5 (1/2) whereas the probability of all independent events (13 genes examined) occurring in 
sequence is 0.00012 (0.513).
Results
Attenuated Growth and Perinatal Death in Csbm/m/Xpa-/- and Csbm/m/Xpc-/- Mice 
TCR-defective Csbm/m mutant mice [16] were intercrossed with GG-NER-defective Xpc-/- [21] 
and GG/TC-NER-defective Xpa-/- [22] animals to investigate whether an increase in the endog-
enous burden of unrepaired DNA damage, as provoked by inactivation of GG-NER, enhances 
the phenotype, including progeroid features. Analysis of UV-induced repair synthesis and 
RNA synthesis recovery (indicative for GG-NER and TC-NER capacity, respectively) confirmed 
complete inactivation of NER in Csbm/m/Xpa-/- and Csbm/m/Xpc-/- animals (Fig. 1A). As expected 
on the basis of previous work, Xpa-/- cells display highest UV-sensitivity, whereas Xpc-/- and 
Csbm/m cells show intermediate sensitivities (Xpa-/- > Csbm/m > Xpc-/- > wt; see Fig. 1B). Interest-
ingly, inactivation of GG-NER in Csbm/m MEFs (as in Csbm/m/Xpa-/- and Csbm/m/Xpc-/- cells) renders 
cells more UV-sensitive than already completely NER-deficient Xpa-/- MEFs. We attribute this 
enhanced sensitivity to the absence of CSB-mediated TCR of UV-induced lesions that do not 
form a substrate for NER. Thus the repair defect in the double mutant appears to be more 
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Figure 2: Skeletal and neurological abnormalities in Csbm/m/Xpa-/- mice. 
(A) Radiographs of wt and Csbm/m/Xpa-/- mice (age as indicated) and photograph of a 15-day old Csbm/m/Xpa-/- mouse (C57BL/6J). (B) 
2D images of micro-CT scans of tibiae taken from Csbm/m/Xpa-/- animals and wt littermate controls (age indicated in the figure). Horizontal 
sections are shown of the upper and lower part of the tibiae e = epiphysis, g = growth plate and d = diaphysis. I = the section through the 
smaller part of the diaphysis, II = section through the broader part of the diaphysis. (C) Growth of tibiae, taken from Csbm/m/Xpa-/- animals 
(light squares) and wt littermate controls (dark squares). (D) Representative footprint patterns of 19-day old wt and Csbm/m/Xpa-/- mice. 
Arrows indicate the trajectory of each mouse. Stride length and front base width measurements on 15-day old wt, Xpa-/-, Csbm/m and 
Csbm/m/Xpa-/- mice. The significantly (asterisk; p<0.001) greater base width in the double mutant mouse indicates ataxia. (E) Representative 
pictures of a TUNEL staining in the retina of wt and Csbm/m/Xpa-/- mice and quantification of the number of TUNEL positive cells. Arrows 
indicate TUNEL positive cells in the outer nuclear layer (ONL) and inner nuclear layer (INL). Note the significantly higher number of TUNEL-
positive cells in both the ONL and the INL in the retina of Csbm/m/Xpa-/- compared to wt mice (asterisk; p<0.05).
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severe than that of the single mutants. We could not detect a similar increased sensitivity 
to ionizing radiation in double mutant cells above that of Csbm/m cells ([12], data not shown), 
supporting the notion that MEFs in culture are already under high oxygen stress [23,24].
As evident from their overall appearance and weight (Fig. 1C to E), Csbm/m/Xpa-/- and Csbm/m/
Xpc-/- pups (hybrid C57BL/6Jx129ola genetic background) displayed a strikingly attenuated 
growth, resulting in pronounced dwarfism. Whereas the number of double mutant pups 
was ~3-fold below that expected for Mendelian inheritance (Supplementary Table S1), E18.5 
Csbm/m/Xpa-/- and Csbm/m/Xpc-/- embryos were present at Mendelian frequency, pointing to 
considerable lethality during or shortly after birth. Importantly, double mutant embryos 
were morpho- and histologically indistinguishable from wt and single mutant embryos (Fig. 
1F, data not shown), indicating that the growth defect was postnatal and did not reflect 
impaired embryonic development per se. In the third week of life, however, Csbm/m/Xpa-/- and 
Csbm/m/Xpc-/- pups developed progressive cachexia (evident from the weight loss after day 
15; see Fig. 1E), ultimately resulting in death before postnatal day 22. Neither removal of wt 
or single mutant pups from the litter (to reduce competition for breast milk), nor moistened 
food pellets (to facilitate intake of solids), improved the physical condition or the lifespan 
of Csbm/m/Xpa-/- and Csbm/m/Xpc-/- pups. Necropsy revealed milk or solid food in the stomach, 
indicating that insufficient access to supplied nutrition was not the underlying cause of 
growth retardation, weight loss, and early death. Importantly, progressive growth retarda-
tion, cachexia and short life expectation (~12.5 years) are also observed in CS patients [13]. 
Combined inactivation of Xpa and Xpc rendered mice without any overt phenotype (data 
not shown), leading us to conclude that the dramatic phenotype of Csbm/m/Xpa-/- and Csbm/m/
Xpc-/- pups results from a combined GG-NER/TC-NER/TCR defect.
Growth and Neurological Abnormalities in Csbm/m/Xpa-/- Mice 
Further analysis of the Csbm/m/Xpa-/- phenotype, performed in an isogenic C57BL/6J back-
ground, revealed a near normal size of the skull at day 11 and 21 (autoradiographs shown 
in Fig. 2A), implying that the (postnatal) growth defect is restricted to the trunk, and to a 
lesser extent, the extremities. All 21-day old double mutant animals showed kyphosis (ab-
normal curvature of the spinal column, Fig. 2A, middle left and bottom right), which was 
also observed in younger Csbm/m/Xpa-/- pups, indicating that it is not determined by terminal 
illness. The normal appearance of the spine in 11-day old double mutant pups excluded a 
prenatal developmental defect and further pointed to an extremely accelerated onset of 
kyphosis, a feature observed in naturally aged (2-year old) C57BL/6J mice (see Fig. 2A, bot-
tom left panel). Two-dimensional images of proximal end-to-mid-diaphysis micro-computed 
tomography (micro-CT) scans of fixed tibiae from 10-, 15- and 20-day old wt and Csbm/m/
Xpa-/- mice revealed retarded, yet steady longitudinal as well as radial (perimeter) growth, 
along with a thinner bone cortex and a less developed growth plate (Fig. 2B). In line with 
this observation, we observed a reduction in tibia length (Fig. 2C). Notably, while Csbm/m/
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Figure 3: Histological examination of Csbm/m/Xpa-/- tissues. 
(A) BrdU staining of the jejunum of Csbm/m/Xpa-/- and littermate control mice, showing normal proliferative capacity of the intestine in the 
double mutant mouse. (B-E) Histological examination of liver sections of 15-day old Csbm/m/Xpa-/- and littermate control mice, stained with 
HE (B), immunostained for the proliferation markers (incorporated) BrdU (C) and PCNA protein, or TUNEL-stained for the presence of apoptotic 
cells (E). Quantification of the number of proliferative or apoptotic cells did not reveal significant differences between Csbm/m/Xpa-/- and wild 
type littermate mice. (F) HE staining of the pituitary of Csbm/m/Xpa-/- and littermate control mice. 
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Xpa-/- pups lose weight in the third week of life, bone growth proceeds, resulting in relatively 
large extremities, a representative feature of CS and TTD [13].
Motor coordination problems, manifesting as tremors and abnormal posture of the hind 
limbs (flexion rather than extension in tail suspension test), became evident around day 10 
in Csbm/m/Xpa-/- mice (data not shown). Foot print analysis revealed a disturbed gait from day 
15 onwards. While wt and single mutant animals maintained a straight path with regular 
alternating strides, Csbm/m/Xpa-/- mice demonstrated a non-uniform alternating left-right step 
Figure 4: Enhanced sensitivity of Csbm/m/Xpa-/- retinal photoreceptor cells to genotoxic insults.
Representative pictures of TUNEL stained retinas of 19-day old wt, Csbm/m, Xpa-/- and Csbm/m/Xpa-/- mice (right panel), 20 hours after 
exposure of animals to 10 Gy of ionizing radiation, and quantification of the number of TUNEL positive cells in the ONL (left panel). Note the 
significantly higher number of TUNEL-positive cells in the retina of Csbm/m/Xpa-/- mice, as compared to wt and single mutant littermate 
controls (p<0.05). Asterisks: * indicates statistically significant differences between unirradiated Csbm/m/Xpa-/- and littermate control mice 
(p<0.05), ** indicates statistically significant differences between unirradiated and irradiated Csbm/m/Xpa-/- mice (p<0.05).
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pattern and unevenly spaced shorter strides (Fig. 2D). Despite their runted size, the front 
base width of Csbm/m/Xpa-/- animals was significantly greater than that of wt and single mutant 
littermates, which likely illustrates an attempt to maintain balance (Fig. 2D). These data are 
consistent with the profound early postnatal ataxia and abnormal cerebellar development in 
Csbm/m/Xpa-/- mice [25], and the progressive neurodegeneration observed in CS patients [26].
We next examined the retina of 15-day old Csbm/m/Xpa-/- pups for the presence of apoptotic 
cells as retinal degeneration is a prominent neurological feature of CS patients [27] and adult 
CS mice (Gorgels et al, pending revision). At this age, cell loss occurs as part of the normal 
development of the retina. Yet, as shown by TUNEL (Fig. 2E) and caspase-3 staining (data not 
shown), the number of apoptotic cells in the outer (ONL) and inner nuclear (INL) layers of the 
retina of Csbm/m/Xpa-/- pups was significantly increased (ANOVA, S-N-K posthoc test, p<0.05), 
as compared to wt and single mutant littermates (Fig. 2E). Thus, the Xpa defect enhanced the 
apoptotic sensitivity of photoreceptor cells in Csbm/m mice, thereby pointing to DNA dam-
age as a trigger for age-related retinal degeneration. As 15-day old Csbm/m mice still have wt 
levels of apoptotic cells, spontaneous photoreceptor loss in the Csbm/m mouse initiates in the 
second/third month of life.
With the exception of substantial loss of abdominal fat, visual inspection and histological 
analysis of most internal organs of 15-day old Csbm/m/Xpa-/- mice did not reveal any obvious 
pathological abnormalities (data not shown). As we did not find any sign of infections, necro-
sis, or abnormal cellular proliferation (as determined by BrdU staining) in the gastrointestinal 
tract of 15- and 21-day old Csbm/m/Xpa-/- animals, intestinal malfunction is an unlikely cause 
of the growth defect (Fig. 3A). In addition, the liver has a normal histological appearance 
(Fig. 3B), while neither BrdU (Fig. 3C), PCNA (Fig. 3D), and Ki67 staining (data not shown), nor 
TUNEL (Fig. 3E) and caspase 3 staining (data not shown) revealed any significant difference 
between Csbm/m/Xpa-/- and wt livers. This finding indicates that aberrant cell proliferation or 
apoptosis in the liver does not likely contribute to the Csbm/m/Xpa-/- phenotype. Moreover, 
inactivation of the p53 tumor suppressor gene failed to rescue the mutant phenotype, as 
Csbm/m/Xpa-/-/p53-/- triple mutant pups appeared indistinguishable from Csbm/m/Xpa-/- pups 
(data not shown). Thus, the precise etiology of the overall physical deterioration and the 
cause of death of Csbm/m/Xpa-/- mice remain unknown. 
Enhanced Ionizing Radiation Sensitivity of the Csbm/m/Xpa-/- Mouse Retina
The spontaneous, age-related and ionizing radiation (IR)-induced loss of post-mitotic pho-
toreceptor cells in Csbm/m mice, underscores the relevance of DNA repair in the removal of 
(oxidative) DNA damage for the long-term survival of terminally differentiated cells in the 
retina (Gorgels et al, pending revision). To test whether Csbm/m/Xpa-/- animals are more sensi-
tive to genotoxic insults than single mutant Csbm/m and Xpa-/- animals, we next examined if the 
additional Xpa defect further enhances the IR sensitivity of the Csbm/m retina. To this end, we 
exposed 19-day old Csbm/m/Xpa-/- pups and wild type and single mutant littermates to γ-rays 
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(10 Gy) and quantified the number of apoptotic cells in the by TUNEL staining 20 hours after 
exposure. As shown in Fig. 4, the number of apoptotic cells in the ONL of untreated (20-day 
old) Csbm/m/Xpa-/- pups further increased, as compared to 15-day old double mutant animals 
(see Fig. 2E). While IR exposure did not increase the frequency of apoptotic photoreceptors 
in the ONL of wt and Xpa-/- animals, Csbm/m mice already show a tendency to increased photo-
receptor loss, as characteristic for mature Csbm/m animals (Gorgels et al., pending decision). In 
contrast, the retina of IR-exposed Csbm/m/Xpa-/- animals showed an almost two-fold increase 
1
Supplementary Table S1.
A. Frequency of viable Csbm/mXpa-/- mice
Csbm/mXpa+/-  x   Csbm/mXpa+/-
Xpa Csb number expected 
(%)  
observed 
(%) 
+/+ m/m 20 25 26 
+/- m/m 45 50 60 
-/- m/m 11 25   14* 
  76 100 100 
*p<0.01
B. Frequency of viable Csbm/mXpc-/- mice 
Csb+/mXpc-/-  x   Csb+/mXpc-/-
Xpc Csb number expected 
(%)  
observed 
(%) 
-/- +/+ 14 25 23 
-/- +/m 41 50 69 
-/- m/m 5 25    8* 
  60 100 100 
*p<0.001 
C. Parallels of human CS symptoms with the mild Csbm/m and severe Csbm/mXpa-/-
mouse models 
CS phenotype Csbm/m Csbm/mXpa-/-
      
UV sensitivity + ++ 
cachexia - + 
premature death - + 
growth retardation + ++ 
relatively long limbs - + 
kyphosis - + 
ataxia - + 
dystonia - + 
Purkinje cell loss - + 
retinal degeneration + ++ 
Supplementary table S2
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in the level of TUNEL-positive photoreceptor cells (Student’s t-test p=0.021). Taken together, 
these findings not only further point to unrepaired DNA damage (likely originating from 
oxidative stress) as the underlying trigger for photoreceptor loss, but importantly, also show 
that inactivation of Xpa further enhances the sensitivity of Csbm/m mice to genotoxic stress. 
Figure 5: Expression levels of genes associated with the somatotroph axis, antioxidant defense, and 
metabolism in mutant and wt mouse liver and other organ at various ages.
(A) Q-PCR evaluation of mRNA levels of genes associated with antioxidant defense (dark gray bars), oxidative metabolism (light gray bars) and 
the GH/IGF1 axis (black bars) in the liver, kidney, heart and spleen of 15-day old Csbm/m/Xpa-/-, Csbm/m, and Xpa-/- pups. For each gene, 
expression levels in the mutant tissue are plotted relative to that of age-matched wt control tissues (dotted line). Error bars indicate S.E.M. 
between replicates (n ≥ 3). (B) Relative mRNA expression levels (fold changes, relative to embryonic day 18) of genes involved in the GH/IGF1 
growth axis, antioxidant defense, and oxidative metabolism in the liver of wt and Csbm/m/Xpa-/- pups, plotted as a function of time. Error bars 
indicate S.E.M. between replicates (n ≥ 3).
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Analysis of the Csbm/m/Xpa-/- Mouse Liver Transcriptome 
To investigate whether a disturbance in growth and metabolism could explain the pro-
nounced accelerated organismal deterioration seen in Csbm/m/Xpa-/- mice, we evaluated the 
liver transcriptome of 15-day old wt, single and double mutant mice (n=4). At this age, the 
Csbm/m/Xpa-/- pups have not yet become cachectic. Two-tail, pair wise analysis of variance 
of Affymetrix full mouse genome arrays revealed 1865 genes with significantly changed 
expression patterns between wt and Csbm/m/Xpa-/- livers (p≤0.01, 1.2 fold change up- or down 
regulated, Supplementary Table S2 (not shown)), a number that significantly exceeds the 
80 genes that are expected to occur by chance under these selection criteria. Among the 
set of 1865 genes, we identified those GO-classified biological processes with a significantly 
disproportionate number of responsive genes relative to those printed on microarrays (False 
detection rate ≤ 0.10). This unbiased approach revealed processes implicated in the deriva-
tion of energy from oxidation of organic compounds, homeostasis of energy reserves, cell 
growth and maintenance and the redox status of the cell. 
Subsequent analysis of these processes led us to identify: 
1. a profound attenuation of the somatotroph axis as evidenced by the consistent down-
regulation of genes encoding main components of the GH/IGF1 axis (e.g. IGF1, Igfbp3, Igfbp4, 
Igfals, Ghr), as well as lactotroph (e.g. Prlr) and thyrotroph functions (e.g. Dio1) in Csbm/m/Xpa-
/- livers, in addition to a decrease in the expression of several genes associated with a variety 
of mitogenic signals (e.g. Esr1, Fgf1, Fgfr3, Fgfr4, Table 1 and Supplementary Table S2). 
2. an extensive suppression of catabolic metabolism in the Csbm/m/Xpa-/- liver, as evident from 
the significant down-regulation of key genes involved in glycolysis, tricarboxylic acid cycle 
Supplementary Figure 1 
Q-PCR evaluation of mRNA levels of genes associated with the GH/IGF1 axis, antioxidant defense, and oxidative metabolism in 2-week old 
Csbm/m/Xpa-/- and 96-week old wt mice. 
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and oxidative phosphorylation pathways (Table 1 and Supplementary Table S2), coupled 
with a significant up-regulation of genes associated with glycogen synthesis (e.g. Gyg1 and 
Gys2 and down-regulation of glycogen phosphorylase, Pygl) suggesting that the Csbm/m/Xpa-
/- liver stores glucose into glycogen, rather than burn it for energy derivation. These changes 
were further accompanied by the broad down-regulation of genes associated with electron 
transport and oxidative phosphorylation (e.g. several cytochrome P450 monooxygenases, 
the NADH dehydrogenase complex and the NADPH-dependent oxidative metabolism; Table 
1 and Supplementary Table S2) and the significant down-regulation of several genes associ-
ated with peroxisomal biosynthesis (Table 1). Apparently, the complete catabolic metabolism 
is restrained in the Csbm/m/Xpa-/- liver.
3. a broad upregulation of genes associated with fatty acid synthesis and transport (several 
genes listed in Table 1 and Supplementary Table S2), the up-regulation of the receptor for 
the adipocyte hormone leptin (Lepr) and the central fat regulator peroxisome proliferator-
activated receptor-gamma (Pparγ). Thus, similar to reserved glucose utilization and enhanced 
glycogen synthesis, Csbm/m/Xpa-/- mice attempt to store rather than burn fat.
4. an up-regulation of genes encoding key enzymatic and non-enzymatic low molecular mass 
scavengers and antioxidant defense enzymes (e.g. Sod1, Prdx2 and 3, Txnip, Ephx1, Hmox1 
and 5 components of the glutathione system; Table 1), suggesting that Csbm/m/Xpa-/- mice try 
to minimize the induction of (DNA) damage by counteracting ROS. 
Importantly, none of these genes were identified as significantly differentially expressed in 
the livers of Csbm/m or Xpa-/- littermate controls (Table 1). Quantitative real-time PCR (Q-PCR) 
evaluation of the expression levels of key genes involved in the somatotroph axis, energy 
metabolism and antioxidant defense in the liver of Csbm/m/Xpa-/- mice, and wt, Csbm/m and Xpa-
/- littermates, as well as further biochemical analysis (see below), confirmed the validity of the 
microarray data (Fig. 5A, upper left panel). 
Postnatal Systemic Changes in Somatotroph Axis, Energy Metabolism, and 
Antioxidant Defense in Csbm/m/Xpa-/- Mice
Next, we analyzed whether the onset of aforementioned transcriptional changes paralleled 
the progressive postnatal growth attenuation, as well as the weight loss observed later. 
Consistent with the normal embryonic development, the expression levels of genes involved 
in the somatotroph axis (Ghr, Igf1, Prlr), antioxidant defense (Gstt2, Hmox1, Ephx1) and oxida-
tive metabolism (Gck, Gyg1, Cs, Ndufs8) did not differ significantly between wt and Csbm/m/
Xpa-/- livers at postnatal day 1 (Fig. 5B). In contrast, during the first two weeks of life, wt mice 
exhibited as expected a robust up-regulation in Igf1, Ghr, Prlr gene expression, a response 
that was virtually absent in Csbm/m/Xpa-/- animals (Fig. 5B, left panels) and well explains the 
severe growth retardation of double mutant pups after birth. Analysis of Gstt2, Hmox1, and 
Ephx1 mRNA levels revealed that the up-regulation of the antioxidant defense system in the 
Csbm/m/Xpa-/- liver already initiated before postnatal day 10, and thus well ahead of the initia-
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tion of the physiological decline (i.e. weight loss) (Fig. 5B, middle panels). When comparing 
mRNA levels of key genes in glycolysis (Gck), TCA cycle (Cs), and mitochondrial oxidative 
phosphorylation (Ndufs8), we noticed that beginning postnatal day 10, Csbm/m/Xpa-/- livers do 
not show the prominent up-regulation of these catabolic genes seen in the wt liver (instead 
expression levels continued to decline), while they up-regulate glycogen synthesis (Gyg1, Fig. 
2B, right panels). In agreement, the enzymatic activity of citrate synthase was significantly 
Figure 6: Transcriptome similarities between Csbm/m/Xpa-/- and naturally aged mice.
(A) Spearman’s r correlation of 16-, 96- and 130-week old mice with 15-day old Csbm/m/Xpa-/- mice, where -1.0 is a perfect negative 
(inverse) correlation, 0.0 is no correlation, and 1.0 is a perfect positive correlation. (B) Similarities between significantly overrepresented 
biological processes. Note that in both Csbm/m/Xpa-/- and naturally aged mice, transcriptional changes were mostly associated with metabolic 
processes. (C) Correlation in significant expression changes of genes associated with the GH/IGF1 axis and oxidative metabolism in the livers of 
Csbm/m/Xpa-/- and naturally aged (96- and 130-week old) mice. An extensive overview is listed in Supplementary Tables S3 and S4.
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lower (p≤0.01) in the liver of 15-day old Csbm/m/Xpa-/- mice (119 ± 15 mU/mg protein), as 
compared to wt littermate controls (70 ± 13 mU/mg protein).
We next determined the expression levels of aforementioned genes in the kidney, heart 
and spleen of the same set of animals employed in the microarray experiment. Expression 
levels markedly mirrored the deviant expression patterns observed in the liver, while mRNA 
Figure 7: Carbohydrate/fat metabolism and IGF1 serum levels. 
IGF1 (A) and glucose (B) in the serum of 7, 10, 15 and 17-day old wt, Xpa-/-, Csbm/m and Csbm/m/Xpa-/- mice (n=6). The levels of IGF1 (ng/
ml) and glucose (mmol/l) in the serum of Csbm/m/Xpa-/- mice are significantly lower than that of control littermates (p<0.0004 and p< 0.04, 
respectively). (C) PAS staining for glycogen and Oil Red O staining for triglycerides in livers of 15-day old wt and Csbm/m/Xpa-/- mice and 96-
week old wt mice. Pictures were taken at 100x magnification. Note the large polyploid nuclei in the 96-week old wt mouse liver and the reduced 
glycogen levels in the Csbm/m/Xpa-/- liver after overnight fasting.
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levels in Csbm/m and Xpa-/- tissues were not significantly different from wt animals (Fig. 5A). 
Thus, attenuation of the GH/IGF1 axis and down-regulation of metabolism, along with the en-
hanced antioxidant/detoxification response, represents a systemic, rather than liver-specific 
response of the Csbm/m/Xpa-/- pups to the DNA repair defect. Interestingly, when 96-week old 
wild type livers were tested for expression levels of this same set of Csbm/m/Xpa-/- responsive 
genes, we noticed a remarkable resemblance (Supplementary Fig. 1).
Comparison of the Csbm/m/Xpa-/- and Naturally Aged Mouse Liver Transcriptomes
The previous result prompted us to investigate whether and to which extent the gene ex-
pression changes in the Csbm/m/Xpa-/- mouse liver overlap with those observed in a natural 
aged liver. To this end,, we first compared the full mouse liver transcriptome of adult 16-, 
96- and 130-week old wt C57Bl/6J mice (n=4) with that of adult 8-week old wt C57Bl/6J mice 
(Supplementary Tables S3, S4 and S5 (not shown), n=4). Using the same analytical method 
as applied to the Csbm/m/Xpa-/- mouse livers, we identified homeostasis of energy reserves, 
oxidative metabolism along with cell growth and maintenance to be significantly overrep-
resented in 96- and 130-week old wt mice, but not in 16-week old animals (Supplementary 
Table S6 (not shown)). These findings fit well with previous studies suggesting the repression 
of oxidative metabolism to represent a conserved response shared by highly diverged spe-
cies [28Next, we implemented a previously described method [29] to evaluate the extent 
of genome-wide similarity between the liver transcriptomes of 2-week old Csbm/m/Xpa-/-mice 
and, wt animals of various ages. We first classified all significantly differentially expressed 
genes in the Csbm/m/Xpa-/- liver transcriptome as having increased or decreased expression (as 
compared to wt), and asked how many of these genes respond in a similar direction in the 
16/8 wk, 96/8 wk, and 130/8 wk data sets. If the Csbm/m/Xpa-/- liver resembles an aged liver, 
one expects the Spearman’s rank correlation coefficient rho (r, +1.0 or -1.0 in case of perfect 
similarity or dissimilarity, respectively, and 0.0 in case of no correlation) to increase with age. 
Notably, whereas the liver transcriptome of Csbm/m/Xpa-/- mutant mice was dissimilar to that 
of 16-week old wt mice (Spearman’s r = - 0.28), as it was with 15-day old littermates, this 
turned into a significant positive correlation when the comparison was made between the 
Csbm/m/Xpa-/- and 96-week old mouse liver transcriptomes (r = + 0.15) and even more with 
the 130-week old wt mouse group (r = + 0.44, p ≤ 0.0001, Fig. 6A). Comparable results were 
obtained when the same approach was applied over the whole mouse transcriptome (includ-
ing all Affymetrix probe sets with signals above the detection cut-off value; see Methods), 
thus avoiding any initial pre-selection or introduction of bias. Using the same approach, we 
did not find a significant correlation between the liver transcriptomes of 15-day old Csbm/m or 
Xpa-/-mice and aged wt mice. 
The genome-wide resemblance between the short-lived Csbm/m/Xpa-/- mice and the 130-
week old mice was substantially higher (>90%) when the comparison was restricted to those 
functional categories that were significantly overrepresented in the double mutant and 
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130-week old mice, such as the GH/IGF1 axis, oxidative metabolism (i.e. glycolysis, Krebs and 
oxidative phosphorylation), cytochrome P450 electron transport and peroxisomal biogenesis 
(Fig. 6B and C; Supplementary Table S7 (not shown)). Despite the occurrence of dissimilarities 
between the liver transcriptome of Csbm/m/Xpa-/- pups and aged wt mice (the latter animals 
showing over-representation of genes involved in the immune and inflammatory responses, 
ATP biosynthesis and protein glycosylation, along with a lack of the anti-oxidant response), 
these findings strongly underline the genome-wide parallels between the Csbm/m/Xpa-/- repair 
mutants and natural ageing, thereby validating the progeria in the double mutant pups. 
Reduced IGF1 Serum Levels, Glucose and Fat Utilization in Csbm/m/Xpa-/- Mice 
In agreement with the down-regulation of Igf1 gene expression in the liver (the main source 
of circulating IGF1 [30]), we observed a significant reduction (p<0.004) in serum IGF1 levels in 
Csbm/m/Xpa-/- mice (Fig. 7A) together with significantly lower blood glucose levels (p<0.04, Fig. 
7B). Following an initial reduction of ~30% (p<0.04) in 7- and 10-day old Csbm/m/Xpa-/- mice, 
blood glucose levels started to drop at day 15, gradually reaching low levels in 17-day old 
Csbm/m/Xpa-/- mice (~3 mM), contrasting the steady blood glucose levels (~ 9 mM) in littermate 
controls (Fig. 7B). The presence of milk and food in the stomach of the double mutant pups 
along with the normal appearance of the intestinal epithelium (Fig. 3A) indicates that the 
hypoglycemia is not due to food intake. Even more, the suppression of the somatotroph 
axis and subsequent decreased IGF1 production in 15-day old Csbm/m/Xpa-/- mice appeared 
not to originate from a pituitary dysfunction as histological examination (Fig 3F) and TUNEL 
Figure 8: Expression levels of genes associated with the GH/IGF1 axis, oxidative metabolism and 
antioxidant defense in DEHP-treated wild type mice. 
Relative mRNA levels of genes involved in the GH/IGF1 growth axis, oxidative metabolism and antioxidant defense in 13-week old wt mice 
treated with a low dose of the pro-oxidant DEHP. For each gene, expression levels in the treated wt mouse livers are plotted relative to that of 
age-matched untreated wt littermate controls (dotted line). Error bars indicate S.E.M. Asterisks indicate statistically significant differences (one-
tailed p≤0.05, see also supplementary methods).
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staining of sections from the pituitary pars distalis, intermedia and nervosa did not reveal any 
abnormalities (data not shown). Moreover, serum GH levels in 15-day old Csbm/m/Xpa-/- mice 
(15.2 +/- 4.2 ng/ml, n=8) did not differ significantly from wt littermates (12.8 +/- 2.8 ng/ml, 
n=6). Interestingly, the normal serum GH levels together with the significant systemic down 
regulation of GH receptor gene expression, likely points to growth hormone resistance in 
15-day old Csbm/m/Xpa-/- mice. 
PAS staining of liver sections from 10- to 20-day old pups and naturally aged mice revealed 
enhanced accumulation of glycogen in unusually large vesicles in Csbm/m/Xpa-/- pups and 
96-week old mice when compared to wt littermates and 8-week old wt mice (Fig. 7C). This 
observation fits our microarray data, suggesting that both the Csbm/m/Xpa-/- and naturally 
aged mice store, rather than utilize glucose. Overnight fasting of Csbm/m/Xpa-/- pups and litter-
mate controls resulted in a near-to-complete depletion of liver glycogen (Fig. 7D) indicating 
that the glycogen accumulation is not due to inability to split glycogen into its constitutive 
glucose monomers. 
Consistent with the broad up-regulation of genes associated with fatty acid synthesis 
(Table 1), oil Red O staining of liver sections from 15-day old pups and naturally aged mice 
revealed enhanced accumulation of triacylglycerides in both compared to control littermates 
and 8-week old mice (Fig. 7C), indicating hepatic steatosis. This and the absence of adipose 
tissue suggest that Csbm/m/Xpa-/- mice display generalized lipodystrophy (loss and abnormal 
redistribution of body fat) [31].
Systemic Changes in Somatotroph Axis and Antioxidant Defense in DEHP-Treated wt 
Mice 
To test whether the presence of endogenous (oxidative) DNA damage can provoke the so-
matotrophic drop and enhanced antioxidant potential, wt C57BL/6J mice (n=6; 4-week old) 
were fed ad libitum for 9 weeks with standard food containing sub-toxic levels of an oxidative 
DNA damage-inducing agent [di(2-ethylhexyl)phthalate, DEHP, 1500 ppm] [32]. Neither 
body weight nor appetite and food intake of DEHP-exposed animals deviated from that of 
untreated control animals. As shown in Figure 8, subsequent analysis revealed suppression 
of the expression of genes associated with the somatotroph axis (Igf1, Igfbp3, Ghr, and Dio1) 
and oxidative metabolism (Gck, Cs and Ndufs8), along with the up-regulation of glycogenin 
1 (Gyg1, Fig 5A) in DEHP-exposed animals. Consistent with the ability of DEHP to generate 
ROS-induced DNA damage in the liver, we also noticed a significant up-regulation of genes 
associated with the antioxidant and detoxification responses (Hmox1, Ephx1, Gsr, Sod1, Gstt2). 
These findings suggest that accumulation of unrepaired (oxidative) DNA damage likely com-
prises one of the causes underlying the observed suppression of the GH/IGF1 and oxidative 
metabolism in Csbm/m/Xpa-/- mice (see also supplementary methods).
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Discussion
Csbm/m mice exhibit several CS features (e.g. attenuated growth, blindness, neurological 
dysfunction), but their phenotype is overall milder than the human syndrome [16] despite 
that the truncation in the N-terminal part (mimicking a mutant allele of CS-B patient CS1AN) 
completely inactivates the protein and TC-NER [16]. Although the severity of clinical features 
in humans does not seem to correlate with the severity of the molecular defect [33], the ab-
sence of the complete spectrum of CS features in the Csbm/m mouse model is likely to originate 
from man-mouse differences (i.e. adaptation to stress, tolerance to DNA damage/genome 
instability), rather than from the nature of the Csbm/m mutation. This idea is supported by our 
observations that XpdTTD and XpdXPCS mice (all carrying causative point mutations) also fail to 
show the severe CS features associated with XPCS and TTD [9,34].
Yet, the present study reveals that inactivation of GG-NER or complete abrogation of NER 
(through inactivation of Xpc or Xpa, respectively) in TCR-deficient Csbm/m mice dramatically 
aggravates the Csbm/m mouse phenotype. As animals were not exposed to exogenous geno-
toxic agents, we attribute this effect to enhanced levels of unrepaired endogenous (oxidative) 
DNA damage. In further support of this, we have shown that Csbm/m/Xpc-/- and Csbm/m/Xpa-/- 
MEFs, as well as Csbm/m/Xpa-/- retinal photoreceptor cells are more sensitive to environmental 
genotoxic insults (i.e. UV-light, ionizing radiation) than their single mutant counterparts. A 
comparable phenotypic deterioration has been noticed when Xpa was inactivated in XpdTTD 
[9], XpdXPCS [34], compound heterozygous XpdTTD/XPCS animals (carrying causative mutations for 
TTD and combined XP/CS; van de Ven et al., pending revision), and XpgdeltaEx15 mice [35]. 
Importantly, Csbm/m/Xpa-/- mice appeared normal at birth, indicating a normal intra-uterine 
development and ruling out that this condition is in fact an embryonic developmental dis-
order. Instead, after birth, the Csbm/m/Xpa-/- pups displayed progressive kyphosis, cachexia, 
photoreceptor loss, and motor dysfunction, all common postnatal manifestations of CS [13], 
as well as of natural mammalian aging [36-38]. Also similar to CS patients (average age 12.5 
years), Csbm/m/Xpa-/- pups fail to grow into adulthood and die before weaning. The relation be-
tween (residual) repair capacity, time and severity of a particular phenotype is well illustrated 
by the retinal photoreceptor loss in the Csbm/m mouse models. While aging C57Bl/6J mice lose 
about 5-10% of their rods and cones in 30 months, TCR-deficient Csbm/m mice have already 
lost about 50% of their photoreceptor cells by the age of 16 months (Gorgels et al., pending 
revision). This spontaneous retinal degeneration in Csbm/m mice originates from enhanced 
apoptotic sensitivity of photoreceptor cells (Gorgels et al., pending revision), evolving in 
the first one or two months after weaning (this study). Interestingly, further crippling of NER 
in Csbm/m animals by inactivation of Xpa accelerates the onset of photoreceptor loss, now 
becoming visible as early as postnatal day 15, and progressively increasing thereafter. The 
strong correlation between the severity of the repair deficiency and the onset of photorecep-
tor loss, as well as the enhanced ionizing radiation hypersensitivity of photoreceptor cells of 
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Csbm/m/Xpa-/- mice (as compared to age-matched Csbm/m animals), well support the hypothesis 
that (oxidative) DNA damage likely underlies the retinal degeneration. 
Full genome transcriptome analysis of the Csbm/m/Xpa-/- mouse liver, aiming at unraveling 
the etiology of the severe double mutant phenotype, led us to identify significant genome-
wide parallels between the 2-week old Csbm/m/Xpa-/- and 130-week, but not 16-week old wt 
animals at the fundamental level of gene expression. Importantly, this resemblance was 
largely attributable to the substantial down regulation of genes associated with processes 
implicated in oxidative energy and growth metabolism, previously revealed by others to 
represent a conserved transcriptional response in aging [28]. 
The down-regulation of genes associated with the GH/IGF1 growth axis in the liver, the 
systemic reduction in GH receptor mRNA levels and the impaired Igf1 gene expression in liver 
and other tissues (resulting in low serum IGF1 levels) likely underlies the postnatal growth 
defect in Csbm/m/Xpa-/- pups. These changes were not due to reduced GH serum levels or 
Figure 9: The proposed link between DNA damage and the decline of the GH/IGF1 somatotroph 
axis. 
ROS are natural byproducts of metabolism and can injure several macromolecules including DNA, thus contributing to a slow but steady 
accumulation of damage, transcriptional stress, impaired replication and eventually the progressive loss of tissue homeostasis and gradual 
organismal deterioration. Cells and tissues will respond by (1) up regulating their antioxidant defense responses that would moderate the 
harmful effects of ROS, (2) employing a battery of genome maintenance pathways that would repair or remove damaged macromolecules and 
help to resist the oxidative stress, and (3) suppressing their GH/IGF1 somatotroph axis along with the oxidative metabolism, thus substantially 
moderating their metabolic activity that would otherwise lead to high oxygen consumption and increased generation of oxidants. To this end, 
the physiologic reduction of the somatotroph axis and oxidative metabolism is envisaged to be beneficial in terms of net life span.
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pituitary abnormalities. Importantly, a steady decline in the GH/IGF1 somatotroph axis is also 
observed in rodents and humans during natural aging [39]. Furthermore, Csbm/m/Xpa-/- pups 
failed to up-regulate metabolism; instead they displayed a sharp, systemic reduction in the 
expression levels of genes involved in glycolysis, tricarboxylic acid cycle (including decreased 
citrate synthase activity), and oxidative respiration, which coincided with the onset of weight 
loss (cachexia). In addition, Csbm/m/Xpa-/- pups up-regulated genes associated with glycogen 
and fatty acid synthesis, leading to increased hepatic glycogen storage and fat accumulation 
(steatosis) and pronounced hypoglycemia. Simultaneously subcutaneous fat tissue was vir-
tually absent. Given that, in mammals, the GH/IGF1 signaling pathway comprises one of the 
major regulators of energy homeostasis to integrate metabolism with growth [30,40,41], it is 
tempting to speculate that reduced IGF1 signaling is responsible for the postnatal metabolic 
shift and growth defect seen in Csbm/m/Xpa-/- mice Interestingly, several CS patients have been 
previously reported with hypoglycemia and low IGF1 serum levels [42,43], low metabolic rate 
[44] and abnormal fat deposition [45]. 
Paradoxically, however, the systemic suppression of the somatotrophic axis and energy 
metabolism, along with the up-regulation of antioxidant defenses, low IGF1 serum and blood 
glucose levels, observed in the Csbm/m/Xpa-/- mouse, are all associated with increased longev-
ity, rather than with the short lifespan of this mouse model. In lower paradigms for life span 
extension (C. elegans, D. melanogaster), genetic interference in the insulin-signaling pathway 
can prolong life multi-fold [46,47]. In mammals, IGF1-deficient, Ames and Snell dwarf mice 
(characterized by defects in the development of the anterior pituitary due to mutations 
in the Prop-1 and Pit1 loci and diminished levels of GH, thyroid stimulating and prolactin 
hormones) combine hypoglycemia, low body temperature, and increased storage of carbo-
hydrates and lipids [39,41] with up-regulation of antioxidant defense capacity and extended 
lifespan [48,49]. Conversely, GH-overexpressing transgenic mice display reduced lifespan and 
antioxidant responses [50]. These findings have also been recently confirmed by our identi-
fication of genome-wide parallels between the extremely short-lived DNA repair mutants 
(i.e. Csbm/m/Xpa-/-, Ercc1-/-) and the extremely long-lived Ames and Snell dwarfs and growth 
hormone receptor knockout (Ghr-/-) mice (Garinis et al. manuscript in preparation). Last but 
not least, IGF1 plasma levels decline with age in humans and rodents [51-53]. Along with this 
hormonal shift, aging cells surmount an intricate antioxidant defense response [54,55] that 
is thought to prevent the detrimental consequences of oxidative stress. Interestingly, the 
progressive, age-related decrease in the somatotroph axis has been suggested to confer a 
selective advantage by postponing the onset of age-related disease and prolonging life span 
through the reduction of toxic free radicals [39]. 
How would repair-deficient mice benefit from such a response? During development, 
the mitogenic action of GH and IGF1 fuels cellular metabolism, thereby promoting tissue 
growth and function [39,56,57]. A high metabolic activity, however, leads to higher oxygen 
consumption [39] and may also increase the ROS burden through the parallel increase of 
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mitochondrial electron transport, peroxisomal fatty acid metabolism and/or microsomal 
cytochrome P-450 enzymes [58]. Despite antioxidant defense and DNA repair, oxidative DNA 
damage will still accumulate, leading to transcriptional stress, impaired replication, cellular 
senescence, malfunction or death and eventually to progressive loss of tissue homeostasis 
and organismal decline (see model, Fig. 9). We hypothesize that complete abrogation of NER 
(by inactivation of Xpa) renders TCR-deficient Csbm/m mice unable to adequately cope with the 
increased burden of DNA damage in the transcribed strand of active genes. This triggers an 
adaptive response i.e. reduction of metabolic activity through down-regulation of the GH/
IGF1 axis to relieve the pressure on their genome. We interpret this as an attempt to limit the 
deleterious effects of arrested transcription, such as cellular senescence and death causing 
accelerated aging. As a consequence, the initially normal growth becomes arrested soon af-
ter birth, leading to severe growth retardation. This scenario provides a plausible explanation 
for the growth defect in CS patients. However, this response is unable to fully compensate for 
the repair defect, thus damage still accumulates to critical levels and triggers apoptosis and/
or senescence, thereby leading to aging-associated pathology such as neurodegeneration 
(as illustrated by the photoreceptor cells in Csbm/m/Xpa-/- mice).
The conceptual link between DNA damage and the systemic adaptive response is sup-
ported by our observation that chronic exposure of wt mice to a sub-toxic dose of DEHP 
(a pro-oxidant that enhances the DNA damage load; see de Waard et al, 2004) triggers a 
response similar to that observed in (untreated) Csbm/m/Xpa-/- mice. Although DEHP at much 
higher concentrations has been previously documented to affect the endocrine function of 
the pituitary, proteome analysis revealed that synthesis of prolactin and growth hormone 
appears unaffected in DEHP-treated rats [59]. This suggests that the observed suppression of 
genes associated with the somatotroph axis and oxidative metabolism in the liver of DEHP-
exposed mice is triggered by DNA damage in the liver, rather than by a pituitary defect or 
hypothalamic defect. 
As one would predict, other short-lived NER mouse models (e.g. Xpg, Xpf mice, [60,61]) or 
NER mutant mice with a milder progeroid phenotype could also show accelerated attenua-
tion of the somatotrophic axis in response to their DNA repair defect. Indeed, Ercc1-/- animals, 
carrying a combined NER/crosslink DNA repair defect and a life span of only a few weeks, 
demonstrate a remarkable genome-wide similarity in liver gene expression profiles with 
Csbm/m/Xpa-/- mice (Niedernhofer et al., pending revision), while XpdXPCS/Xpa-/- and compound 
heterozygous XpdTTD/XPCS/Xpa-/- mice contain lower serum IGF1 levels (van de Ven et al., submit-
ted). Furthermore, XpdTTD mice, which manifest accelerated aging in many (but not all) organs 
and tissues, have recently been shown to display features related to a caloric restricted-like 
phenotype and suppression of the GH/IGF1 axis in a limited set of organs and tissues, stress-
ing the segmental nature that is characteristic of all progeroid syndromes and the systemic 
nature of the response [62]. Finally, proper glucose homeostasis and normal IGF1 levels were 
recently shown to require Sirt6 activity, a chromatin deacetylase that may promote DNA 
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repair [63]. As ROS-mediated DNA damage appears to be the underlying cause of the Csbm/m/
Xpa-/- progeria, it is tempting to speculate that one can attenuate the premature onset of 
age-related features by directly counteracting the harmful byproducts of metabolism (i.e. 
ROS), and consequently DNA damage. Interestingly, an antioxidant-based nutraceutical 
intervention pilot study with Csbm/m/Xpa-/- mice, aiming at extending life span and delaying 
onset of pathology, yielded promising results (van der Pluijm et al., unpublished results).
Acknowledgements
We thank Wiebeke van Leeuwen and Willem Sluiter for assistance with X-ray analysis and 
citrate synthase activity measurements, respectively. This research was supported by the 
Netherlands Organization for Scientific Research (NWO) through the foundation of the Re-
search Institute Diseases of the Elderly, as well as grants from SenterNovem IOP-Genomics 
(IGE03009), NIH (1PO1 AG17242-02), NIEHS (1UO1 ES011044), EC (QRTL-1999-02002; LSHC-
CT-2005-512113), and the Dutch Cancer Society (EUR 99-2004). L.J.N. was supported by Post-
doctoral Fellowship #PF-99-142 from the American Cancer Society. JHJH is CSO of DNage. 
227
Premature Aging in Csbm/m/Xpa-/- mice
References
 1.  Harman D (1956) Aging: a theory based on free radical and radiation chemistry. J Gerontol 11: 
298-300.
 2.  Schriner SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, et al. (2005) Extension of murine life 
span by overexpression of catalase targeted to mitochondria. Science 308: 1909-1911.
 3.  Melov S, Ravenscroft J, Malik S, Gill MS, Walker DW, et al. (2000) Extension of life-span with super-
oxide dismutase/catalase mimetics. Science 289: 1567-1569.
 4.  Orr WC, Sohal RS (1994) Extension of life-span by overexpression of superoxide dismutase and 
catalase in Drosophila melanogaster. Science 263: 1128-1130.
 5.  Ishii N, Fujii M, Hartman PS, Tsuda M, Yasuda K, et al. (1998) A mutation in succinate dehydroge-
nase cytochrome b causes oxidative stress and ageing in nematodes. Nature 394: 694-697.
 6.  Hamilton ML, Van Remmen H, Drake JA, Yang H, Guo ZM, et al. (2001) Does oxidative damage 
to DNA increase with age? Proc Natl Acad Sci U S A 98: 10469-10474.7. Lu T, Pan Y, Kao SY, Li C, 
Kohane I, et al. (2004) Gene regulation and DNA damage in the ageing human brain. Nature 429: 
883-891.
 8.  Martin GM (2005) Genetic modulation of senescent phenotypes in Homo sapiens. Cell 120: 523-
532.
 9.  de Boer J, Andressoo JO, de Wit J, Huijmans J, Beems RB, et al. (2002) Premature aging in mice 
deficient in DNA repair and transcription. Science 296: 1276-1279.
 10.  Hanawalt PC (2002) Subpathways of nucleotide excision repair and their regulation. Oncogene 
21: 8949-8956.
 11.  Spivak G, Hanawalt PC (2005) Host cell reactivation of plasmids containing oxidative DNA lesions 
is defective in Cockayne syndrome but normal in UV-sensitive syndrome fibroblasts. DNA Repair 
(Amst).
 12.  de Waard H, de Wit J, Gorgels TG, van den Aardweg G, Andressoo JO, et al. (2003) Cell type-
specific hypersensitivity to oxidative damage in CSB and XPA mice. DNA Repair (Amst) 2: 13-25.
 13.  Nance MA, Berry SA (1992) Cockayne syndrome: review of 140 cases. Am J Med Genet 42: 68-84.
 14.  Bootsma D, Kraemer KH, J.E. C, Hoeijmakers J (2002) Nucleotide excision repair syndromes: 
Xeroderma Pigmentosum, Cockayne Syndrome and trichthiodystrophy. New York: McGraw-Hill 
Medical Publishing Division. 211-237 p.
 15.  Vermeulen W, Rademakers S, Jaspers NG, Appeldoorn E, Raams A, et al. (2001) A temperature-
sensitive disorder in basal transcription and DNA repair in humans. Nat Genet 27: 299-303.
 16.  van der Horst GT, van Steeg H, Berg RJ, van Gool AJ, de Wit J, et al. (1997) Defective transcription-
coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition. Cell 
89: 425-435.
 17.  van der Horst GT, Meira L, Gorgels TG, de Wit J, Velasco-Miguel S, et al. (2002) UVB radiation-
induced cancer predisposition in Cockayne syndrome group A (Csa) mutant mice. DNA Repair 
(Amst) 1: 143-157.
 18.  Hasty P, Campisi J, Hoeijmakers J, van Steeg H, Vijg J (2003) Aging and genome maintenance: 
lessons from the mouse? Science 299: 1355-1359.
 19.  de Boer J, Hoeijmakers JH (2000) Nucleotide excision repair and human syndromes. Carcinogen-
esis 21: 453-460.
 20.  Mitchell JR, Hoeijmakers JH, Niedernhofer LJ (2003) Divide and conquer: nucleotide excision 
repair battles cancer and ageing. Curr Opin Cell Biol 15: 232-240.
228
Appendix III
 21.  Cheo DL, Ruven HJ, Meira LB, Hammer RE, Burns DK, et al. (1997) Characterization of defective 
nucleotide excision repair in XPC mutant mice. Mutat Res 374: 1-9.
 22.  de Vries A, van Oostrom CT, Hofhuis FM, Dortant PM, Berg RJ, et al. (1995) Increased susceptibility 
to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 377: 
169-173.
 23.  Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, et al. (2003) Oxygen sensitivity severely 
limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 5: 741-747.
 24.  Busuttil RA, Rubio M, Dolle ME, Campisi J, Vijg J (2003) Oxygen accelerates the accumulation of 
mutations during the senescence and immortalization of murine cells in culture. Aging Cell 2: 
287-294.
 25.  Murai M, Enokido Y, Inamura N, Yoshino M, Nakatsu Y, et al. (2001) Early postnatal ataxia and ab-
normal cerebellar development in mice lacking Xeroderma pigmentosum Group A and Cockayne 
syndrome Group B DNA repair genes. Proc Natl Acad Sci U S A 98: 13379-13384.
 26.  Itoh M, Hayashi M, Shioda K, Minagawa M, Isa F, et al. (1999) Neurodegeneration in hereditary 
nucleotide repair disorders. Brain Dev 21: 326-333.
 27.  Traboulsi EI, De Becker I, Maumenee IH (1992) Ocular findings in Cockayne syndrome. Am J 
Ophthalmol 114: 579-583.
 28.  McCarroll SA, Murphy CT, Zou S, Pletcher SD, Chin CS, et al. (2004) Comparing genomic expression 
patterns across species identifies shared transcriptional profile in aging. Nat Genet 36: 197-204.
 29.  Fraser HB, Khaitovich P, Plotkin JB, Paabo S, Eisen MB (2005) Aging and gene expression in the 
primate brain. PLoS Biol 3: e274.
 30.  Frystyk J (2004) Free insulin-like growth factors -- measurements and relationships to growth 
hormone secretion and glucose homeostasis. Growth Horm IGF Res 14: 337-375.
 31.  Ahima R, Osei SY (2004) Leptin and appetite control in lipodystrophy. J Clin Endocrinol Metab 89: 
4254-4257.
 32.  Seth PK (1982) Hepatic effects of phthalate esters. Environ Health Perspect 45: 27-34.
 33.  Horibata K, Iwamoto Y, Kuraoka I, Jaspers NG, Kurimasa A, et al. (2004) Complete absence of 
Cockayne syndrome group B gene product gives rise to UV-sensitive syndrome but not Cockayne 
syndrome. Proc Natl Acad Sci U S A 101: 15410-15415.
 34.  Andressoo JO, Mitchell JR, de Wit J, Hoogstraten D, Volker M, et al. (2006) An Xpd mouse model 
for the combined xeroderma pigmentosum/Cockayne syndrome exhibiting both cancer predis-
position and segmental progeria. Cancer Cell 10: 121-132.
 35.  Shiomi N, Mori M, Kito S, Harada YN, Tanaka K, et al. (2005) Severe growth retardation and short 
life span of double-mutant mice lacking Xpa and exon 15 of Xpg. DNA Repair (Amst) 4: 351-357.
 36.  Arking R (1998) Biology of aging; observations and principles. Sunderland: Sinauer Associates. 
528 p.
 37.  Kalu DN (1995) Bone. In: Masoro, editor. Handbook of Physiology of Aging. New York: Oxford 
University Press. pp. 395-411.
 38.  Weiss A, Arbell I, Steinhagen-Thiessen E, Silbermann M (1991) Structural changes in aging bone: 
osteopenia in the proximal femurs of female mice. Bone 12: 165-172.
 39.  Carter CS, Ramsey MM, Sonntag WE (2002) A critical analysis of the role of growth hormone and 
IGF-1 in aging and lifespan. Trends Genet 18: 295-301.
 40.  Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, et al. (2003) Insulin-regulated hepatic gluco-
neogenesis through FOXO1-PGC-1alpha interaction. Nature 423: 550-555.
 41.  Longo VD, Finch CE (2003) Evolutionary medicine: from dwarf model systems to healthy cente-
narians? Science 299: 1342-1346.
229
Premature Aging in Csbm/m/Xpa-/- mice
 42.  Park SK, Chang SH, Cho SB, Baek HS, Lee DY (1994) Cockayne syndrome: a case with hyperinsu-
linemia and growth hormone deficiency. J Korean Med Sci 9: 74-77.
 43.  Fujimoto WY, Green ML, Seegmiller JE (1969) Cockayne’s syndrome: report of a case with hy-
perlipoproteinemia, hyperinsulinemia, renal disease, and normal growth hormone. J Pediatr 75: 
881-884.
 44.  Ellaway CJ, Duggins A, Fung VS, Earl JW, Kamath R, et al. (2000) Cockayne syndrome associated 
with low CSF 5-hydroxyindole acetic acid levels. J Med Genet 37: 553-557.
 45.  Laszlo A, Simon M (1986) Serum lipid and lipoprotein levels in premature ageing syndromes: 
total lipodystrophy and Cockayne syndrome. Arch Gerontol Geriatr 5: 189-196.
 46.  Kenyon C (2005) The plasticity of aging: insights from long-lived mutants. Cell 120: 449-460.
 47.  Partridge L, Gems D, Withers DJ (2005) Sex and death: what is the connection? Cell 120: 461-472.
 48.  Brown-Borg HM, Bode AM, Bartke A (1999) Antioxidative mechanisms and plasma growth hor-
mone levels: potential relationship in the aging process. Endocrine 11: 41-48.
 49.  Brown-Borg HM, Rakoczy SG (2000) Catalase expression in delayed and premature aging mouse 
models. Exp Gerontol 35: 199-212.
 50.  Bartke A, Chandrashekar V, Bailey B, Zaczek D, Turyn D (2002) Consequences of growth hormone 
(GH) overexpression and GH resistance. Neuropeptides 36: 201-208.
 51.  Florini JR, Harned JA, Richman RA, Weiss JP (1981) Effect of rat age on serum levels of growth 
hormone and somatomedins. Mech Ageing Dev 15: 165-176.
 52.  Johanson AJ, Blizzard RM (1981) Low somatomedin-C levels in older men rise in response to 
growth hormone administration. Johns Hopkins Med J 149: 115-117.
 53.  Rudman D, Kutner MH, Rogers CM, Lubin MF, Fleming GA, et al. (1981) Impaired growth hormone 
secretion in the adult population: relation to age and adiposity. J Clin Invest 67: 1361-1369.
 54.  Camougrand N, Rigoulet M (2001) Aging and oxidative stress: studies of some genes involved 
both in aging and in response to oxidative stress. Respir Physiol 128: 393-401.
 55.  Ji LL, Leeuwenburgh C, Leichtweis S, Gore M, Fiebig R, et al. (1998) Oxidative stress and aging. 
Role of exercise and its influences on antioxidant systems. Ann N Y Acad Sci 854: 102-117.
 56.  Bartke A (2003) Is growth hormone deficiency a beneficial adaptation to aging? Evidence from 
experimental animals. Trends Endocrinol Metab 14: 340-344.
 57.  Chandrashekar V, Zaczek D, Bartke A (2004) The consequences of altered somatotropic system on 
reproduction. Biol Reprod 71: 17-27.
 58.  Beckman KB, Ames BN (1998) The free radical theory of aging matures. Physiol Rev 78: 547-581.
 59.  Hirosawa N, Yano K, Suzuki Y, Sakamoto Y (2006) Endocrine disrupting effect of di-(2-ethylhexyl)
phthalate on female rats and proteome analyses of their pituitaries. Proteomics 6: 958-971.
 60.  Harada YN, Shiomi N, Koike M, Ikawa M, Okabe M, et al. (1999) Postnatal growth failure, short life 
span, and early onset of cellular senescence and subsequent immortalization in mice lacking the 
xeroderma pigmentosum group G gene. Mol Cell Biol 19: 2366-2372.
 61.  Tian M, Shinkura R, Shinkura N, Alt FW (2004) Growth retardation, early death, and DNA repair 
defects in mice deficient for the nucleotide excision repair enzyme XPF. Mol Cell Biol 24: 1200-
1205.
 62.  Wijnhoven SW, Beems RB, Roodbergen M, van den Berg J, Lohman PH, et al. (2005) Acceler-
ated aging pathology in ad libitum fed Xpd(TTD) mice is accompanied by features suggestive of 
caloric restriction. DNA Repair (Amst).
 63.  Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, et al. (2006) Genomic instability and 
aging-like phenotype in the absence of mammalian SIRT6. Cell 124: 315-329.
230
Appendix III
 64.  Cheo DL, Meira LB, Hammer RE, Burns DK, Doughty AT, et al. (1996) Synergistic interactions 
between XPC and p53 mutations in double-mutant mice: neural tube abnormalities and acceler-
ated UV radiation-induced skin cancer. Curr Biol 6: 1691-1694.
 65.  Nakane H, Takeuchi S, Yuba S, Saijo M, Nakatsu Y, et al. (1995) High incidence of ultraviolet-B-or 
chemical-carcinogen-induced skin tumours in mice lacking the xeroderma pigmentosum group 
A gene. Nature 377: 165-168.
 66.  Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T (1993) p53 is required for radiation-induced 
apoptosis in mouse thymocytes. Nature 362: 847-849.
 67.  Sijbers AM, de Laat WL, Ariza RR, Biggerstaff M, Wei YF, et al. (1996) Xeroderma pigmentosum 
group F caused by a defect in a structure-specific DNA repair endonuclease. Cell 86: 811-822.
 68.  Vermeulen W, Scott RJ, Rodgers S, Muller HJ, Cole J, et al. (1994) Clinical heterogeneity within 
xeroderma pigmentosum associated with mutations in the DNA repair and transcription gene 
ERCC3. Am J Hum Genet 54: 191-200.
 69.  Ma GT, Roth ME, Groskopf JC, Tsai FY, Orkin SH, et al. (1997) GATA-2 and GATA-3 regulate 
trophoblast-specific gene expression in vivo. Development 124: 907-914.
 70.  Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, et al. (1999) Characterization of progressive 
motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci 19: 
3248-3257.
Chapter 1
CurriCulum 
vitae
Chapter 1

233
Curriculum vitae
Naam: Karin Elin Maria Diderich
Geboren: 27 mei 1975, Rotterdam
1987-1993 Erasmiaans gymnasium, Rotterdam
1993-2000 Geneeskunde, Erasmus Universiteit Rotterdam
 Stages:  
 Klinische Genetica, Karolinska Institutet, Stockholm 
 Celbiologie, Erasmus Universiteit Rotterdam (Dr. P. Fraser) 
 Genetica, University of Maryland, Baltimore (Dr. G. Barcak) 
2000-2005 Promotie onderzoek Celbiologie & Genetica, Erasmus Universiteit 
 Rotterdam (Prof.dr. J. Hoeijmakers, Prof.dr. J. van Leeuwen, Prof.dr. G. 
 van der Horst)
2005  Agnio Interne Geneeskunde, Havenziekenhuis, Rotterdam
vanaf 2006 Aios Klinsiche Genetica, ErasmusMC, Rotterdam 
234
Publications
‘Intergenic transcription and developmental remodeling of chromatin sub-domains in the 
human b globin locus.’ by J. Gribnau, K. Diderich, S. Pruzina, R. Calzolari and P. Fraser, Molecu-
lar Cell, Vol. 5(2), 377-386, February 2000
‘Accelerated bone aging in the trichothiodystrophy mouse model.’ by K. Diderich, 
J. Hoeijmakers and J. van Leeuwen, Journal of Gerontology, Vol. 58(11), 969, November 2003
‘Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD muta-
tions.’ by E. Compe, P. Drane, C. Laurent, K. Diderich, C. Braun, J. Hoeijmakers and 
J. Egly, Molecular Cell Biology, Vol. 25(14), 6065-6076, July 2005
 
‘Accelerated aging pathology in ad libitum fed Xpd(TTD) mice is accompanied by features 
suggestive of caloric restriction.’ by S. Wijnhoven, R. Beems, M. Roodbergen, J. van den Berg, 
P. Lohman, K. Diderich, G. van der Horst, J. Vijg, J. Hoeijmakers and H. van Steeg, DNA Repair, 
Vol. 4(11), 1314-1324, November 2005
‘Impaired genome maintenance suppresses the growth hormone--insulin-like growth factor 
1 axis in mice with Cockayne syndrome.’ by I. van der Pluijm, G. Garinis, R. Brandt, T. Gorgels, 
S. Wijnhoven, K. Diderich, J. de Wit, J. Mitchell, C. van Oostrom, R. Beems, 
L. Niedernhofer, S. Velasco, E. Friedberg, K. Tanaka, H. van Steeg, J. Hoeijmakers and 
G. van der Horst, PLoS Biology, Vol. 5(1):e2, January 2007 
‘Symptomatic hypoparathyroidism based on a 22q11 deletion first diagnosed in a 43-year-
old woman.’ by K. van den Berge, K. Diderich, P. Poddighe and A. Berghout, The Netherlands 
Journal of Medicine, Vol. 67(3), March 2009 
235
Cursussen 
Masters Course in Molecular and Cell Biology, 10 januari -18 mei 2000, Erasmus Universiteit 
Rotterdam
Classical Methods for Data Analysis, 18 september -6 oktober 2000, Erasmus Universiteit 
Rotterdam
Cursus Proefdierkunde Art. 9 van de Wet op Dierproeven, 30 oktober -17 november 2000, 
Erasmus Universiteit Rotterdam
MGC cursus ‘Transgenesis, Gene Targeting and Gene Therapy’, 8-12 januari 2001, Universiteit 
Leiden
Microarray course, 2 en 3 april 2001, NKI/AvL-KWF Central Microarray Facility, Amsterdam 
MGC cursus ‘Oncogenesis and Tumour biology’, 2-5 oktober 2001, Erasmus Universiteit Rot-
terdam
Basiscursus Stralingshygiene en Instellingsgebonden Stralingshygienische Regelgeving 
EMC, 1 juli 2002, Erasmus Universiteit Rotterdam
Safe Laboratory Techniques/ Risicobeheersing in Laboratoria, oktober 2002, Erasmus Univer-
siteit Rotterdam
MGC cursus ‘Towards comprehending scanned array; expression profiling’, november 2002, 
Universiteit Leiden
MGC cursus ‘From yeast to man. Comparative Gene Function Analysis.’, 17-21 februari 2003, 
Universiteit Leiden
MGC cursus ‘From development to disease’, 20-22 mei 2003, Erasmus Universiteit Rotterdam
Course Molecular Medicine, 21-25 juni 2004, Erasmus Postgraduate School Molecular Medi-
cine, Erasmus Universiteit Rotterdam
236
Presentaties en internationale congressen 
2nd Joint MGC-ICRF Graduate Student Colloquium, 16-19 mei 2001, Brugge, België
First Conference on Functional genomic of Ageing, 24-27 april 2002, Sevilla, Spanje
4th Joint MGC-Cancer Research UK Graduate Student Conference, 7-10 mei 2003, Lille, Frankrijk
‘Genetic Toxicology’ Conference, 10-15 augustus 2003, Oxford, Engeland
Posterpresentatie
EU-US Workshop on Molecular signature of DNA damage induced stress responses, 26-30 
september 2003, Cortona, Italië
Posterpresentatie
5th Joint MGC-Cancer Research UK Graduate Student Conference, 12-15 mei 2004, Leuven, 
België
Voordracht
31st European Symposium on Calcified Tissues, 5-9 juni 2004, Nice, Frankrijk
Voordracht en European Calcified Tissue Society Young Investigator Award
Conference of the Research Institute of Diseases in the Elderly, 17 juni 2004, Den Haag
Voordracht
Najaarsvergadering van de Nederlandse Vereniging voor Calcium- en Botstofwisseling, 
28 en 29 oktober 2004, Zeist
Voordracht
dankwoord
Chapter 2

239
Dankwoord
Nu er eindelijk een boekje ligt, wil ik graag een aantal mensen bedanken die een belangrijke 
rol hebben gespeeld bij de totstandkoming van dit proefschrift. 
Mijn promotoren van de afdeling Genetica, Jan Hoeijmakers en Bert van der Horst wil ik al-
lereerst bedanken voor de mogelijkheden die ik heb gekregen, met name veel dank voor de 
ruimte om ook te beginnen aan het TTD werk. Beste Jan, ook heel erg bedankt voor je steun 
en de snelle correcties in de eindfase. 
Zonder mijn promotor van de afdeling Inwendige Geneeskunde, Hans van Leeuwen zou dit 
boekje er zeker niet gekomen zijn. Beste Hans, heel veel dank voor de prettige samenwerking, 
je inspirerende en opbeurende commentaren! 
All the labmembers of 730, 734 and 738, many thanks for the pleasant environment in the lab. 
Renata, heel erg bedankt voor je hulp met het muizencohort. Inês, heel erg bedankt voor al je 
hulp met de figuren! Judith, Inês, Hennie, Ingrid, Renata, Phebe en Karin K., bedankt voor de 
gezelligheid binnen en buiten het lab.
Alle collega’s van het ‘calcium en botten-lab’: Claudia, Cok, Irene, Sander, Bram, Marijke, 
Marjolein, Ksenija, Halima en Marco, bedankt voor de goede samenwerking, jullie hulp en 
de gezelligheid. 
Alle collega’s van de ‘endocriene labs’: Frank, Axel, Jenny, Piet en Bas, bedankt voor de goede 
samenwerking, jullie hulp en input. 
Many thanks to my colleagues from the Department of Orthopaedics: Harrie, Erwin and Judd 
for your input and the pleasant collaboration. 
Ook heel veel dank aan de collega’s van het RIVM; Harry, Dolf, Susan en Evert voor jullie hulp 
en de plezierige samenwerking. 
I would also like to thank our collaborators in Germany and Portugal for their input. 
De ondersteuning van de computer-experts, fotografen (Ruud, bedankt voor je hulp met de 
plaatjes), secretaresses en dierverzorgers (Patrick, bedankt voor je hulp met de orbitapunc-
ties) was onmisbaar, bedankt.
Joost and Peter, thanks for the inspiring introduction in basic science. 
Al mijn huidige collega’s van de afdeling Klinische Genetica wil ik bedanken voor hun in-
teresse. Beste Anneke en Fred, veel dank voor jullie ‘bemoeienissen’ en de ruimte om een 
doorstart te maken. Beste Anja W., veel dank voor je wijze woorden. Beste kamergenoten van 
de WZD en de 20e, veel dank voor jullie steun. Lieve Esther, ik vind het meer dan geweldig dat 
je mijn paranimf wil en kan zijn. Jouw levensinstelling is een groot voorbeeld. 
Mijn familie (papa, bedankt voor de typefouten-check) en vrienden wil ik bedanken voor 
hun interesse en steun gedurende de hele periode. Kära mormor, du var min stora stöd i 
den största delen av arbetet. Jag är mycket ledsen att du inte fick vara med till slutet. Tack så 
mycket för ditt ständiga interesse i ‘mina celler och möss’. Alex, heel veel dank voor je steun 
(thuis en als cateraar op de late avonden in het lab) en met name je geduld. Gelukkig heb je 
240
me wel overtuigd niet langer te wachten op het boekje; Thomas is zo geweldig en dat wordt 
zijn broertje/ zusje vast ook. 
Colour 
figureS
Chapter 3

243
Chapter 1
XPC-hHR23B Elongating RNA Pol II
CSB
GG-NER TC-NER
Genome overall Transcribed DNA
RNA
CSA
TFIIH
XPG
others
TFIIH
XPG
TFIIH XPG
XPA
RPA
TFIIH XPG
ERCC1-XPF
TFIIH XPG
XPA
RPA
TFIIH XPG
XPA
RPA
ERCC1
-XPF
Replication factors
Figure 2
Figure 2: Mechanism of nucleotide excision repair.
This figure shows the principle of nucleotide excision repair (NER) and its two subpathways, global genome NER (GG-NER) and transcription-
coupled NER (TC-NER). In GG-NER, the XPC/hHR23B protein complex recognizes the helix distorting lesion. When RNA polymerase II is stalled 
upon a lesion, TC-NER is initiated by  the CSA and CSB protein. In both GG-NER and TC-NER the lesion recognition step is followed by recruitment 
of TFIIH. The XPB and XPD helicases from the TFIIH complex unwind the DNA around the lesion. The initial open complex is stabilized by XPG.  
Next, XPA verifies the lesion and RPA stabilizes the open intermediate by binding single stranded DNA. The structure specific endonucleases 
XPG and ERCC1/XPF cleave 3’and 5’of the lesion, respectively. The resulting 24-32 nucleotide fragment, containing the lesion, is subsequently 
removed and the remaining single strand gap is filled by the regular replication machinery and the resulting nick is sealed by ligase I or ligase III 
(adapted from Hoeijmakers, Nature 2001).
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Figure 3
Figure 3: ‘Tiger tail banding’ in hair from a TTD patient.
Adapted from Liang et al., J Invest Dermatol. 2006. 
Figure 5
Figure 5: Bone remodelling phases.
During bone remodeling resting bone lining cells secrete RANKL which activates mononuclear cells of the haematopoietic lineage to fuse on 
the activated bone surface and form differentiated active osteoclasts. Subsequently, osteoclasts resorb bone after which formation is coupled to 
resorption by the appearance of pre-osteoblasts in the resorption cavity. A cement line is formed which marks the limit of resorption and acts as 
attachment or glue between the old and new bone. Finally, in the formation phase osteoblasts fill the resorption cavity with new bone. Initially 
this is osteoid, unmineralized bone matrix, which then becomes mineralized. 
Figure 4
Figure 4: Different lineages derived from the mesenchymal stem cell.
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Figure 2
wt 91w
TTD 52w
Figure 2: Thickness distribution and bone parameters in wild type and TTD mice. 
Cortical thickness distribution in aging wild type (A) and TTD mice (B) with the arrow indicating the direction of change with aging. Comparison 
of thickness distribution in 52-week-old TTD mice (dotted line) compared to 91-week-old wild type mice (solid line) (C). Bone parameters 
in aging wild type mice (solid triangles) and TTD mice (open triangles): bone volume (D), cortical thickness (E) and perimeter (F). TTD mice 
compared to wild type animals: # p<0.05, ## p<0.01, ### p<0.001; TTD mice and wild type animals compared to their 26 week time point: * 
p<0.05, ** p<0.01, *** p<0.001; error bars represent SEM. 
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A
Figure 3
Figure 3: Histomorphometric analysis of cortical bone and Backscatter Scanning Electron 
Microscopy of wild type and TTD mice. 
Calcein double labeling of endosteal and periosteal bone formation in wild type and TTD mice (A). Quantified endosteal apposition (B), 
quantified periosteal apposition (C) and mineralization status (D) in wild type (solid symbols) and TTD (open symbols) mice. TTD mice compared 
to wild type mice: # p<0.05, ### p<0.001; TTD mice compared to their 13 week time point: * p<0.05, ** p<0.01; error bars represent SEM. 
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Figure 1: TTD mice show accelerated skeletal aging. 
(A) 3D thickness distribution (volume density) in aging male (A left panel) wild type and (A right panel) TTD mice, with the arrow indicating the 
direction of change with aging. (B) Comparison of thickness distribution in 52-week-old TTD male (dotted line) compared to 91-weeks-old wild 
type male (solid line). 
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Figure 3: Decreased bone strength in TTD mice.
 Bone strength, mineralization and bone formation rates in long bones of aging wild type (solid bars/ symbols) and TTD males (open bars/ 
symbols). (A) Bone strength depicted as Ultimate Load, (B) bone mineralization, (C) perimeter and (D) MOI. Calcein labelling at sites of 
periosteal apposition in 78-week-old (E) wild type and (F) TTD mice. (G) Endosteal apposition and (H) periosteal apposition. TTD vs. wild type: 
ANOVAs * p<0.05, *** p<0.001; error bars represent SEM. 
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total volume
Figure 1
Figure 1: Area of interest for micro-computed tomography analyses.
The bone parameters were measured in the vertebral body. The line represents the width of the vertebra. The ellipse area depicts the total 
endocortical volume (TV) in which trabecular bone volume (BV) was determined. 
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Figure 4Figure 4: Histomorphometric and histopathological analysis of vertebrae. 
Trabecular bone volume fraction in aging wild type mice (solid bars) and TTD mice (open bars) (A), 2D histology (panel 1-4) images of vertebrae 
of aging TTD mice with the highest trabecular bone volume fraction; disorganized appearance indicated by arrow (B). Transversal section of 
vertebrae showing an increase in bone mass accompanied by a reduction of medullary spaces (indicated by arrows) in a 104-week old TTD 
mouse compared to a wild type mouse (C). Increased magnification showing empty osteocyte lacunae (indicated by arrows) in vertebrae of a 
104-week old TTD mouse compared to a wild type mouse (D). TTD mice compared to wild type mice: # p<0.02; error bars represent SEM. 
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Figure 1: Bodyweight and abdominal cavity in wild type and TTD mice.
Bodyweight in wild type (closed symbols) and TTD mice (open symbols); (A) females and (B) males. Error bars represent SEM; significance 
compared to 26 w: *= p<0.05, **= p< 0.01, ***= p< 0.001 and significance compared between genotypes: ##= p< 0.01, ###= p< 0.001. 
(C) abdominal cavity showing (lack of) fat mass in a wild type mouse and a TTD mouse. 
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5
Figure 5: Aromatase expression, Oil-Red-O staining and leptin levels in wild type and TTD mice.
(A) aromatase expression in fat of wild type mice. (B) Oil-Red-O staining on livers from a 78-week-old male wild type and TTD mouse. Staining 
of triglycerides indicated by arrows. Pictures were taken at 100x magnification. Serum leptin levels in wild type (closed symbols) and TTD mice 
(open symbols); (C) female and (D) male mice. Error bars represent SEM. 
